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Blood platelets have the ability to stick avidly to one another and to
damaged surfaces in blood vessels and by so doing form platelet aggregates.
These aggregates form the initial obstruction to blood loss from a wound
and blood flow through a thrombosing artery and vein.
Platelets are stimulated to aggregate by a specific chemical messenger,
ADP, which apparently acts on receptor sites on the platelet surface.
Platelets themselves contain large stores of ADP which are explosively
released when platelet aggregation is promoted by thrombin, adrenaline,
collagen or 5 Hydroxytryptamine. These promoters of platelet aggregation
can be studied in vitro where the ADP they induce platelets to release
produces a dose-dependent (primary) aggregation which is partially
reversible.
This thesis reports the finding that some platelets undergo a further
('secondary*) aggregation, much more marked than the primary one, to form
large persistent aggregates. Secondary aggregation occurred because small
amounts of ADP in the plasma were causing the platelets to release nearly
all their stores of ADP and to Show an exaggerated aggregation response to
ADP.
Studies in man showed that there are two grades cf secondary platelet
response. Host platelet suspensions derived from normal healthy controls
showed a self-limiting secondary aggregation, but 20/ showed a powerful
progressive 'chain-reactive* type of aggregation.
Studies carried out on 'sick* patients in the 'hyperthrombotic' period
following acute illness showed that the incidence of the 'chain reaction*
response had risen to 7Q&
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In animal studies most mammals failed to show any secondary aggregation
reaction. A self-limiting response was observed in blood derived from some
baboons and guinea pigs. Only the oat showed a consistent * chain reaction'
response. This is the only animal which develops arterial thrombo-eabolic
disease in its natural environment.
This association between second;try aggregation and arterial thrombosis,
and the high incidence of the chain-reactive response during the 'hyper-
thrombotic' state following acute illness, suggests that secondary platelet
aggregation may be a significant factor in the pathogenesis of thrombotic
disease in man.
Furthermore, inhibition of this reaction by newly available drugs
may offer a new approach to the prevention and perhaps treatment of





The first microscope which gave sufficient definition for viewing
bodies of 2-3ju» and so blood platelets, was developed by Lord Lister's
father in about 1826. Over the next few years shed blood was examined
with increasing care and many small particles were described and drawn.
From their reports it seems likely that by 1846 blood platelets had been
seen independently by Gulliver, Addison, Arnold and Zimmermann (for review
see Robb-3mith 1967), although none of these workers realised the significance
of these small bodies. Lonnts (1841) is sometimes credited with the discovery
of the blood platelets for his description of 'les globulins du chyle*, however,
as dilution of the blood with water increased the number of *les globulins*,
he may easily have seen what he thought he saw, namely chylomicrons.
T. tf. Jones ?R3 (1851), working in London with the frog foot
preparation, was the first person to notice the accumulation at sites of
injury of cells from the blood; but amphibian platelets are both nucleated and
larger than mamalian platelets and so a cross correlation between the two was
not made. The next advance was made by Sir William Osier in 1871. He made
an in vivo study of the mesenteric blood vessels of a mammal and saw, in addition
to red and white blood cells, small disk shaped bodies which he correctly
correlated with the blood platelets in shed blood from man. He also noted
that platelets had the ability to form clumps of a ' -ranular' appearance.
Finally, the correlation between vessel injury and platelet 'granular'
mass formation was made by Biaoaaero (1881) and was confirmed and amplified
by Eberth and Sehimmelbusch (1886). Like Osier, these workers studied
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From section of half-hour thromlma produced by forcible ligature of femoral artery of dog (see text).
Shows masses of blood plates containing bands of fibrin and leucocytes. Zeiss D. ocular 3.
Fig. 1.1.
Section of thrombus drawn by Welch 1887•
mammalian mesenteric blood vessels, but with the additional manoeuvre of
vessel injury. They found that a mass of blood platelets formed at the
injury site. The individual platelets in this mass developed a granular
appearance and then the platelets appeared to fuse into a granular mass,
certainly their individual outlines could no longer be distinguished by
light microscopy.
Welch (1887) extended the applicability of this sequence of changes to
the thrombotic situation, by observing the changes which occurred when the
femoral artery of a dog was injured by tying a tight ligature around it.
After the ligature was released platelets adhered and aggregated at the site
of injury, forming large, irregular masses. Then, between five and fifteen
minutes after the injury, thick fibrin strands formed between the platelet
masses, and white blood cells migrated into the thrombus (Fig. 1.1.).
Welch followed the progress of these platelet-fibrin thrombi, and found
that, two days later, they had a homogeneous appearance to light microscopy
and a response to staining which was 'indistinguishable from fibrin'.
This progression from platelets to 'fibrin' lead him to postulate that the
so-called 'fibrin thrombi' found in man, were the later stages of a platelet-
fibrin ('white') thrombus, and did not arise de novo as fibrin deposits.
The electron microscope ha* shown that he was right (vide infra).
Eberth and Schixamelbusch (1886) used the term 'viscose metomorphose*
to describe the development of a granular appearance in individual platelets
in a platelet aggregate. Their name has since given rise to confusion and
controversy, for it has been subsequently applied to granular changes in a
platelet aggregate ('viscous metamorphosis* Wright and Ilinot 1917) and to
the biochemical aspects of the platelet release reaction (vide infra). In
idie authors opinion the confusion caused by the use of this term has hindered
understanding of platelet aggregation, and its use should be abandoned.
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Thus by the end of the 18£0's the initial events, of platelet adhesion
to injured vessels followed by platelet aggregation, with later strengthening
by fibrin 3trands, were known. No important further advances were made in
this field until the advent of the electron microscope and of improved
biochemical methods.
ADHESION
Adherence of blood platelets to injured vessel walla is the first
event in the formation of a haemostatic plug or a thrombus. The platelets
do not adhere to normal vascular endothelium subjected to a laminar blood
flow. They are able to adhere when only minor endothelial damage is present
(French et ai 50), but only temporarily (5). It is the exposure, by damage,
of vessel wall connective tissue (collagen) which produces a firm base for a
platelet-fibrin mass, for platelet adherence to collagen is rapid and firm
(Bounameaux 20, itookam 156, Kjarheim and liovig 96a, Johnson et al 86).
The platelet-collagen reaction is a hi^ily specific one, as is shown by
its abolition by a collagenase (Hovig 78) and by altering the helical
structure of the collagen molecule (Nosel et al 155, 185). It differs from
platelet to platelet aggregation, in that calcium, which is essential for
aggregation, is not required for adhesion (Spaet and Zucker 154, Spaet and
Lejnieks 172).
PLATELET AGSRESAT10N
Platelet aggregation (platelet adhering to platelet) is ths property
of blood platelets which allows them to form the main mass of a haemostatic
plug and a vrhite thrombus; it has the effect of supplying the •bricks'
and part of the 'mortar* (the remainder of the 'mortar' is provided
subsequently by thick fibrin threads).
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until the 1960's, our knowledge of platelet aggregation was limited
to morphological observations, and to the demonstration that thrombin would
induce platelets to aggregate (sharp 165)* In I960, Hellem (72) reported
that a substance released during the boiling of red blood cells was a
potent platelet aggregating agent. Analysis of the red cell extract showed
that the active substance was the adenine nucleotide, adenosine disphesphate
(ADP) Gaarder et al (54). Closely related adenine nucleotides (adenosine
triphosphate or ATP, adenosine monophosphate or AMP, and. adenosine) did not
produce aggregation.
Before the discovery by Gaarder et al (54) of it's platelet aggregating
properties, ADP had been known mainly for its part in the ATP intracellular
energy transfer process. Cne preceding piece of information, however, gave
special interest to the ADP story. In 1956 Professor Born (11) had shown
that blood platelets themselves contained a very high (almost uniquely so)
concentration of adenine nucleotides. This raised the possibility that
the plotelet3 themselves and not red blood cells (which had after all to be
boiled) could be the source of the ADP. Subsequent work with labelled
adenine nucleotides (Holmsen 75, 74, 75, Ireland 84) showed that there
wore two rou^ily equal pools of adenine nucleotides in platelets. One
was metebolically active, and is presumed to be concerned with ordinary
intracellular energy transfer; the other apparently served no metabolic
function, and had an unusually high concentration of ADP, indicating that
a specialised storage process was occurring. This stored adenine nucleotide
pool with a high ADP content, is now known to be released when the platelet
is stimulated by certain platelet aggregating agents (Holmsen 75» 74, 75,




The'two-tier' hypothesis of platelet aggregation. ADP is first released
into the plasma from platelets (by thrombin, collagen, 5H-T) or by damage
to 'cells' (first tier), and this free ADP then stimulates platelets to
aggregate (second tier). The inhibitors of the platelet aggregating
action of each stimulator are given beside the appropriate arrow (-*v"0 •
Since 1962 many new platelet aggregating substances have been
discovered in addition to the original ones, thrombin and ADP (for reviews
see Marcus 112, Miehal and Firkin 113). The ones likely to be of
physiological (and pathological) importance are the catechol amines
(adrenaline and noradrenaline, Mitchell and Sharp 121, O'Brien 138),
collagen (in addition to stimulating adhesion, Eovig, 78, 79) and
5-Hydroxytryptamine or serotonin (O'Brien, 139). Thrombin (84) collagen (73)
and the catechol amines (117) induce platelets to release the adenine
nucleotides of their matubolically inactive pool; 5 hydroxytryptamine (5R-T)
is suspected also to induce a release (139, Haslaa, 69), but it is at most
a small one (139).
'The release of AD1 from platelets by aggregating agents such as thrombin,
collagen, and adrenaline suggests a 'two tier' action ^Fig. 1.2.). The first
'tior' consists of the release of ADP, and the second, of the action of the
released ADP on the platelets to produce aggregation. There is other
evidence for the two-tier hypothesis. Inhibitors of aggregation are known
which act on individual aggregating agents (e.g. heparin on thrombin,
collagenase cn collagen etc. see Fig. 1.2.) without at the same time inhibiting
the aggregation produced by other agents or ADP, but inhibitors of ADP
induced aggregation (adenosine, 2 ohioroadenosine (13)) inhibit the
aggregation of all aggregating agents. Even more convincing is Haslaas
demonstration (68, 69), that the enzyme system pyruvate kinase-phosphoenol
pyruvate (ph - PET'), which removes ADP rapidly from plasma, prevents thrombin
and adrenaline from producing aggregation, even although the ADP-release
induced by these substances is still occurring.
There are two exceptions to this two tier system, the first phase of
adrenaline aggregation (vide infra), and the phenomenon of Secondary
Aggregation of blood platelets, which is the subject of this thesis.
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Secondary Aggregation (S.A.) was first described by Macmillan (106)
in 1966 and has since been confirmed by several groups of workers (Mills
et al 118, 116, Sucker and Peterson 196, 197, O'Brien 142, 143, Hardisty
et al 64, 65), S.A. is a marked, almost maximal, aggregation response in
platelet rich plasma induced by low concentrations of ADP. It is associated
with the release by the platelets of their ADP stores. This ability of ADP
to induce the release of more ADP from platelets means that it is performing
both first and second 'tier' actions. It thus can produce a self-
propagating platelet aggregation/platelet ADP release reaction. S.A. will
be described fully in the results section and its possible implications will
be discussed at the end of this thesis. Zucker and Peterson (196) have shown
that platelet factor 3 activity is released when ADP induces S.A. (but not in
the absence of S.A.), indicating that S.A. also promotes coagulation.
As was mentioned above, the catechol amines occupy a unique position.
O'Brien (138, 139, 140) showed that adrenaline produced two phases of
aggregation, in contrast to the one phase occurring with other aggregating
agents, Whereas in all ADP mediated aggregation platelets change from their
in vivo shape of disks (Osier 146, Algire 2) to irregular spheres (Zucker and
Borelli 195, Macmillan and Oliver 109, O'Brien 141), in the first of the two
phases of adrenaline aggregation the aggregating platelets retain their in vivo
disk shape (O'Brien 141, 144 rlacmiilan 106). This suggests that ADP is not
involved in the first phase of adrenaline aggregation, a suggestion which is
supported by the demonstration that concentrations of the adrenaline
inhibitor phentolamine, too small to affect ADP induced aggregation, cause
complete disaggregation of the adrenaline first phase, (riacmillan 106,
Mills et al 117). The second phase of adrenaline aggregation, like the
aggregation induced by other aggregating agents, is mediated through, ADP
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released by the platelets (Mills et al 117, 0*Brien 139, Macmillan 106,
Haalam 69)*
There is a strong association between the release of the platelet
stores of ADP and degranulation of the platelets (Hovig 78,79, Mills et al 116,
Marcus 112). Amitriptyline inhibits S.A. while leaving the F.A. response
to ADP unaltered (Pills et al 118), and the platelets in aggregates formed
in amitriptyline treated plasma, do not show degranulation (Fills et al 116).
These observations suggest that the nucleotide ,pool* is in one of the granules,
as does the general principle that it would be difficult otherwise for the
cell to maintain a store of adenine nucleotides with a high AD"" content.
The way in which platelets are induced to aggregate by ADP has not
yet been discovered, nor has the nature of the bridge between platelets.
It is however reasonably certain that ADP acts on specific receptors sites
on thaplatelet aurface, because concentrations far too small (10~®M) to form
a monolayer around the platelet (about 10- M) produce aggregation, and because
adenine nucleotides closely related to ADinhibit aggregation (Born and
Cross 15, Mustard and Packha- 133), suggesting the presence of a competitive
inhibition mechanism.
In 1964 (hoarder and Laland (54a) suggested that ADP may be both
stimulating platelets to aggregate and forming part of the bridge between
them. These workers noted that the only other adenine nucleotide which caused
platelet aggregation, a synthetic substance adenosine tetra-phosphate, was also
the only other nucleotide which (like ADP) had an uneven number of negative
charges. Aggregation is known to be calcium dependent (111), and these
workers hypothesised that ADP became fixed to platelet receptor sites and
the odd negative charges on addecent platelets were then joined through a
calcium bridge. It is now nown that ADP does not become firmly fixed to
platelets (Bom 14, Salesman et al 159* 170), Also, in view of the transient
nature of much platelet aggregation, it is unlikely that a strong link, such
as a co-valent calcium one, is present.
Several workers have subsequently offered explanations of how ADP may
alter the function of the platelet membrane as a prelude to aggregation.
Spaet and Lejnleks (172) suggested that conversion of ADP to MP provided
energy for aggregation, but this conversion can be prevented by I'Cli (Salaaan
et al 159) while leaving platelet aggregation unimpaired. Salzman has
suggested (160) that the ADT is producing 'product inhibition' of the action
of a platelet membrane ecto-ATPase, but again there are several objections to
this theory (Fdchal and Firkin 115). The most interesting suggestion is the
recent one by Packham et al (149) and Mills and Smith (119), that since platelet
aggregation inhibitors of widely varying structure have the common link of
affecting the cyclic-AI-ff system in the platelet membrane, the ADP 'message*
may be being transmitted to the rest of the cell through cyclic ASP, the
recently discovered intracellular 'messenger* substance (198).
At the other end of the process, the inter-platelet bridge, there has
been an as yet unsubstantiated suggestion of a combination between the two
portions (actin and myosin) of the contractile protein thrombosthenin
situated on adjacent platelets (Booyse and kafelson 9a, b, c,). It will be
interesting to see the reports of follow up studies on this possible mechanism.
After platelet aggregates have formed they often break up (disaggregate),
sometimes to a marked degree. Born and dross (17) suggested that this night
be due to the inhibitory action of ADP degradation products (MP and adenosine).
Subsequent work ha3 shown, however, that this degradation is relatively slow
(Ireland and Mills £5), and disaggregation is in fact occurring while about 80f
of the ADP d03e i3 still present. Since AMP and adenosine are weak
inhibitors of ADP mole for mole (15), the platelets are disaggregating inspite
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of a persisting aggregation-inducing stimulus. O'Brien (139) showed that
a grossly pharmacological dose of ADP (lOOptt/L) in inoubatod platelet-rich
plasma, made the platelets refraatory to ADP. This refractory response
mechanism was found still to occur with 1ADP/L by Rosenberg and Holmsen
(154), and by the author (108) to be still present at the physiological dose
range of ADP of 0.5-1.5«Vl" I* al30 occurred following the addition of low
concentrations of thrombin and 5H-T. It is thus likely that, following the
aggregation-prone response to ASP, the platelets pass into a refractory
state. This refractory state may be the reason for disaggregation.
Tho work described so far hrss been concerned with the in vitro
situation. Several workers have shown correlations between the results
in vitro and the effects of aggregating agents in experiments on intact animals
Systemic infusions of ADP into cats (Born and Cfross 16,) rabbits (Sua field and
Toaich 23) and ran (Pavey and lander 36) all produced a fall in platelet count.
In the rabbit, a preceding infusion of the ADP inhibitor adenosine protected
the animal from thrombocytopenia to a subsequent ADP infusion (152).
Mustard et al (128, 129) investigated the pathological changes which
occurred when ADP and thrombin were infused into pigs. Both these substances
produced platelet aggregates in small vessels. The ADP induced aggregates
broke up within a few minutes and the thrombin induced ones persisted for
upwards of an hour. This showed that in the pig ADP induced aggregation is
a transitory phenomenon. An interesting finding in Muistard's work on ADP
Infusion was the occurrence of cardiac arrhythmias after the platelet
aggregates had dispersed.
Another experimental model which has been vised, is rabbit cortical
vessels exposed by craniotomy. When these vessels are injured by artery
forceps a small injury ('minor1) produced no change and a large ('major')
one induced platelet aggregation ('white body' formation) at the site of the
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damage (Honour and Ross-Ruasell 76a). Honour and Mitchell (76) showed
that the application of platelet aggregating agents to 'minor' injury-
sites resulted in white body formation at this normally quiescent site.
In vitro inhibitors of the aggregating agents, both specific and general
(adenosine), were equally inhibitory in this in vivo situation. These
workers later showed (18) that systemic infusion of the A.DP inhibitor
adenosine prevented 'major' injuries from inducing 'white body* formation.
This finding suggests that the stimulus causing platelets to aggregate
onto a damaged vessel wall in vivo is ADP.
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gliiJJTIOMS Qj x-'LaJiLitflS
The prime role of the platelet is in haemostasia (vide infraJ.
Platelets also provide an essential part of the intrinsic coagulation
system, a lipid material (Platelet Factor 3). It's precise chemical nature
is not known but it certainly contains phosphatides similar to, or a mixture
of, phosphatidyl ethanolamine, phosphatidylserine and inositol phosphatides
(176# 6)*
Ihere is increasing evidence that platelets play an important part
in most responses of the blood to injury (146). Platelets adhere to
bacteria both in vivo and in vitro (77* 101). They phagocystose foreign
material* and the platelet count is reduced during anaphylactic reactions
(£9) and after injections of bacterial endotoxins (157* 175). In rats, the
Piateleta seem to play an essential part in the production of anaphylactic
shook v56)* but the relevance of this finding to man is not yet known.
One further effect of platelets is their endothelial supporting
function (Johnson et al 86). The absence of platelets allows petechial and
purpuric haemorrhages to develop and their presence prevents this escape of
red ceils from vessels. The mechanism of this protective function of
platelets, of maintaining *vascular integrity', has not been eluoidated.
Finally, platelets are an important constituent of thrombi
xvide intra).
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BLOOD PLATELUT3 AND HA2H0STASI3
The work of Bizozzero (9) and ilberth and Schimmelbusch (40)
In the 1860*8 has been confirmed by subsequent studies using light
(Roskam et al 55» Jorgenson and Borchgrevink 91 * 92) and electron
microscopy (Kjarheira and Hovig 96a). The sequence of events is now
known to be, vessel contraction, then platelet adhesion and aggregation
at the sites of the cut blood vessels, and following these two events
the formation of thick fibrin strands around and in the spaces in
platelet a gregates. These events produce a stable and impermeable
platelet-fibrin plug (•consolidated' plug) (for review see Roskam 156).
Coagulation alone can produce haemostasia in capillaries, but this is
not an important factor in achieving haemostasia (91, 92). Over the
two weeks or so following an injury the platelet-fibrin mass is
organised to scar tissue composed of new collagen.
Both normal platelets (quantitative and qualitative) and
normal coagulation, are necessary for the formation of a consolidated
plug. When the platelet component is defective, prolonged bleeding
occurs from small puncture wounds ('bleeding time* test). The bleeding
time is normal in patients with coagulation defects, because the
platelet plug and vessel contraction can arrest the bleeding, but
microscopy shows that the plug is friable and unstable (jorgenson et al
93)• It is therefore understandable that this friable plug can become
dislodged, allowing bleeding to recommence.
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BLOOD PLATELETS AND THROMBOSIS
In a recent electron microscopy study on experimental
thrombosis (in pigs), Mustard et al (130) have confirmed and extended
Welch's observations (184) of 1887. The sequence of events found by
Mustard and his co-workers was the same as that during the formation of
haemostatic plugs. Platelets were found adhering to collagen and
attached to these were aggregates of platelets encased in fibrin.
In the two days following the injury the platelet-fibrin mass was
invaded by mononuclear cells which part digested the platelets, and
then phagocytoaed the parts and whole platelets. By five days, many
fibroblasts were seen and a little new collagen, and by fourteen days,
the platelet-fibrin thrombus had been converted to an intimal scar
which was rich in smooth muscle cells and collagen, and covered with
normal endothelium.
This process, of repairing the injured artery to near its
normal state, is an efficient one, and is a necessary one for maintaining
the life of an animal. However, in man, an extension of this process,
thrombo-atherosclerosis, is now the main cause of death in adults in
industrialised countries, due to its effects on coronary and cerebral
blood vessels.
The mechanism of the development of thrombo-atherosclerosis
remains the subject of controversy to this day, and the purpose of this
part of the review is to assess the part thrombosis is playing in this
process, by describing the pathological evidence derived from man
himself.
In 1949 Duguid (39) revived the 'encrustation' theory of
f
atherosclerosis, when he demonstrated fibrin staining material on
arterial walls which was being converted to fibrous plaques. This
showed that at least some atherosclerotic plaques were formed in this
way. The problem of assessing how many plaques are so formed, is
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complicated by a 'tip of the iceberg* phenomenon. Since a thrombus
is organised in a few days or weeks into a fibrous plaque, the number
of thrombotic deposits seen at any one time is likely to only be a
very small percentage of the total number which are occurring.
The iceberg phenomenon is also operating in very diseased
arteries, as has been shown by Mitchell and Schwartz (122). These
workers examined the coronary artery vessels of patients dying after
a myocardial infarction. When the time between the infarction and
subsequent death was taken into account, they found a progression from
totally occluded coronary arteries in all patients dying in the first
forty-eight hours after the infarction, to stenotic fibro-atherosclerotic
plaques in patients dying at four months after the infarction. This
suggests that organisation of thrombi is a major factor in the
production of stenotic atherosolerotic plaques.
The same conclusion has been reached by the other workers in
this field (Crawford 30, Branwood and Montgomery 20a), because they
frequently found thrombus on atherosclerotic plaques, often layers of
thrombus. As Crawford (30) has said *it will be appreciated that the
natural history of most of these cases (of atherosclerosis) is one of
recurring episodes of thrombosis. At an early stage when blood flow
is rapid and the lumen widely patent, the thrombi are small. They
become rapidly consolidated by the blood pressure and incorporated in
the wall. But with successive deposits stenosis builds up and there
is a tendency for larger thrombi to form and be less completely
incorporated in the vessel wall, until ultimately occlusive thrombosis
occurs.*
The reported incidence of occlusive thrombosis in patients
dying of recent myocardial infarction has varied widely, as reviewed
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by Crawford (30). Davenport found 60/', Branwood and I'ontgomery only
21% with recent mural thrombus in a further 38$. But these workers
did not separate their patients into forty-eight hours and increasing
time periods, nor was the most informative technique of serial
sectioning of all narrowed areas used. Mitchell and Schwartz (122)
finding of 100.- (see above) would therefore appear to be nearer the
true incidence.
Some occlusions are due to atheromatous debris and not
white (platelet-fibrin) thrombus. The most careful study to date is
probably the one of serial sectioning of 40 occlusions of coronary
arteries by Friedman and dyers (51). These workers found an
atheromatous deposit ('abscess*) which had ruptured into the vessel
lumen as the initial event in all the occlusions. A platelet-fibrin
thrombus was the cause of the block in 58 occlusions, with atheromatous
debris the cause in the other two. Constantinides (29) has reported
parallel findings in occluded cerebral arteries.
In sudden death from ischaemic heart disease, there has been
a lower incidence of occlusions (drawford, Dexter and Teare, 31).
Thrombotic occlusions were present in 50$, and fresh non-occlusive
thrombosis in a further 20$. The incidence of thrombosis was hi^iest
in the younger patients, especially those under forty years. Those
without occlusive thrombus had severe stenotic lesions of their coronary
arteries, a finding which was also made by Sranwood and Montgomery (20a).
The deaths in those patients without a thrombotic occlusion have been
attributed to cardiac arrhythmia, thought to be caused by ischaemia.
An alternative cause of arrhythmia would be transient block of the
stenotic vessels by platelet aggregates, like that shown to cause
arrhythmia in animals (Mustard et al 130). Thus some of these deaths
could be due to a transient or subsequently dislodged platelet aggregate.
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Fig. 4 Diagram illustrating the propagation of deep
vein thrombi from a nidus in a valve pocket (A) and
the deposition of successive layers offibrin, platelets,
etc (B and C). Retrograde extension occurs when
there is venous blockage from propagation (D).
Fig. 1.3. '
Diagram of the stages in the pathogenesis of deep vein thrombosis
from Sevitt 1971.
There would seeia to be a little doubt that platelet-fibrin
thrombi and their organisation is the major mechanism in thrombo-
atheroselerosis. What remains uncertain is how other markers of the
atherosclerotic trait, such as hyperlipidaemia, obesity and cigarette
smoking, are acting on this process. Are they responsible for
atheromatous abscess formation, or for the bursting of these abscesses?
Or do they promote thrombogenesis or prevent fibrinolysis, or otherwise
impair the arterial walls ability to organise thrombi, or even increase
the amount of scar tissue formed? Ko doubt future research will
answer these questions, but the morphologic evidence, based on findings
in man himself (not on animal experiments), leaves little doubt of the
thrombotic pathogenesis of most atherosclerosis.
Platelet-fibrin thrombi are also the major event in the
initiation of deep vein thrombosis, a cause of significant morbidity and
mortality following acute illness. The major worker in this field has
been Sevitt who recently reviewed his own and other peopleb work (163).
Deep vein thrombi arise in the areas of turbulent blood flow around
venous valves (162), as layered platelet-fibrin thrombi (see Fig. 1.3.)
which eventually gives rise to a block of the vein. Red coagulation
thrombosis then occurs, ami parts of the red thrombus sometimes become
dislodged and ambolise to the lungs.
1
Layered white thrombi are also one of the sources of arterial
emboli. They arise in areas of turbulent blood flow, such as
fibrillating atria, and arterial aneurysms; and on areas of vascular
damage, such as endocardial myocardial infarctions and eroded
atherosclerotic plaques.
This short review only includes a part of the very large
literature on platelets and the part they play in health and disease.
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There have been many extensive reviews of different aspects of
the literature in recent years of which the most helpful are,
in the authors opinion, those by Marcus and Zucker 1965 (ill)#
Kowalski and Jlawiarowski 1967 (98), Johnson and Seegers 1967
(78), Marcus 1969 (112), Michal and ?irkin 1969 (113) and
Mustard and Packhaa 1970 (133).
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StJMARY OF REVIEW
1 • In vitro studies on man and animals have shown that the biochemical
mechanism of platelet aggregation is centred on ADP. A store of
ADP is present in platelets and is released by substances such as
thrombin, collagen, adrenaline and 5 H-T. This released ADP then
acts on specific receptor sites on platelets making them capable
of aggregating with other platelets,
2. In vivo studies suggest that in vitro studies are relevant to
platelet aggregation behaviour in the intact animal, and in one
study in man.
3. Blood platelets are the major initial constituents of haemostatic
plugs, of thrombi on atherosclerotic plaques, and of the white head
of venous thrombi.
4. After adhesion of platelets to collagen in an injured vessel,
a platelet mass is formed by the clumping of platelets to each
other (platelet aggregation). The platelet mass is then
strengthened by the formation of fibrin strands in it's spaces and
around it.
xxvi





Needles: Disposable plastic and steel needles. Sizes G20 and No.1.
Syringes; Plastic disposable syringes.
Glassware: All glassware was siliconlsed. (Siliclad, Clay-Man® Inc., N.Y).
Centrifuge Tubes: 50 ml. containers. Siliconised glass or polythene
Micrometer syringes: Burroughs Wellcome Ltd. One turn of the head
(50 marks) delivered 0.01 mis. The needles used for the delivery were
G26 stainless steel.
lagpotic stirrers for plasma: Magnetised plastic strip (Eclipse,
J. Neill & Co (Sheffield) Ltd.) was placed in a 3 mm. length of polythene
tubing (NO.3 sterivao, Allen & Hanburys) and the ends were sealed with
molten plastic. They were checked for comparability in the aggregation
apparatus.
Aggregation Apparatus:
1. Modified Titrator (Evans Electro-selenium Ltd.).
a cadmium sulphide photo-resistor cell (Mullard orp 12) was
substituted for the standard selenium photo-electric cell. A red
filter (EEL606) was placed in front of the cell. The table for
holding specimens was removed, and a plastic water jacket
(Professor G. V. R. Bom*s Workshop, Royal College of Surgeons,
London) was inserted.
2. 6v.D.C. stabilised supply (Cossor Instruments Ltd., England).
3. Honeywell strip Chart recorder - 1mV full scale deflection,
Type I 153X18/V-II-III-/IV/-R.
4. Circuit Pig. 2,1. The photo-cell (a) was situated in one arm of
a Wheatstone bridge circuit. Variable resistances (b) of 25k and
5E were placed in the opposite arm (allowing coarse and fine
adjustment of the baselinei. A 6v DC stabilised supply was connected
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across the balancing arm. Changes in the balance arm were recorded
across a 100 ohm variable resistance (sensitivity control) by the
recorder.
5. The stirrer motor of the EEL titrator revolved at 1500 rpm and was
exactly followed by the magnetised stirrer in the plasma (both
checked with a stroboscope).
Centrifuge: M.S.E. super minor with a head for four 50 ml. buckets.
Taohometer (Smiths Industries): Pull scale reading on higher
sensitivity 0 to 1000 and on lower sensitivity 0 to 5000.
Water Bath: Sensitive to - 0.5°C (Type SB2, Grants Instruments (Camb.)
Ltd.).
Microscope; Reichert, Biozet, with phase contrast attachment.
Parafilm: (Lindsay and Williams Ltd., London).
Cleaning of glassware and plastic: After rinsing, the apparatus was
soaked for one hour in Pyroneg solution. Then it was re-rinsed ten
times. Distilled water was used for the last three rinses. The glass
Q
was dried in a hot air oven at 37 C.
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PAINTS
Adenosine disphoaphate from equine muscle (Sigma (Chemicals T.td).
A stock solution in saline) was prepared and divided into
2 ml. aliquots. These were stored at -20°C until used and a new
batch of aliquots was prepared every two months.
Other chemicals were prepared and stored in the same way.
Adenosine, adenosine monophosphate, adenosine triphosphate
(all Sigma Chemicals Ltd).
Adrenaline acid tartrate (Burroughs Wellcome Ltd).
Thrombin - bovine (Parke-Davis).
Collagen was prepared from human achilles tendon obtained postmortem
(method of Btovig 78). It was stored at - 4°C, and a batch was only
used for two weeks.
Heparin (Pularin, Evans) was dissolved in saline to give the required
strength and stored at -4°C.
KL>TA Trisodium salt (Hopkln St Williams)
Oaloiura Chloride A AOnfl stock solution in distilled water was prepared.
Citrate anticoagulant 3.8; Trisodium nitrate was prepared in de-ionised
distilled water by the Pharmacy department. It was stored at 4°C.
14
mixm.
Prepare, txon of platelet rich and ^l^tclet poor plaaaa.
Blood was collected by clean venepuncture and two syringe technique
into 20 ml. syringes wbich contained the anticoagulant. The
anticoagulants were 2 mis. 3.Q citrate (final concentration in blood
O.38;-0; 2 mis. 20 rn& EDTA (final concentration 5mM)? or 200 units
heparin in 0.2 mis. (final concentration 10u/ial). The blood and
anticoagulant were mixed using a bubble of air drawn into the syringe.
The anticoagulated blood was discharged into a 50 ml. centrifuge tub®
and incubated at 37°C for 3 ndns. It was then eentrifugcd at 150g. for
10 mina. at room temperature. The platelet rich plasma was removed to
a level of about 0.5 oms. above the blood/plasma interface, and
transferred to a test-tube in a waterbath at 37°C where it was stored
until it was used. The residue of blood and plasma wa3 re-centrifuged at
460g., and the platelet poor plasma was removed to a level of about 0.5 ens.
above the plasma/blood interface. It was stored at 37°C.
Platelet aggregation: theoretical and practical details are described
in Chapter Three,
Platelet counts: Blood and plasma specimens were collected in sequestrine
plastic tubes and platelet counts were performed by the method of Dacie
(34)# using phase contrast microscopy.
Platelet shape estimations; Specimens were fixed in formalin solution
and examined and counted according to the wet preparation technique
described by Zucher and Borelli 1954 (1S9). The specimens in this test
and. tests of platelet morphology (see below) were coded before counting
in order to make the examination a •blind* one.
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Fig.2.2LooseAdhesionf. plateletsinan aggregate.Nearly- allplateletsindi¬ viduallyindent fiable.
Fig.2.3ModerateAdhesionf plateletsinan aggregate.Platel ts individuallyseenat theperipheryoft aggregate,butnoi itscentre.
l*t5\r i'K*;/Pi^S«*fM' j4•%w• , $*"*s,f' ,-»\*w»v*>f •* Fi:;*-,.y";'•%.. *,»^VV.%■■. .uF-V>V.•- &3r-.v*«&.V«fv.ftsi$i-,.;-""«;V-ft-,
;:VA
c._
Fig.2.kMarkedAdhesionof plateletsinanaggregate. Individualplateletsc n nolo gerbeseenatth edgesoftheaggre ate.
Three categories of chape were counted:-
(a) Disks - platelets whose short diameter (as they turned over in the
wet preparation) was 30 percent or less of the long diameter.
(b) Spheres - roughly spherical platelets whose shortest diameter was
not less than 50 percent of the longest one.
(°) Others - shapes intermediate between disks and spheres, or degenerate
shapes.
Platelet aggregate morphology; Specimens were fixed as for platelet
shape.
(a) Sises of aggregate. Aggregates were recorded in the eiae ranges of
2-10, 11-20, 21-50 platelets and then as 50 plus platelets to $ HPF
(high power field 400x), i-1 HPF, 1-2 HPF, 2-5 EPF and 5 plus EPF's.
The percentage of the total platelets in each of the aggregate
sis© ranges was estimated visually by comparing identical dilutions of
the original platelet rich plasma (FRp) and aggregated HIP with each
other. The estimate was recorded as the percentage of the
originally single platelets (i.e. 100#) present in the aggregates
of each range of aggregate 3ise. This method is semi-guantititive,
however in a series of duplicates, examined in & blind experiment,
the results in the pairs were similar.
(b) Horuholo -y of larger aggregates. The aggregates were slowly and
firmly squashed by pressing the slide against the covorslip (Sharp
166). The degree of separation of the platelets produced by the
compression indicates the strength of inter-platelet bonds.
Specimens were classified in the following categories:
(1) Loose adhesion - nearly all platelets in the aggregates
individually identified (Fig. 2.2).
(2) Moderate adhesion - Individual platelets identified at the
edges of the aggregate, but not at its centre (Fig. 2.3).
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(3) Harked adhesion - Individual platelets not seen even at the
edge of the aggregates (Fig. 2.4).
A specimen was classified on the adhesion category which was dominant.
Although the method is seni-quantitative, blind examination of duplicates
produced similar results.
Measurement of the aggregating activity present in a PEP supernatant
During platelet aggregation substances such as adenine nucleotides,
5 H-T and adrenaline may be released by the platelets and those
substances added to the PRP are altered by plasma and platelet metabolism.
Some are stimulators and some inhibitors of aggregation. One often
wishes to know the sum of the effect of their interaction on platelets,
but some of these substances may not yet have been identified and the
interactions of those already identified are complex. Their composite
effect has been measured in this thesis biologically - by adding the
supernatant to fresh PRP. The aggregation produced by the supernatant
was compared with that produced in the same PRP by known concentrations
of ADP.
In some experiments the total aggregating activity of the supernatant was
measured. In most only the ADP-like aggregating effect was estimated.
This was separated from the total by adding the adrenaline and 5 H-T
inhibitor, phentolamine, and the thrombin inhibitor, heparin, to the
test PSP (Macaillan 106).
Method.
Aggregated specimens of plasma were allowed to stand for 45 sees to allow
the larger aggregates to sediment (sedimentation and centrifugation of
aggregated specimens gave equivalent results). 0.25 mis of supernatant
was then drawn into a plastic 1 ml. syringe and injected at 60 sees after
the end of aggregation (i.e. 15 sees after the sedimentation period)
into a fresh specimen of plasma (calibration plasma). The aggregation
17






















produced by the supernatant in the calibration plasma was compared
with that produced by platelet poor plasma (PPP), prepared from the
plasma under test, to which known concentrations of ADP had been added.
The aggregating activity in the supernatant was expressed as its ADP
equivalent activity in u moles per litre (v®). When the calibration
specimen contained heparin and phentolamine the activity of a supernatant
was called it's ADP-like aggregating activity and was also expressed as
u moles per litre.
Reoroducibilitv. A pool of supernatant was prepared from platelets
which had released aggregating activity in response to ADP (Secondary
aggregation, Hacmillan 106). The pool was stored at 4°C and four sets
of diluted specimens, each in duplicate, were prepared. Bach set
consisted of a specimen of undiluted supernatant, of pooled supernatant
diluted to 60 percent, and to 30 percent (by PPP from the same specimen)
and of PPP oontaining known quantities of ADP. The preparation took
45 minutes. The four sets were stored at -20°C. The ADP-liko
aggregating activity in the supernatant and it's dilutions was measured
using calibration plasma from four different subjects. Calibration
plasma specimens contained phentolaraine (4p0 and heparin (10 units/ml).
The experiment lasted a total of six hours. The results are shown in
Table 2.1.
The average ADP-like aggregating activity in diluted supernatant matched
closely with the dilutions made i.e. 60, to 63.5', and 30/S to 31$. The
range of results were, mean - 20$ for 100$ supernatant; mean - 25$ for
60$ dilution and mean - 30$ for 30/ dilution. The duplicate results in
each calibration plasma were close together whereas there was a wider
variation between the different calibration PRP's.
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This shoved that the range of the results of - 20 to - 30 ,
was due sore to biolo ical variations in the response of the
calibrating plasma than experimental technique. The degree of
variation found is of the order expected with biological materials.
Validity. Direct comparisons were not made between aggregating
aotivity and biochemical Measurements of adenine nucleotides,
5H-T, and catecholamines in the same plasma. However the results
obtained by this biological method are the case as those subsequently










Platelet adherence to non-platelet
surfaces (eg. collagen and glass).
Platelet adherence to other platelets
to form platelet aggregates.
The breaking up of platelet a -gregates,
resulting in smaller aggregates or
single platelets.
An in vitro phenomenon measuring the
reduction in the platelet count produced
by varying stimuli (usually glass) which
cause platelet adhesion plus platelet
aggregation, and possibly disruption of
the platelets.
An aggregation response to ADP, occurring
in all platelet rich plasma, in which the
aggregation process increased in extent
gradually with increase in the added
ADP concentration (P.A. was followed by
disaggregation at up to, and including,
the lOpM ADP dose).
A second wave of aggregation to ADP,
occurring in only some platelet rich
plasma. It produced an abrupt increase
in aggregation of near maximal extent.
No disaggregation followed for at least
five minutes. The ADP concentration
which first produced S.A. was called the
S.A. point ADP concentration.
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Three types of S.A. occurred
(1) 3iphasic S.A.: The strongest S.A. It was
able to reverse established disaggregation, and
so produced a markedly biphasie aggregation
tracing.
(2) ITon-ohaaic S.A.i A weaker S.A. It was able
to continue the primary aggregation process but
.
, *
did not reverse established disaggregation.
(3) Level S.A.: A non-phasic S.A. in which the
increased aggregation reached a steady (level)
state lasting at least five minutes.
Ch«±n—reactive S.A.: An S.A. process which was able to extend it's
aggregations-inducing potential beyond the plasma in which it occurred
to further specimens of the plasma, so producing a marked aggregation
chain reaction.




The question of which type of analysis to use in this
thesis was discussed with Dr. Barr, Director of the Statistical
Department, Oxford Regional Board. The measurements of the
•secondary aggregation* reaotion of platelets were made by finding
which of a range of concentrations of a chemical produced the
reaction; also a significant, but quantifiable (see Chapter Seven),
biolo ;ical variation was present. Both these facts argued strongly
for a conservative approach to the analysis. It was decided to use
the leas sensitive parametric range of testa which demand more
experiments and greater agreement to achieve significance, and it
was felt that confidence could be placed in the 5% (fc = 0.05)
probability level. The use of parametric tests allowed direct
analysis of the experiments whioh gave the part qualitative, part
quantitative data, inherent in studies of the secondary aggregation
reaction of blood platelets.
The tests were performed according to the directions given
by Langley 1968 (ref 100).
Asterisks are used in the tables to denote levels of
significance, on the scale shown below (this will not be repeated for
each table in the text).
* j> =<0.05 ** =<0.01 »**/>= <0.002 *»** f> =<<0.001
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CHAPTER THREE
In vitro TIKASUaKKSMTS OP PLATELET ADHESION ASP AGGREGATION
1. ^ppyCTION
In vitro measurements of platelet adhesion and aggregation
involve the obtaining of preparations containing a highly metabolioally
active 'cell*, the platelet, and exposing them to an acute stimulus as
comparable as possible to the ones occurring in vivo during haemostasia
and thrombosis.
Obtaining platelet preparations means for practical purposes
obtaining whole blood i.e. a plasma, red cell, white cell, platelet
mixture. Unless the blood is immediately tested (Salzman (158),
Busfield (25), it must be either cooled (which damages platelets (192),
or anticoagulated (or it will olot). Thus, if separation of platelets
from red cells is contemplated, one must either damage them with cold
or alter their behaviour with anticoagulants. Anticoagulants are not
necessarily a lesser upset than cooling, however they do allow easier
handling of platelet preparations, more exact observation of platelet
behaviour, and the use of more complex tests.
Platelet adhesion and aggregation studies are hampered by a
problem which is common to much biological material from man - no
absolute standards can be prepared. An additional problem is that the
number of platelets in plasma varies over a wide range giving difficulties
in quantitation.
In spite of these drawbacks much has been accomplished, as will
be seen from the preceding review. But it is important to remember the
degree of manipulation which occurs before testing, and the degree of
comparability of the stimuli used to the in vivo situation it is
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1.Allelementsasbove bloodpresent 2.BothadhesionSoma yvariables andggregationthatfurthermore presentsp cifictests neededtofih causeofhang 3.Onlytwoobservation points,withunknown inbetweenandfter¬ wards
1.SimpleapparatusTechnicaldifficulties andproceduralitfalls ofplateletcounting methods 2.Standardisationof apparatusveryimportant anddifficult 3.Techniquerequires constanttactime withstimulusandconstanl volume
Platelet aggregation (BornsMethod)




2.Manystimula tsorec mplic ted canbeusedinseriesequipm nt orparallel 3.Samplingforbiochemical ormorphological studies U.Workatbody temperature
intended to mimic, when considering the possible relevance of in vitro
findings to the in vivo situation.
2. PRINCIPLES OF TESTS OF PLATELET ADHESION AND AGGREGATION
There are three main groups of tests j-
(1) Adhesion tests - the adhesion of platelets to various substances,
especially glass, is observed directly.
(2) Aggregation tests - platelets, separated from red cells and
most white cells, are stimulated to aggregate, and the effects
of the stimulus are followed in different ways; visually, by
optical or ultrastruetural microscopy, and automatically by
recording the changes in the density of the plasma.
(3) Platelet stickiness teats - platelets are induced to adhere to
a surface (usually glass), other platelets aggregate onto the
adherent ones (142, 149) and yet other platelets form non-
adhering aggregates; some platelets may disrupt. This is
thus a composite test. The combined effects of these three
processes are calculated from platelet counts taken before
and again after the blood has been exposed to the stimulus.
3. CRITI3PE OP THE TESTS
The advantages and drawbacks of the three groups of tests are
given in Table 3.1.
(a) Tests of adhesion involve microscopic study of blood or platelet
rich plasma in contact with an adhesion-inducing surface.
Collagen in injured tissue has been used (174), but the effects
of this reaction was until recently only roughly quantifiable.
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Spaet et al (173) have now developed a technique which may solve
this problem. It is easier to quantitate tests in which glass
is the stimulus, but the mechanism of adhesion to glass shows
differences from that of adhesion to oollagen (20), suggesting
that different platelet properties may be being measured.
^ests of platelet atiaicirrafsfl have their earlier origins in
Horowitz and Jurgens (124) experiments, in which they drew non-
anticoagulated blood back and forth through a capillary tube.
The modern era of this test was initiated by Helen Payling Wright
(186). She constructed a vaseline coated, revolving bulb which
allowed intermittent and moving contact between blood and a clean
non-vaseline coated glass coverslip. The platelets were counted
at zero time and again at intervals of 20 mine. The decrease in
platelet count was taken to be an estimate of platelet adhesiveness.
Many variations of this technique of prolonged contact with a small
glass area have been developed since (111, 61). A new generation
of te3ts with a Bhort glass contact time was introduced by Moolten
and Vroman (123) in 1949 and the technique was much improved by
Hellern (72). In order to increase the area of glass Hellem used
many small glass beads packed into a container. This represented
a major advance in standardisation as he was able to pump blood
through the beads at a standardised rate. He also described many
of the technical end sample variations which affect the results,
and which are now known to be crucial for worthwhile results.
Others continue to be added, (61, 53, 55). Modifications are
plentiful, with Busfielda (22) the m03t attractive. Unfortunately
it is not possible to work at body temperature with these methods.
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The numerical basic of platelet stickiness tests is the platelet
count. As Mitchell (55) has so aptly said, ttonly those who have tried
to decide whether a blob in a counting chamber is, or is not, a
platelet, can appreciate the difficulties of this laboratory procedure,
and understand the ease with which observer bias may occur".
The place of this teat in studies of platelets and their
disorders has become clearer with the passage of time. Its greatest
use is as a clinical method for screening patients and populations
It has the advantage of allowing interaction of all elements of
the blood. However the corollary of this is that when changes or®
detected it is necessary to perform more specific tests to find out
which component of whole blood is producing the change. Are the
red cells releasing more (or less) ADP? (e.g. measure red cell
fragility): or are the platelets varying in adhesion, or aggregation,
or disintegration?, or are the white cells or plasma (e.g. fibrinogen)
responsible? Thus Uiis test has a position analogous to that of the
whole blood clotting time in coagulation work, any abnormality mu3t
be investigated further to find it's cause, and a negative result does
not exclude an abnormality.
(c) ffests of platelet agfiye^t^n; In these tests the platelets are
separated from the red cells, thus limiting the number of reactants.
The act of separation introduces the possibility that one will be
studying an atypical platelet population, and this possibility has
been studied in this thesis. Also the red cells could theoretically
affect the platelet^ by releasing ADP during the separation process,
but there is no proof that this actually occurs.
These theoretical disadvantages are outweighed by the many
advantages of being able to study a single process, aggregation.




























Fig. 3.1 Diagramatic representation of the correlation between
plasma light transmission and the formation and







Fig. 3.2 Diagram of the apparatus of the
turbidimetric method of Born.
/
PBP which were shaken after the addition of aggregating agents
(Sharp, 165, 166).
Method of Born; Professor Born (12, 17) noted that as aggregates
formed in a test-tube of PHP the density of the plasma decreased
(Pig. 3.1 ) and he harnessed this change to develop a much improved
and automatic method of measuring aggregation (Pig. 3.2). A light
was shone through the plasma on to a photo-electric cell, and the
changes in plasma density were recorded by noting the changes in
light transmission. A continuous recording of the aggregation and
disaggregation of platelets was thus possible. Other advantages
of this method are that the stirring is carried out automatically
by a magnetic stirrer and revolving magnet, and that the tubes
containing the plasma can be enclosed in a water-jacket, allowing
work at body temperature.
This method is sensitive, for example even changes in platelet
shape can be detected (Hacaillan et al 1965, 109; O'Brien 141, 144).
Specimens of plasma and aggregates can be removed, and so
correlations can be made between the tracings of light transmission
and microscopical or biochemical tests.
DESCRIPTION OF TIE TIRBIDIMGTRIC METHOD USED IN Till? THESIS
1. Equipment: The types and specifications have been listed in the
materials section of Chapter Two.
2. Preparation of the equipment:
(a) The water-jacket was perfused with water at 37°C for 20 mins.
before use.
(b) The light source was centred on the lens system. This was
achieved by moving the light source until inserting a glass
tube containing saline into the curvette (saline blank)
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reduced the light transmission by less than J5&. This centring
of the light source was important as turbid solutions such as
plasma were found to block differing percentages of the light
transmission at different positions of the li?ht source (unlike
coloured solutions or coloured filters),
(c) The part of the L.T. scale required for an experiment was marked
on to the recording paper. To do this a saline blank was
inserted into the cuvette find previously calibrated blue filters
were inserted into the light path.
(d) Micrometer syringes were filled with active chemical solutions,
taking care to avoid air bubbles in the syringe and needle (G26)»
The needle was bent to a right angle in such a way that the
bevel would face the aide of the tuba of plasma d\?ring an
injection.
3. The technique of measuring platelet r, gregration.
Using a disposable 1 ml syringe, 1 ml of plaama was transferred
from the store of PHP in the waterbath to the tube used for testing. This
tube was then incubated at 37°G for at least two minutes. It was wiped
dry and placed in rhe cuvette, and alignment marks on the tube and the
water-jacket were opposed.
The stirrer was added and recording started. After an interval
of exactly 15 or ©xaotly 30 seconds the injection of active agent was
started. The injection took from two to five seconds (0.005 ml to 0.025 ml).
After the injection the needle was wiped against the side of the tube.
The changes in plasma light transmission were recorded for three
to ten minutes.
In many experiments the tracings produced by increasing
concentrations of an aggregating agent were superimposed by backwinding the
chart to a constant starting point. This made comparisons much easier.
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Li -ht transmission. light extinction. density ana optical density, a;id
tfte tracings of aggregation
Platelets vary In size and shape, and this variability is even
greater in platelet aggregates. For this reason only descriptive scales
can be strictly applied to the light changes in aggregating platelet rich
plasma, and the 'light transmission' scale i3 therefore used. Density is
inversely proportional to light transmission (0 L.T. = completely dense
to light, 100a L.T. = no obstruction to light), and to avoid the mental
gymnastics of this conversion the terra light extinction which corresponds
directly with density has bean used by some '68). In this thesis the
simpler word 'density' will be used. Density as a general term is not to
be confused with 'optical density' which applies only to particles of 1y
or less. The optical density scale is used in some ports of platelet
aggregation tracing interpretation (vide infra) but in the full knowledge
that it is not strictly applicable.
The platelet aggregation tracings were recorded in such a way
that the top of the tracings were positioned at a low light transmission
(high density) and the bottom of the tracings at a high light transmission
(low density). Thus a fall in the tracing indicated that the light




Photograph of Dose-response curve to ADP of platelet rich plasma
In this, and subsequent dose response curves, the plasma was stirred
for 15 or 30 seconds and then,at the point marked by an arrow, ADP
was added. The number beside each tracing is the final concentration
of ADP. The tracings produced by increasing concentrations of ADP
have been superimposed by back winding the chart. ADP was added to
this plasma in concentrations of from lpM to IOjjM. After a small
initial rise in the tracing, there followed a fall which increased
with the ADP concentration. Then the tracing showed a further rise
which decreased as the ADP concentration was increased.
CHAPTER FOUR
PLATELET AGtt^gATIOi^IJAGG^GA'nO^ (D0SE-RESP0H5E CTJRVBS) TO ADP IN
rotAH CITRATED PRP AT BODY TSi-iPEttATLRE (37°C).
THE DOSE-RESPONSE CURVE TO ADP
Previous work. Born (12, 17) and O'Brien (122) have described this
response as one of increasing aggregation and decreasing disaggregation
as the ADP concentration was increased. Born was working at room
temperature, and O'Brien, using hot air, at 37°C.
Present Investigation. Pig. 4.1. shows a dose response curve to ADP of
the type described by Bom and O'Brien. The tracings which occurred
with increasing concentrations of ATP have been superimposed to aid
comparison (see methods).
Before the addition of ADP, small baseline oscillations were
present. The addition of ADP was followed by three changes.
1. Oscillations ceased and the tracing rose.
2. A fall in the tracing with, at high ADP concentrations,
a reappearance of oscillations.
3. A variable return of the tracing towards the baseline,
which was of lesser degree as the fall increased.
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MICROSCOPY OF SPECIMENS TAKEN DURINS TRACING CHANGES.
Previous work. All investigators have confirmed Born'3 original
observation of the presence of aggregates visible to the naked eye
as the density of a plasma decreased (tracing falls), and of breaking
up of the larger of these visible aggregates as the density subsequently
increases (rise of tracing).
Present study. The initial rise in the tracing which followed the
addition of ADP, was investigated by microscopy of samples removed from
plasma undergoing this change. Thai the microscopical appearance of the
aggregation and disaggregation processes was investigated.
1. Loss of baseline oscillations and rise of tracing.
Previous work. In vivo blood platelets are disk shaped (2, 7, 9) and
this in vivo disk shape is well maintained in citrated plasma at 37°C
(189). ADP has been shown to change the shape of platelets from disks
to spheres coincident with aggregation (195).
O'Brien, 1965, (141) and Kacmillan and Oliver, 1965, (109) noted
that when plasma containing disk shaped platelets was stirred a swirling
effect could be seen by the naked eye, presumably due to the disk shape
of the platelets resisting stirring.
The light transmitted by this swirling plasma oscillated (141, 109).
When the shape of the platelets was changed from disk to sphere by ADP the
swirling ceased and the plasma density rose. The light transmission showed
corresponding changes.
The experiment described below is an extension of the work
reported in 1965*
Present investigation. Samples from the same pool of plasma were stirred
for 5 mins. After 30 sees, stirring saline or low concentrations of ADP
(0.1, 0.2, 0.4 juH) were added, (using these low concentrations the earliest
stages of the 'rise' were exposed). Samples were taken for microscopical
31




























examination during the *pr©-addition* period of stirring and at four
points after the addition. Three experiments were performed and they
gave the same results.
Results Fig. 4.2.
1. PBP saline. Oscillation of the tracing persisted for the 5 mins.
of the experiment. The microscopy samples contained over 80?' of
•disk* shaped platelets throughout the 5 mins. At the *pre-addition*
point most of the residual platelets were *indeterminate' in shape.
At 5 mins, about 50 percent of the residual platelets were 'sphered*,
A few aggregates of disks (2-5 platelets) were observed,
2* ADP 0,1 v''. Coincident with the small rise in tracing and partial
loss of oscillations induced by the ADP, the percentage of single disk
platelets fell from 84$ to 60$ and of single spheres roae from 2 to 30$.
Further spheres were present in aggregates of 2-10 platelats and an
estimated 15/ of the platelet population was in aggregates. Ey
5 mins, almost complete disaggregation had occurred and the percentage
of disk platelets had risen to 77, and of spheres had fallen to 15/'.
5. m 0r2 The rise of the tracing was more abrupt and oscillations
ceased, Sy the top of the rise the percentage of disk shaped platelets
had fallen from 84$ to 20, with a corresponding rise in the percentage
of spheres. 25$ of the platelet population was in aggregates of
spheres which varied in size from 2 platelets to 20 platelets* Over
the next 5 mine complete disaggregation occurred, and the percentage
of the disk shaped platelets rose to 62$,
4. App 0,4 uH. After an abrupt rise in the tracing there followed a
fell, and soon afterwards a further rise. Subsequently the tracing
fell towards the baseline.
By the top of the rise only 5$ of the platelets were still disk














80 L 30 sees
Fig. 1;.3.
Diagram of the tracings used for tracing/microscopy correlations
ADP was added after 30 seconds stirring (arrow with box).
Samples were taken from the specimens at the points shown by plain arrows,
percent Of the platelet® were la a -gr-gjites, and the sine of
aggregates ranged fro® 2 platelets to 50 - ■% H,P.P. (high power
field, se© methods). Over the 5 nine of observation over fO
of pistoleta became single. The remainder wore in small aggregates
(2 to 20 platelets). Over 40,< of platelets rssuaod their previous
shape of disks.
1, ADP produced sphering of disk shaped platelets and soma sphorioal
platelets formed aggregates. These changes were detected by the
turbidimetrio method of observing PRP. Over 5 tdn3 a marked
disaggregation and nodorate regaining of the disk shape occurred.
2, There? was a marked variation in the response of the platelets.
Only some changed to sph rae. Only suae sphered platelets formed
aggregates, .aad those aggregates varied in thoir size,
3, The variability of the platelet response was precunably due to the
different ages of the platolet population of a FBP.
Previous work. Born and Hume (J9) have de«30®atrated a rapid diaappoeraaoe
of single platelets during the fall of the tracing produced by ADP-nodiated
platelet aggregation. These workers then studied Jvg density of tho
larger aggregates paying particular attention to the changes in the density
of aggregates during 'secondary* aggregation (106). This density was
inoreased compared to that of 'primary* aggregates.
Present work, Speolmens of plasma were removed for microscopical study
at several points of a moderate aggregation response (25 - 35, of initial
plasma 0.1).) and of a very marked aggregation response ('secondary'
aggregation). So© Pig. 4,3. for diagramatio representation of the
tracings and the sampling points. The stuaplea were examined for the
percenta;© distribution of the platelets in different sises of aggregates,
33
































































































































and for the degree of intern-platelet adhesion in the larger aggregates
(as described under methods). Pour experiments were performed at eaoh
level of aggregation and the pattern of the changes was similar.
Hepu^s fab!? 4,1.
1. Moderate fall. As expected microscopy confirmed the presence of
aggregates but the pattern of their formation was unexpected. By
the top of the rise some of the aggregates were nearly as large as
those present during the late stages of the aggregation process.
The greatest involvement of platelets in large aggregates occurred
at half-fall. The percentage of platelets in larger aggregates at
the full fall point was less than that in larger aggregates at the
top of the rise. At all points single platelets and platelet
aggregates of all the sizes up to the maximum one occurring were
present. Adhesion of platelets to each other in the aggregates was
'loose1 at all times.
2. Marked fall (S.A.). By the top of the rise many aggregates, some
large, were present. The number of single platelets and aggregates
of 2-10 was small at all times. During the 3Q/1 to 100$ fall time
period, aggregates of sizes 10 platelets to -j- HFF almost disappeared,
with almost all platelets forming into large aggregates. However
the largest aggregates were present at the 30$ fall position.
The degree of internal adhesion of platelets in the aggregates
increased steadily from 'loose* to 'marked' from the 30/ to 100$ fall
position.
3. Disaggregation (subsequent rise of tracing). Microscopy of specimens
taken while the tracing was rising confirmed the break-up of aggregates.
But the degree of disaggregation was less marked than that suggested
by the degree of return of the tracing to the baseline.
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When the tracing returned to the level of the top of the 'rise',
disaggregation was microscopically incomplete (although it could
become complete over the next 5 to 10 aims). After a tracing
returned from a medium fall to the level of the oscillating baseline,
upwards of 505" of the platelet population was atill in small
aggregates (up to 1/16 EPF).
Samples taken after the small disaggregation which follows some
marked falls (vide infra, primary aggregation) followed for 10 mins
showed 20a plus of platelets were single. But many aggregates of
up to 1 HPF in size were 3till present, and these showed moderate
adhesion of the platelets.
Summary of microspore correlations with the tracings.
1• The light transmission from stirred human platelet rich plasma
was an oscillating one and it correlated with a disk shape of
the platelets.
2. When ADP was added to the plasma three changes occurred.
5. First, oscillations ceased and the tracing rose. This change
correlated with a change of platelet shape from disk to sphere
and with aggregation of some of those spheres.
4. Second, the tracing fell and this correlated with further
platelet aggregation. A few aggregates near to the maximum
size occurring to a particular AD* concentration were already
present before the fall in tracing started. The largest
aggregates were present at about the 50^ fall position of the
tracing.
5. Finally* the tracing rose. This rise correlated with macro-
and microscopic disaggregation. The microscopic extent was
less than that suggested by the degree of rise of the tracing.
6. Throughout the microscopic study there was considerable
variation in the individual responsiveness of the platelets.
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Only la the Tory marked aggregation falls, where aggregates
of aisoa 10 to about 200 platelets (■£ HPP) disappeared, was
this variation absent. She variation would be expected




Dose response curve to ADP of a PRP which showed Primary Aggregation
(P.A.) only.
Increasing concentrations of ADP produced increasing aggregation. This
increase was initially rapid and then slower. Aggregation was followed
by disaggregation which decreased in extent as the ADP concentration
rose; but which was still just present at the IOjiM ADP dose.
#
(i>A, )
This type of response was found in ail platelet rich plasma
from man. A plasroa showing this response is shown in Fig. 4.4. The
lowest ADP concentration producing aggregation varied from 0.01 to
1 .0 jiM. The degree of aggregation increased in direct proportion to
the ADP concentration, initially rapidly and later more slowly. The
maximum concentration used was 10 uM, as this is at the upper limit of
the (ADP) which platelets can release in their response to aggregating
agents (116, 117, 74, 65).
Aggregation was followed by disaggregation. The degree of
disaggregation decreased as the aggregation increased, but it was still
present in slight degree after the 10 y3& ADF dose. When the aggregated
plasma was stirred for 10 mins further disaggregation occurred. In this
10 tains the tracing returned to the baseline level following AD? additions
of up to about 3 but not after higher doses of ADF (Kacaillan 106).
Addition of the pharmacological ADP dose of 100 jM produced
vory marked aggregation with little or no disaggregation during 10 mins
of stirring.
Measurement of the .A. process
The widely used (13, 67, 139) measurement for primary aggregation
of the percentage fall (O.D. scale) in density produced by a fixed dose of
ADP will be used. In this thesis 1 ADP was the fixed dose in most
experiments.
■Suma^y of primary aggregation (P.A.)
1. The primary aggregation (p.A.) response is one showing a gradual
increase in aggregation directly proportional to the added (ADP).
This was followed by disaggregation which was inversely proportional
to the ADP concentration. However, slight disaggregation was still
occurring after a 10 jiH ADP addition.
2. P.A. will be characterised by the percentage fall in O.D. of a plasma






-response curve to ADP of a FRP which, in addition to P.A.,showed
I 2
MINS.
biphasic Secondary aggregation to 0.2j?pM ADP
The 0.25pM ADP addition induced a small primary aggregation which was
followed by disaggregation. -After the disaggregation was complete there
occurred a further, very marked, and near maximal aggregation
(•...»= expected P.A. response). This is Secondary aggregation (S.A.)
and the shape of the tracing of P.A. plus S.A. is biphasic. The
0.5pM ADP addition induced a larger primary aggregation which reached a
trough. Then instead of showing primary disaggregation (dotted line)
S.A. occurred. The l.OjuM addition produced a fusion of P.A. and S.A.
and a degree of aggregation which was not increased by ADP IOjjM.
SECONDARY ACSRSGATJON (S.A.) TRACING.
JjntyQduotion
In moat plasma from man the •primary* aggregation response to
added ADP was interrupted by a further very marked aggregation ('secondary'
aggregation). The author's original description of the process and the
subsequent confirmation of it's presence are detailed in the review
(Chapter l).
Present Study.
The stage of the P. A. process at which it was interrupted by S.A.
varied widely in plasma from different subjects. Tory rarely S.A.
occurred after stirring alone. In the remainder of the plasma it occurred
after ADP additions anywhere between 0.25 yuM ADP and 10 jfl* ADP. In a few
plasma S.A. was not detected.
Dose-response curves to ADP of plasma from patients and volunteers
showing the range of S.A. responses are described below.
Results.
The S.A. process was most easily seen then it was very active,
for it then converted a small P.A. response into a very marked aggregation
(maximal or near maximal).
The most active form is shown by Pig. 4.5. In this plasma
0.25 yuM added ADP produced the expected very small P.A. aggregation. This
was followed by a small disaggregation, which was slightly impaired in
degree (for expected, see Pig 4.5). Instead of proceeding to further
disaggregation and a regaining of disk shape by the platelets (as expected,
see Pig. 4.2), after about one minute of the disaggregation phase the
tracing started to fall again. The speed of this fall gathered momentum
and the oscillations of large aggregate formation started to appear.
The prooess continued until very marked aggregation was present.
Comparison of this tracing of the S.A. response with that induced by
10 UK ADP during P.A. (Fig. 4.4) » showed that the degree of aggregation
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Fig. U.6.
Dose response curve to ADP showing biphasic S.A. to 0.75>pM
Tne addition of 0.25 to 0.75pM ADP induced P.A. The disaggregation
phase of the 0.75)M tracing was interupted by a secondary aggregation
which continued to a near maximal extent. l.OpM ADP produced fusion
of P.A. and S.A. lOpM ADP only slightly increased the degree of
aggregation.
= expected P.A. response
4
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MINS.
Fig. U.6.
Dose response curve to ADP showing biphasic S.A. to 0.75>pM
The addition of 0.25 to 0.75pM ADP induced P.A. The disaggregation
phase of the 0.75jJM tracing was interupted by a secondary aggregation
which continued to a near maximal extent. l.OpM ADP produced fusion
of P.A. and S.A. IOjiM ADP only slightly increased the degree of
aggregation.
= expected P.A. response
*
present after S.A. was markedly the greater of the two. Furthermore,
stirring of plasma in which S.A. had occurred for 10 mins did not
produce any disaggregation (in marked contrast to even a 10 jaM ADP
addition in the primary aggregation type of response). A small
increase in plasma density occurred when plasma which had undergone
S.A. were stirred for 1 hour, but microscopy showed this was due to
disruption of aggregates (frayed edges of aggregates and platelet
•debris1)# n<>t disaggregation.
The addition of 0.5 yjM ADP to the plasma shown in Fig. 4.5
produced a faster onset of S.A., for the S.A. response interrupted the
early part of the disaggregation following the P.A. response. 1 yuM and
10 uM ADP additions further increased the speed of onset of S.A., and P.A.
and S.A. became inseparably fused. But none of these higher ADP
additions added significantly to the degree of aggregation.
Fig. 4.6 shows the dose-response curve to ADP of a plasma which
gave the S.A. response to a 0.75 ADP addition. At this ADP
concentration the S.A. process again interrupted the disaggregation
following the P.A. response. It had the same very marked aggregation
tracing as the plasma depicted by Fig, 4.5.
The ability of the S.A. process to reverse disaggregation
resulted in the separation of the two aggregation phases by a
disaggregation process. The S.A. in plasma showing this biphasic
tracing, of P.A. and S.A. seen separately, will be called •biphasic* S.A.
Demonstrating the biphasic stage required careful titration of
the ADP addition, for as is shown by Figs. 4.5 and 4.6. a small further
increase in the ADP addition produced fusion of P.A. and S.A. However,
the abrupt increase to near maximal aggregation which S.A. produced was
so striking, when compared to the small P.A. response to low (ADP) and
the •step'1 by step* nature of P.A., that, even when P.A. and S.A. were




Dose-response curve to ADP showing biphasic S.A. to 1.5pM ADP
P.A. occurred at 0.5 J-iM addition. At ljuM ADP addition the disaggregation
phase of P.A. was interupted by a further aggregation process (giving
a biphasic tracing) but this did not develop to a marked extent i.e.
it was partial S.A. The next ADP dose (1.5pM) induced a fully developed
S.A. process; P.A. and S.A. can still be separated. At the next dose
level of 2pMj aggregation of P.A. and S.A. were indistinguishable.
10pM ADP did not increase the aggregation response. ( = expected
response from P.A. only).
Fig. k.8 .
Dose response curve to ADP of a PRP -which showed non-phasic S.A. to
3pM ADP
The response was of P.A. type until the disaggregation phase of the
2pH addition. This was impaired (for expected see dotted line). The
3juM addition was followed by a continuing aggregation process with
P.A. and S.A. fused_,which continued to a near maximal response for
the plasma (which was less marked than for biphasic S.A.). The UjJM and
lOpM additions showed the same pattern with a small increase at each
dose in the extent of the aggregation.
A further example of •biphasic* S.A. ia given in Pig. 4.7.
This plasma showed a 'pre-S.A.* response, for a seeond aggregation
interrupted the disaggregation phase which followed the P.A. response
to 1 ADP. But this further aggregation faded away without reaching
a near maximal extent (S.A. was produced by the ADP addition).
Thus the S.A. process sometimes affects the aggregation in a plasma
at the ADP addition before S.A. occurs.
Pig. 4.8 shows the S.A. process in a plasma where the higher
dose of 3jM ADP was required to induce secondary aggregation. The
process was less marked in this plasma, but still produced more
aggregation than 10 yM ADP added to a plasma showing only the P.A.
response. Again the aggregates persisted for 10 mins without
disaggregating. This less active S.A. reaction was not strong enough
to reverse an established disaggregation process, though there was a
small ♦bump* in the tracings of some plasma where P.A. joined S.A.
This type of S.A. tracing will be called 'non-phasic*.
The ADP addition required to induce S.A. in twenty plasma was
correlated with the type of S.A. tracing which resulted. Eleven plasma
allowed a 'biphasic* response and in these the ADP addition inducing S.A.
was 1.5 jM or les3. line plasma showed the 'non-phasic' response, in
eight 2 pK ADP or more was required to induce S.A. and in one 1.ADP
was sufficient. The correlation between biphasic S.A. and an inducing
ADP addition of 1.5 or less, and non-phasic S.A. and an inducing ADP
dose of 2yuM or more, was significant at the 1^ level (Fisher's d test).
There was a sub-division of non-phasic S.A. which became very
interesting when the mechanism of S.A, was investigated (next chapter).
In a few plasma the increased aggregation response of S.A. levelled out
(Fig. 4.9) instead of continuing, as it had in the other plasma. Ho




Dose response curve to ADP of a FRP which showed 'level' non-phasic S.A.
to 3pM ADP.
0.5 and ] .0 pM ADP induced a P.A. response and 2y$*[ ADP induced quite
marked aggregation and there was very little disaggregation. 3pM ADP
was followed by a marked aggregation response which became level and
continued for 3 mins with no disaggregation. 5pM ADP was also followed
by aggregation which became level (cf continuing aggregation of biphasio
and other non-phasic S.A.). lOpM produced a small further increase in
aggregation.
This type of tracing was called 'level' S.A.
Quantifying Syoondayy Aggregation*
S.A. can be separated on the appearance of the tracings into
biphasio, non-phasic, and level. To increase further the power of
discrimination between plasma, the dose of ADP necessary to induce S.A.
was used as a measure of S.A. activity. The fully developed S.A. process
was used as the end point, and was defined as a 'continuing aggregation,
lasting for at least 3 mins, which reached GOfi or more of that occurring
with 10 jM ADP'. This point will be called the 'S.A. point'.
The scale of ADP concentrations used to determine the S.A. point
vas: 0.25}$, 0.5}$, 0.75}$, 1}$, 1.5}$, 2}iM, 3}iM, 4}iH, 5jM, 7.5}$ and
10>$.
Microscopy of specimens after 5tiA.
Specimens removed from plasma which had undergone S.A. showed
the following features:-
1. Less than 25,000 single platelets/cu.ram. (many of which were deformed).
2. Very few aggregates in the 2 platelets to HPF range.
3. Many aggregates sized i-2 HP?, all of which showed marked adhesion.
After biphasio S.A. the number of single platelets was usually
<1 Oth/cu.mm. Also the aggregate size and the degree of 'marked' adhesion
in the aggregates was greater than after non-phasis S.A. Microscopy of
S.A. aggregates which had been stirred for one hour showed no break-up of
the aggregates, but their edges had become ragged. There was a marked
increase in the amount of platelet 'debris' (which probably accounts for
the small increase which occurred in the density of the plasma).
Summary of secondary aggregation (5.A.)
1. In most plasma from man a second wave of aggregation occurred during
an ADP dose-response curve. This has been called 'secondary'
aggregation (S.A.).
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On the appearance of the tracings S.A. was divided into:
(i) Biphasic: S.A. interrupted the disaggregation which
followed P.A. (correlated with an inducing ADP concentration
of 1.5 ADP or less).
(ii) Non-phasic: S.A. was unable to interrupt established
disaggregation (correlated with an ADP addition of 2 ^if? ADP
or more).
(iii) Level: Son-phasic S.A. where the aggregation reached a steady-
state of less than maximal degree
The presence of the S.A. response in a plasma resulted in:-
(i) Maximal or near maximal aggregation of the platelets in a plasma,
to ADP additions which would otherwise have only a small P.A.
response (through biphasic S.A.) or a moderate P.A. response
(through non-phasic S.A.).
(ii) The aggregation of nearly all the platelets into large, very
persistent aggregates with marked inter-platelet adhesion (in
contrast to the mainly transient aggregates formed during P.A.).
The accuracy of the measurement of S.A. was increased beyond the
separation of the three types of tracing by determining the lowest
ADP addition which induced S.A. (s.A. point (ADP)). Eleven dose
levels of ADP in the range 0.25 - 10 uM were used.
42










































































0.5 0.75 1.0 1.5 2 3 4 5 7.5
S.A. point ADP jjM/L (Log.)
10
The ADP-like aggregating activity (pM/L) present in plasma after S.A.
The aggregating activity (log) has been plotted against the S.A. point
log £adPJ pM. The diagonal line shows the concentration of the added
ADP pM/L.
0= normal S.A. □ = level S.A. ©= S.A. absent
*
CHAPTER FIVE
?HE qagimsfl OF sijcoHiW AoqffljftffW
iropugatoH
In the previous chapter the presence of 3.A. in some human
plasma was described. The next stage was to try and find out why
S.A. occurred. Two primary factors were possible* an increased
aggregating response of the platelets, and an increase in the aggregation
stimulus in the plasma. As platelets are known to release ADF when
stimulated by thrombin and collagen, an increase in aggregating activity
in the plasma due to platelets releasing endogenous ADP was the most
likely mechanism. Several secondary affects could however be occurring,
such as the plasma affecting a platelet's ability to undergo S.A., or
there could be a combination of mechanisms which varied in their
importance.
EXAMINATION FOR aGGKSGATIKG ACTIVITY IK PLASMA AFTER S.A.
1 • ADP-iike aggregating activity present after S.A. had occurred.
Plan of study. The supernatant of plasma which had been induced to
undergo S.A. was examined for ADF-like aggregating activity (see
methods). After addition of the S.A. point ADP concentration the
plasma was stirred for 3 mins to allow S.A. to occur, ther the
supernatant was examined.
Results Fig. 5.t. (32 subjects).
The total ADP-like activity jti-i/h in the supernatant has been
plotted against the S.A. point ADP concentration. The diagonal broken
line shows the amount of ADP added (this is an over-estimate as some of
the added ADF will have been metabolised by the time the supernatant
was examined).
All the plasma showing S.A. contained an excess of ADP-like
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Table 5-1. Comparison of the total aggregating activity present after













(1) 0.5 2.8 3.2 None
(2) 1.0 8.1 9.3 None
(3) 2.0 5.1 h.9 0.2
00 2.0 (level) 3.2 2.9 0.3
(5) 2.0 (level) 2.5 2.7 None
(6) h.o h.9 5.3 None
aggregating activity over the original ADP addition. The three plasma
which showed only P.A. showed a decrease compared with the ADP addition.
Thus S.A. and an excess of ADP-like activity in the plasma were
correlated. (Wilcoxon stun of ranks, p^ 0.002).
The size of this excess of ADP-like activity varied through wide
limits from 1yM Plasma with an S.A. point of 1#5pM ADP
or less had a higher excess than plasma with an S.A. point of 2jiM ADP
or more (Wilcoxon, p./0.01). Five plasma with the 'level* type of
S.A. were tested (narkedQ Fig.5.1.). The release of ADP-like
activity in these plasma was low.
These findings were reported in outline in 1966 (Maorillan, 106)
and in 1968 Mills et al confirmed the presence of an ADP release using
a specific biochemical method (116).
2. Comparison of total and ADP-like aggregating activity present after S.A.
Platelets are known to release substances other than adenine
nucleotides and among these are other platelet aggregating agents,
the catechol amines and 5H-T (116, 196). In addition to producing
aggregation these latter substances are also capable of a synergistic
action with ADP (139, 117).
Present study. Supernatant from plasma which had undergone S.A. was
tested for both ADP-like activity (i.e. with the inhibitors heparin
and phentolamine present) and for total aggregating activity
(i.e. no inhibitors).
Results. Table 5.1. (six subjects).
The total aggregating activity was slightly greater than the
ADP-like aggregating activity in two subjects and slightly less in four.
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The group contains biphacic 8.A. plasma (two), aon-phasie S.A. (two)
and level S.A. (two).
Comments. The total aggregating activity released during S.A. was no
greater than the ADP-like activity release in six plasma which
included all types of 3.A.
3. neceaaary for the release of AP'-lihe agjivlty,
The release of ADP and S.A. have been associated in the preceding
work. To see if the release and S.A. could be separated the following
combinations were tested for ADP-like activity.
1. PEP + S.A. point (jDp) - stirred for 3 rains (3.A.).
2. FRP + S.A. point Quip) - mixed and incubated for 3 rains.
3. PRP + S.A. point (ADP) - stirred for 3 rains.
Six experiments were performed using biphasic S.A. plasma and
they gave similar results.
Results. A marked release of aggregating activity occurred only
when PRP was stirred after the addition of ADP. ADP and no stirring
produced no release or only a small one. In stirred platelet poor
plasma a decrease in activity occurred.
Comment. Stirring was necessary for a marked release of ADP at
4 4
the S.A. point ADP concentration.
4. ffie timing of the release of ADP-like activity.
The ADP-like activity present in plasma which was undergoing
S.A. was measured at four points during it's development; at the
top of the rise, and at 30., fall, at 60* fall and at near tOO« fall
of the tracing.
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Table 5.2. Timing of the release of ADP-like activity during S.A.
ADP-like aggregating activity
(arbitary units)
(1) (2) '(3) (U) (5) (8) Mean
Change from
preceeding column
(1) Top of rise 2 6 3 2 0 0 2.2
(2) Fall of 30% 6 16 20 16 5 h 11.2 Increase-*
(3) Fall of 60% 21 38 31 35 Hi 2k 27.2 Increase-*
(It) 2-|- mins
(near 100$)
25 33 33 ' 37 13 27 28.0 N.S.
Results. Table 5.2 (Six subjects). The units are arbitary.
There was only a low ADP-like activity at the top of the rise,
probably due to the added ADP. The increase in activity was marked
at the 30/c fall point (p <0.05) and showed a further definite increase
over this at the 60^ fall point (p<< 0.05). Little or no further
increase in activity occurred between 60$ fall and near 100^' fall.
Sumarv. In six plasma the release of ADP-like activity occurred
during the first 60?i of the fall of the tracing.
5. ADP-like activity in supernatant from the nre-S.A. point specimen.
In some plasma the early stages of S.A. can be detected in
the tracing as impaired disaggregation occurring at ADP doses which
were less than the S.A. point ADP concentration (see Chapter Pour).
In these pre-S.A. specimens there was sometimes a small increase in
ADP-like aggregating activity in the supernatant above the added
ADP concentration.
THE EFFECT OF THE PLASMA OR THE S.A. POINT
The best way to try and answer this question is to separate
platelets, wash off as much of their plasma coating as possible, and then
resuspend them in another plasma. Unfortunately this is not possible
because such a separation can only be performed with EDTA plasma and
EDTA prevents the S.A. response (see Chapter Seven, Expt. 3). Only a
partial answer therefore is possible.
Present Study. PRP was diluted by 33/ with it's own (parent) PPP and
the S.A. point was measured. This was compared with the S.A. point of
the same PRP similarly diluted with PPP from a separate plasma with a
differing S.A. point. Further dilutions would have lowered the S.A.
point too much for the test. Both mixtures were incubated at 37°C for
20 miww before testing, to permit an interchange of constituents between
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Table 5«3. Effect on S.A. point of a plasma of incubating it with a
foreign platelet poor plasma
Subject
S.A. point (ADPpM)
(1) (2) (3) (k) (5) (6)
(1) Subject PRP + own PPP
SA point of 'foreign PRP
(2) Subject PRP + fereignNPPP
0.5 1.5 2.0 2.5 b.o 7.5
7.5 5.0 Nil 1.0 1.0 1.0
0.5 1.75 2.5 2.5 k.o 7.5
Difference (1) and (2) None 0.25 0.5 None None None
the platelets and plasma.
Results. Tablet 5.3 (Six subjects)
The difference between the S.A. points of the parent PRP and
the •foreign* PRP was wide in four experiments (Expts. 1,2,3,6). The
S.A. point in these four was unaffected by the interchange in two
experiments, and minimally affeeted in the other two (Expts. 2,3)* When
the S.A. points of the plasma involved was closer (Expts. 4»5)» there was
no difference.
Comment. 33% dilution of a PRP with PPP from a separate PRP with a
differing S.A. point had little or no effeot on the S.A. point.
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A D P - LIKE AGGREGATING ACTIVITY PRESENT AFTER S.A.
>
.5 0.75 1.0 1.5 2 3 4 5 7.5 10
S.A. point ADP mil ( Log.)
Fig. 5.4.
The ADP-like aggregating activity (pM) present in plasma after S.A.
Tlpis figure is a repeat of Fig. 5*1. with horizontal lines at the lOpM
and supernatant aggregating activity levels. Of the 29 subjects
showing S.A. the ADP-like aggregating activity in the supernatant was
^IOjjM in 26 and in IX.
In the introduction to this chapter the theoretical poasibilitioe
of a change in platelet responsiveness or the presence of a release of
aggregating activity were stated. A release of ADP has been detected,
and It was also found that the total release of aggregating activity and
ADP-like activity were equal. The results of Chapter rtour showed that
3,A, produced a greater aggregation response and failure to disaggregate
(even whan non-phasic) than tOpK AD? added to P.A*—only plasm* Yet a
closer look at the amount of aggregating activity released (Pig. 5.4.)
shows that the activity present in idle supernatant of twsnty-eix of the
twenty-nine plasma showing S.A. was</10pM and it was,/ 5.5}M in eleven
Of the twenty-sevem.
Thus it must be assumed that the platelets are more reactive to
the available aggregating activity during S.A. than they are during P.A.
This is particularly so in the plasma showing level S.A., in idiom the
release of aggregating activity was particularly small.
An increased aggregation response can be due to either an absolute
increase in aggregation, or to a decrease in disaggregation. The relative
importance of these two mechanises cannot be deduced from the present
series of experiments. However it is worthy of note that the tracings
and microscopy show a marked failure to disaggregate.
The only small increase in aggregating activity in some of the
plasma undergoing full S.A. suggests that possibly only a part of the
aggregating activity released into the plasma is essential for 3*1, If
this is so than, an increase in platelet responsiveness would be a major
factor in S.A., with it's importance masked by the large size of the
release of ADP in most S.A. plasma.
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Fig.5.3 Effectoftransferringup rnatantfromaggregatedbiphasicS.A.plasmatomorebiphasicS A.pl sma S.A.plasmawasinducedtondergoS A.byitS.A.pointADP concentration(1.5jJM)andbiphasictr c ngo curred(left specimen);0.25misofsupernatantw strans erred(1:5ilution)toafur heraliquotft eplasma,whereinducedanS.A.responsewithP.A.a dS. .fus d.fterthisS.A.hadoccurredfurth rtransfers(1:25,125ofo iginal1.5pMaddition)weremade.Theseagainpr ducedS.A.Achain reactionofmaximalaggreg tiona dADPreleasew soccurring.
AGGREGATION CHAIN REAOTIOIi IHDU RID BY S.A.
There is available after S.A. endogenous platelet ADP free in
the plasma which theoretically could induce further PRP to undergo S.A.,
with yet further release of endogenous ADP. If such a continuing
reaction occurred it could initiate a chain reaction of aggregation.
This possibility was tested experimentally.
Present study. Plasma showing the P.A.-only response, and other plasma
showing biphasic S.A. were used. The pharmacological dose of 100 ADP
was added to the P.A.-only plasma, and the much lower S.A. point (ADP) to
the S.A. plasma. After aggregation had occurred one quarter of the
supernatant (0,25 mis) was added to a further 1 ml. of the same plasma
(this is equivalent to 20$ of the released and added ADP). After the
aggregation this produced in the second plasma specimen had occurred,
the transfer, and so the dilution, was repeated, by adding 0.25 mis. of
the supernatant to a further fresh sample of the same plasma.
Results;
1. P.A.-onlv plasma. Pig. 5.2. 100juH ADP was added to the plasm,
and after aggregation had occurred the transfer described above (20, of
original addition) was performed. The plasma sample showed a slightly
reduced aggregation response. The next transfer (4$ of the original lOOyM
addition) was followed by a marked reduction in the aggregation. The
third transfer (<^of the original addition) was followed by only a
minimal aggregation response. This loss of aggregation response was
that which would be expected from the dilution produced by the transfer.
2. S.A. plasma. Pig. 5.3. shows the result u:=ing a plasma with
an S.A. point of 1 .5>juM ADP. The addition of 1.5pM (i.e. only 1.5 percent
of the do3e used in the P.A.-only plasma experlaent above) was followed by
a biphasic S.A. tracing. The same transfers, and so dilutions of the
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added dose, were made. In contrast to the P.A.-only plasma the S.A.
plasma showed an S.A, response with each transfer. Thus S.A. was
producing a release of more than four times the ADP needed to initiate
S.A. in a further aliquot of the same plasma. Thus an aggregation
chain-reaction was occurring.
The transfers could be continued until the store of plasma
was exhausted, and eight to ten transfers were performed on other
biphasic S.A. plasma without any break in the chain-reaction. Also,
using plasma showing very active S.A., transfer of as little as 0.1 ml.
(i.e. only 10> of supernatant) from a post-3.A. specimen was sufficient
to initiate, and support, the aggregation chain reaction.
In contrast to biphasic S.A. plasma, non-phasic S.A. plasma
supernatant failed to initiate or support an aggregation chain reaction,
with the unusual exception of some of the non-phasio S.A. plasma with an
S.A. point of 1.5juM.
Quantitation of the aggregation ohain-reaction potential of S.A.
The preceding experiment showed that the theoretical possibility
that the S.A. process could result in an aggregation chain reaction was
oorreot. The biphasic S.A. plasma nearly always gave the chain-reaction
when only 20 of the aggregating activity after S.A. was transferred (in
some biphasic S.A. plasma it occurred with the transfer of <(10, of the
aggregating activity), whereas only a few of the plasma which showed a
non-phasic S.A. tracing gave an aggregation chain-reaction with the 20
transfer.
The aggregation chain-reaction potential of the S.A. in a
particular plasma, can be considered from the alternative viewpoint of
how many further units of plasma could be induced to undergo S.A. by the
released aggregating activity. If 20, of the aggregating activity
present after S.A. induces one further specimen of plasm to undergo S.A.,








Chainreaction potentialfoneu t ((2)/(3)) Firstcycle= Secondcycle= Thirdcycle=
37.1+ll li7 3b 9 1,370532k 1,000,0006,92,8577
1.950 1 211 610
of inducing at least five further units of the same plasma to undergo 3.A.
(i.e. 1 00p/2Q»)} the aggregating activity released by S.A. in each of these
five units could each induce five more units of plasma to undergo S.A.
2
(i.e. 5 or 25) and after the next cycle of S.A. there would be enough
2
aggregating activity present to produce S.A. in 25 i.e. 625 units.
The chain-reaction potential of an S.A. plasma can be exactly
calculated, by dividing the aggregating activity release released during
S.A. by the S.A. point of the plasma. The results of thi3 calculation,
using the fi aires for release of aggregating activity and S.A. point
reported at the beginning of this chapter (Fig. 5.1), are given in
Table 5.4. To emphasis® the effects of the geometric scale of increase
which occurs during a chain-reaction, the effects of the second and third
cycles of such a reaction are given.
A plasma with an S.A. point of 0.25iuM/L ASP and a release
produoing 9.25pft/L ADP-like activity had the aggregation chain-reaction
potential to induce S.A. in 37 further units of plasma in tho first cycle,
1370 units in the second cycle, and greater than one million unit3 in the
third. In this plasma the potential is obviously enormous. The chain-
reaction potential of three cycles of reaction reduces rapidly as th® S.A.
point ADP concentration rises, being 16,900 for 0.75 S.A. point, 2,800 for
1.0, 577 for 1.5, and then falling to the low level of 6 for the S.A.
point of 2fM ADP.
Although the level of released ADP-like activity falls as the
S.A. activity of the plasma decreases, it is still, at the 2j.ilA/L ADP S.A.
point, 30/ of the release occurring at the 0.25)uM/L ADP S.A. point. But
during the 3eme period, the aggregation chain-reaction potential has fallen
to 0.01?o of it's value at the 0.25)uM/L ADP S.A. point. Thus the major
determinant factor of the chain-reaction potential is the S.A. point ADP
concentration.
These calculations have shown the crucial importance of
relatively small changes in the S.A. point A1)P concentration. In
the S.A. point range 0.25^M-1 *5jM/L ADP a fast reducing, but important,
chain-reaction potential was present, whereas S.A. points of 2^M ADP/L
and above were associated with minimal potential for a chain-reaction.
This point is underlined when one calculates that the increase in
S.A. point activity from 2pH to 0.25pM ADP was associated with
a one hundred thousand times increase in aggregation chain-reaction
potential.
To emphasis© this rapid increase in chain-reaction potential,
for only a 3mall decrease in the ADP concentration required for S.A.
two new terms for describing the S.A. process will be used in the
remaining parts of the thesis. The S.A. in a plasma with an S.A. point
of 0,25 to 1«5uM ADP/L will be called Chain-Reactive S.A.. to stress
it's marked ability to induce S.A. in a further sample of the same
population of platelets. In plasma with an S.A. point of ^uH or more,
the S.A. will be termed Self-limiting S.A.. to stress it*s relative
inability to induce further platelets to undergo S.A. This division








(1) Reversible aggregation (P.A.)
(2) Increased and persisting aggregation
(3) Release of platelet ADP stores l = s
Fig. 5.5.
Diagram to show how the responses of platelets to ADP during
secondary aggregation become self-perpetuating.
SPMMARY OF CHAPTER FIVE
1. During S.A., aggregating activity van released by the platelets
into the plasma. This activity behaved as though it was entirely due to
ADP.
2. The platelets responsiveness to ADP was increased during S.A.
and such a change could be an important part of the S.A. response.
3. The combination of a release of ADP with an increased
responsiveness to ADP is sufficient to explain the S.A. process. Thus
the ability of ADP to induce S.A. was due to the platelets showing a
triple response as compared to the single one (aggregation) which they
show during P.A. A self-propagating aggregation process resulted
(Fig. 5.5). The added ADP was acting as a trigger, but S.A. soon
became self-sufficient.
4. Due to the release of ADP, some S.A. had the ability to initiate
a powerful aggregation chain-reaction, an ability which correlated closely
with the presence of a biphasic tracing. It correlated even more closely
with an S.A. point of 1.5 ytt/L ADP or leas and such plasma have been
called * chain-reactive * S.A. plasma.
5. The factor which determined the magnitude of the chain-reaction
potential, was the S.A. point ADP concentration. The potential of three
cycles was very large for an S.A. point of 0.25pH and 100,000 times less
for an S.A. point of 2 ADP. The rapid fall in aggregation chain-
reaction potential for only relatively small changes in S.A. point ADP
concentration over the range 0.25uM to 2uH ADP has been stressed.
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CHATTER SIX
EFFECT OF 5.A. OH THUOMBIK. ADRKNAL1K9 AND COLLa(Fff INDUCED AGGftfiCATION
IKEaODUCTIOK
The S.A. reaction has been studied so far by adding exogenous
ATP. In vivo one would expect the ADP released from injured tissues and.
damaged red cello to have the same effect as that of exogenous ADP, as it
is exogenous to the platelet oell.
A further important source of ADP is the release by the platelets
of their rich storescf ADP. This release is induced by thrombin,
adrenaline, collagen and 5H.T. (see Chapter 1). Since the platelets will
have entered an altered state when they -undergo the release reaction, it
i3 important to find out whether or not this endogenous platelet ADP will
induce 3.A* in these altered platelets.
There are practical difficulties in attempting to show this.
Since thrombin and collagen release ADP as part of their direct effect,
ADP release is not, as in ADP induced S.A., a marker of S.A. The search
for S.A. during the aggregation produced by these substances had therefore
to be based on the appearance of the aggregation tracings. A search
was made for an abrupt increase to a near maximal aggregation response at
a lower than expected doss of aggregating agent. In order to increase
the ease of finding any such change, plasma showing the marked S.A.
response of biphasic S.A. were compared with plasma which showed only
P.A. A direct correlation between 3.A. to ADP and the second phase of
adrenaline induced aggregation has already been reported (wacmillan 1966)




Fig6.1. Thrombininducedplat letaggr gation LeftPjasmashowingonlyP.A.withADP.T r mbin( )R ght induced,aggr gationaftershortel y.T e aggregationincreasedndegr ew ththrombin concentrationsfupt0.6un t .Thiwas followedbydisaggregationuntilthepo twhere fibrinformation(F)preventedfu h robservation.Theresponsei imilartPAADP.
T
I
Plasmashowingbip asicS.A.withADP.T r mbin(T) induceda'P.A.'responseat0 1unitsa dinit ally at0.2units.Thena^bip asictr ci gwithecondary aggregationoccurred.0.3'unitsind cedfus nof P.A.andS. .Itwasinterruptedbyfibrinfo mation. Thefinalext ntofaggrega ionwasmoderatelyinc ed
bytheS.A.ascomparedth tintP.A.-onlylasma.
(expected'primary'thrombinaggr gation).
THE SEARCH FOR S.A. TRACINGS DURING THROMBIN. COLLAGEN. AHP ADRENALINS
/^GREG^ON.
First, plasma which showed P.A. only and biphasie S.A. were
compared, and then, plasma w'nich showed non-phasic S.A. were examined.
Thrombin
Previous work. Thrombin is an active platelet aggregating agent which
exerts it's full action over a smaller range of concentration than ADP
(139). At the higher thrombin concentrations fibrin forms and prevents
further observation. Thomas (177) has demonstrated a biphasic response
to thrombin in some human plasma.
Present study.
1. Plasma showing P.A.-only to ADP (Fig. 6.1. left).
In these plas a increasing concentrations of thrombin
produced a gradually increasing aggregation response.
This was followed by a decreasing, but always present,
disaggregation. At higher thrombin concentrations
fibrin formed, initially during the disaggregation phase,
and then during the aggregation phase.
The thrombin concentration required to produce the most
marked aggregation effect was 0,45 to 0.7 units.
The ADP-like aggregating activity released by the stage
of marked aggregation was measured in three plasma.
It was 4.8; 5.2; and 6.0uM.
/
2. Plasma showing StAT to ADP (fig, 6f1 right).
In biphasic S.A. plasma, a biphasic aggregation tracing
occurred with thrombin (see Fig.6.1 ri^it 0.2 units).
The second aggregation phase had an identical appearance
to the S.A. tracing induced by ADP i.e. it rapidly
resulted in marked aggregation with no subsequent
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disaggregation. Thus an abrupt increase in aggregation
had occurred (cf Fig. 6.1 left) with a biphasic tracing.
The lowest thrombin dose inducing the S.A. response in
this series was 0.01 units i.e only 2.5$ of the thrombin
concentration producing a lesser aggregation in P.A.—only
plasma. In plasma with non-phasic S.A. an abrupt
increase in aggregation occurred but a biphasic tracing
was rare. This aggregation also proceeded to a maximal
aggregation with no subsequent disaggregation in 10 mins.
Thrombin concentrations of 0.15 to 0.4 u were required.
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Fig6.2. Collageninduc dplat letag r gation. LeftPlasmashowingonlyP.A.tADP.teraRight latentperiodof30-90secasl whapec ngeoccurr d^ Collagen( )75to200unitsproducedslight aggregation,and500u itsp oducedmo erate aggregation.
Plasmashowingbip asicS.A.tADP.Collagen10un ts producedashapec nge.15u itswaf llow dbyn ar maximalaggregation.Thisappe redmoapi ly,but increasedonlybylittlextentwithcollagen20and 100units.Ihadnppearancesimilartohebi h sic S.A.tracingoADP;resuitedinmarkedin rease aggregationoverth tf500uni sithl tandplasma.
(expected'primary'collagenaggregation)
Colleen
Previous work. The aggregation produced by collagen occurs after a
latent period, is of slower speed than with other aggregating agents,
and is not followed by disaggregation (TO, 124).
Present study.
'• Plasma showing only P.A. to ADP (jig. 6.2 left).
The previous findings were confirmed. There was a latent
period of 30-90 sees followed by a slow aggregation process
and no disaggregation. The extent of the aggregation was
only moderate for 500 units (top of an arbitrary range).
2. Plasma showing S.A. to ADP (Fig. 6.2. right).
In plasma showing a biphasic S.A. response small doses
of collagen produced a minimal aggregation (10 units
Pig. 6.2. right). A small further increase in collagen
dose (15 units) produced an abrupt increase in aggregation
to near maximal, which had the S.A. tracing appearance.
It thus fulfils the criteria for an S.A. response. S.A.
produced a marked increase in the maximum degree of
aggregation possible to collagen because ♦primary* collagen
aggregation is only moderate in extent at it*s maximum.
The lowest concentration of collagen which was followed by
S.A. was half of one unit i.e. only 0.1$ of the collagen


























Adrenaline induced platelet aggregation
Top: Plasma showing only P.A. to ADP; After a latent period of
about 15 seconds the oscillations decreased and the tracing fell
slightly. Then aggregation levelled out and remained steady. There
was only a little difference between the effects of adrenaline
1/uM and lOOpM. This is the adrenaline first phase of aggregation.
Bottom: Plasma showing chain-reactive S.A. to ADP: Adrenaline O.UpM
induced a first phase. An increase of adrenaline to 0.75>pM
induced, in addition to the first phase, a second aggregation
which was marked and continued until aggregation was near
maximal. This is the adrenaline second phase and it is similar
in appearance to S.A. to ADP. Adrenaline lOOpM increased the -
speed of' onset but not the extent of the secondary aggregation.
The second phase allowed a very marked increase in the aggregation
response over the first phase response (.... Expected 'primary'
adrenaline aggregation).
Adrenaline.
Previous work. 0' Jirion (123) has shown that adrenaline and
noradrenaline induce platelet aggregation in two phases. The first
is snail, and the platelets aggregate without losing their in vivo
disk shape. APP is probably not involved (69, 106). The second
phase produces a maximal response. O'Brien found that it was absent
in some of the plasma he was examining (123, 124, 125).
Present study.
1. fllapma showing P.At^only to A?P (fig. 6,?, top).
These plasma showed only the first phase of adrenaline
aggregation. After a short latent period there was a
small fall in the tracing and oscillations were preserved.
APP—like aggregating activity was tested for, but none was
detected. There was no spontaneous disaggregation but
complete disaggregation was produced by the preceptor blocker
phen tola-nine (Kacsillan 106).
2. Plasm showing 3.A. to APP (Fig. 6.3. bottom).
In these plasma the first phase was interrupted by a rapid
maximal aggregation (see 0.75 pM)» the O'Brien second phase.
The tracing was identical to the tracing of a biphasic S.A.
response to APP. This maximal response was obtained in all
plasma showing S.A. with APP. The adrenaline concentration
inducing S.A. varied from 0.005 to 100^pM.
APP-like activity was detected at an early stage of the second
phase and increased in concentration during the phase until it
was comparable to, or exceeded, the concentration produced by
S.A. to APP.
The increase in aggregation allowed by S.A. was very marked,
and marked aggregation only occurred when S.A. was present.
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Table 6.1. S.A. point dose to ADP, thrombin, adrenaline, and collagen
in plasma from 25 subjects7
S.A. point concentration
Subject Platelet
count ADP THR Adrenaline Collagen
(103/cu mm) pH/L units pM/L units
1* 785 0.25 .15 .005 2
2* Uio 0.5 .05 .1 1
3* 350 0.5 .05 .05 1
U* 570 o.5 .01 .5 0.5
5* 280 o.5 .05 .25 l
6* 560 0.75 .125 .05 20
7 210 0.75 .20 .75 15
8* 255 0.75 .225 .5 25
9* 355 1.0 .075 .2 10
10 320 1.0 .15 .1 25
li 555 1.5 .225 1.0 20
12* 195 1.5 .225 3.0 15
13 520 2.5 .15 .5 7.5
1U 305 3.o .25 .5 15
15 250 3.0 .225 .75 20
16*
'
275 3.0 .225 7.5 75
17 520 5.0 .225 1.5 15
18 275 5.0 .20 100 20
19 360 5.0 .20 5.0 30
20 310 8.0 .55 3.0 60
21 380 10 F 0.5 100 500
22* 530 10 F 0.5 100 5oo
23 560 10 F 0.6 .100 5oo
2i|* 260 10 F 0.5 100 250
25 580 10 F 0.5 100 250
F = fibrin formed before S.A. occurred
THR = thrombin * selected patients
Analysis by Friedmans Test 1937
IT
Ql'AN^ATIVE CORRELATION BETWEEN THE S.A. TRACINGS INDUCED 3Y ADP.
THROMBIN AND COLLAGEN IN TIE SAME SUBJECT.
Previous work. None.
Present study.
Plan of study. Each plasma was tested with ADP, thrombin, collagen
and adrenaline to determine the S.A. point, if any, to each. The plasma
were taken from patients (selected for high S.A.) and from volunteers,
and consisted of 12 with a chain-reactive S.A. response to ADP, 8 with
self-limiting S.A. and 5 with only a P.A. response. The four dose
response curves could not always be completed in the 30-90 minute period
after venepuncture when the S.A. point to ADP is stable (see Chapter 7),
and, to allow for this, the order in which the different aggregating
agents were added was randomised.
Results. Table 6.1.
The results have been tabulated vising the S.A. point to ADP as the marker.
The platelet counts show no significant difference between the S.A. and
P.A.-only plasma.
The results showed an absolute correlation between absence of S.A. to
ADP and absence of an S.A. tracing to thrombin, adrenaline and collagen,
in the five plasma tested. Examination of the other results suggested
that the S.A. point doses of the four aggregating agents in any one
plasma were comparable. Kriedman's correlation test was applied and
a very highly significant correlation was found {/) =<0.001).
A correlation was also found within the upper ten S.A. plasma group and
the lower ten S.A. plasma group. (j? =<0.01 for S.A. points 0.25-1 .OjM/L
ADP;/' =<0.01 for S.A. points 1.5-IOjaM/L ADP).
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ADP Thrombin Adrenaline Collagen
Subject 1 6.0 (2) 13.8 (1) 5.9 (3) h.9 00
it 2 U.75(3) 6.25(2) 7.25(1) 2.5 (U)
if 3 17.5 (1) 12.0 (2) 9.0 (3) 7.5 (h)
if k 7.8 (2) 8.1 (1) 7.5 (3) 6.U (i;)
Friedmans correlation testj-
2
aggregating agent to release X = 8 .li*
2
subject to release X = 6.3 (N.S.)
0
The figure in brackets is the ranking order for the release-inducing
power of each aggregating agent.
Release of ADF-like activity during 3.A, to different aggregating: agents.
ffo preyious york.
Present study. Plasma from four subjects was induced to undergo S.A.
by adding ADP, thrombin, adrenaline and collagen. The release of
ADB-like activity at the S.A. point of each aggregating agent was
measured.
Results. Table 6fi2.
There was a wide variation in the degree of release from the four
subjects and the four aggregating agents, but there was some order
in this. A correlation (j? =<^0.05) existed between the degree of
release induced and the aggregating agent, with thrombin most effective,
ADP next, then adrenaline and least effective collagen. The correlation
between each subject and the degree of release achieved (on only four
subjects) was nearly significant ( <^0.10^ 0.05).
S.A. to thrombin, collagen, adrenaline and the initiation of an
aggregation chain-reaction.
In chain-reactive S.A. plasma the supernatant from specimens induced
to undergo S.A. by these three substances initiated the aggregation
chain-reaction. In self-limiting S.A. plasma the chain-reaction
nearly always oeased after the first cycle, presumably because of
dilution of the originally added thrombin, collagen and adrenaline,
which is, unlike the ADP, not self-generating.
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Fig. 6 .k • Pathways -which can initiate S.A.
SUMMARY OF CHAPTSR SIX
1. S.A. was looked for and detected during the aggregation induced
by adrenaline, thrombin and collagen.
2. Only those plasma shoving S.A. to exogenous ADP showed this
response to the endogenous ADF release induced by thrombin and collagen.
3. Through the action of the S.A, process the aggregation response
was increased and more persistent aggregates were formed. This increased
aggregation occurred, as with the S.A. to ADP, to lower doses of these
aggregating agents (often very much lower) than were necessary for a
marked •primary' response. Also, the absolute degree of aggregation
was increased to inverse proportion to the size of the 'primary* reaponse,
i.e. a little for thrombin, moderately for collagen and markedly for
adrenaline.
4. There was a cross-correlation bet-ween the doses of ADP,
adrenaline, thrombin and collagen required for S.A. in an individual
plasma. Thus any of the four may be used for measuring the S.A.
activity of a plasma.
5. In chain-reactive S.A. plasma, thrombin, collagen and adrenaline
initiated the aggregation chain-reaction. This indicates that the
pathways leading to this chain-reaction includes these substances.
Pig. 6.4 shows all the pathways.
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CHAPTER SEVEN
THE EFFECT OH ADP INDUCE!) AGGRGATION OF VARYIHQ THE EXPERIMENTAL
CONDITIONS AND EE TIME OP TAKING SAMPLES.
INT^OpDC^ON,
Platelet function is known to be affected markedly by
differences of experimental techniques, such as anticoagulant and
temperature (Hellem 72 and reviews 100, 61), but in this previous
work total aggregation has been studied, without the separation of
P.A. from 3.A. It was therefore necessary to repeat, with reference
to S.A., much of the work previously performed on total aggregation.
Since these experiments were performed other workers have reported
results relating to some of them and these will be detailed with the
relevant experiments. In most of the experiments the results
obtained for P.A. are given, as well as those for S.A., to help in
comparisons with previous work. As well as enabling the construction
of a reliable technique for estimating S.A., many of the experiments
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Table 7.2. The effect of storage at 37°C on S.A. point to ADP
Time after
Venepuncture 1 2 3 u 5 6 7 8 Change
30 mins 0.75 1.5 3.0 3.0 3.0 3.0 7.5 Nil
60 mins 0.75 1.5 U.o 3.0 3.0 U.O 7.5 Nil
90 mins 1.0 1.0 U.o 3.0 U.O 5.0 7.5 Nil
120 mins 1.0 3.0 5.0 3.0 7.5 5.0 10 Nil Decrease*
150 mins 1.0 5.0 10 5.0 10 • 10 10 Nil Decrease*
O.D. PRP 0.i|6 0.33 0.27 0.33 0.U5 0.50 0.38 0.U1
Decreases in activity below the baseline value are
underlined
Analysis by Wilcoxon Signed Ranks Test
Experiment One.
Effects of gtor&gro of cltrated ?iasna at 57°f on P. A. and S.A. to ADP.
Previous work. O'Brien noted that the aggregation response (total) at
37°C decreased with time (137), and other workers agree.
Present study.
1. Primary aggregation. Plast^a from four subjects was stored
at 37°C. Three dose levels of APP were added to each plasma
in a fixed sequence and the sequences were started at the
following times after venepuncture, 30 sins, 45, 60, 75 and 90 mins.
Results. (Table 7.1.). A systematic variation occurred.
The P.A. response rose from the baseline level of 30 rains to
beoome significantly higher (p - <0,002) at 45 and 60 mins.
At 75 rains it was near to baseline levels and at 90 mins had
fallen below the baseline levels (^ = <0,05).
The degree of the increase was small (only 1 to 7/0.
Co- inserts. P.A. should be measured at a fixed time after
venepuncture and between 30 and 75 rains. In survey work
30 to 40 rains was used.
2. Secondary aggregation. Plasma from 8 subjects was stored at
37°C. The S.A. point to ADP was determined 30, 60, 90, 120
and 150 rains after venepuncture.
Results. Table 7.2 shows the results. The baseline values
ranged from an S.A. point of 0,75y&/l> ADP to S.A. absent.
S.A. became less active in two plasma at 60 mins, four at
90 mins and six at 120 mins.
Corranenta. In survey work the S.A. point should be determined
within 90 mins of venepuncture to prevent a storage deterioration
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Experiment Two.
Effect of at.orfop citrated plasma at 4° R.T. (20~24°0) and 37°C on
P.A. and 3.A. tested at 57°0.
Previous work. Dsing rabbit plasma, Constantine (26) found total
aggregation at 37°C increased from 20 to 90 mins when plasma was stored
at R.T. Using the lower test temperature of R.T., Harrison et al (67)
reported a stable aggregation response from human plasma stored at R.T.
Present study. Experiment one has shown a very small increase in P.A.
when plasma was stored and tested at 37°C. In the present experiment
a plasma sample was divided into three parts; one was stored in ice
chips, one in water at R.T. (20-24°C), and one in water at 37.5°C.
Testing was started after 20 mins storage. Specimens were incubated
at 37.5°C for 2 mins before testing to bring them up to the test
temperature.
Reacts Table 7t?.
1. P.A. Storage at R.T. produced an increased aggregation in
six of seven plasma {j> = <(0.05). This increase shoved a
marked variation of from 0 to + 86^. This variation could
not be correlated with the initial level of P.A., or with
the S.A. activity of the plasma. The P.A. value in plasma
stored at 4°C was higher than that in plasma stored at 37°C
in five of seven subjects, but the extent of the increase was
less than after storage at R.T.
2. S.A. The S.A. point ADP concentration after R.T. storage
was equal to that after 37°C storage in two subjects, and
one dose level more active in four subjects (N.S.). The
S.A. points were equal after 37°C and 4°C storage in three
subjects and S.A. was one dose level less active after 4°C
storage in the other three subjects (H.S.).
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Conclusion
1. Storage of plasma at R.T. increased the P.A. response
relative to storage at 37°C. The extent of this increase
varied widely and was unpredictable.
2. S.A. activity was increased by storage at R.T. by one dose
level in the majority of plasma.
3. 4°C storage tended to increase P.A. and decrease S.A.
activity.
4. Storage of plasma at 37°C is preferable to storage at
R.T. or 4°C.
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Effect on platelet shape of three anticoagulants, three plasma
storage temperatures and stirring. "
Plasma from the same blood was anticoagulated with 0.38$ citrate (CIT),
3 mM EDTA, and 10 u/ml heparin (HEP). After storage at 37°C, 22-2i|°C
(RT) and u°C the plasma was warmed to 37°C and stirred. Baseline
oscillations = many disk shaped platelets. No oscillations = mostly
spherical platelets. A fall of the tracing = aggregation.
4
Experiment Three
Effect of different anticoagulants on platelet shape and stability.
and on F.A. and S.A.
1 • Jhaoe. storage temperature, and stirring in heuarinised.
citrated and BDTA plasma.
Previou-s work. Platelets in vivo are disk shaped. It was shown by
Zuekar et al (189) that in citrated at 37°C most platelets
preserve this disk shape. They found that cooling resulted in sphering
of platelets and also produced a few more grotesque shapes. The change
from disk to sphere was complete after 20 ruins at 4°C. Platelets in
heparinised plasma showed the same sequence on cooling, with lees
preservation of disk shape at all stages. In EBTA, sphering was
immediate even at 37 C. The tracings produced, when PRP anticoagulated
in these three ways was stirred, have been described (Macmillan and
Oliver, 1965).
Plan of study. As has been shown earlier in this thesis (and 141» 144)
the stirring of disk shaped platelets produces an oscillating tracing,
and of sphered platelets a steady tracing. Citrated (0.38/),
heparinised (1 Ou/ml) and EDTA (3''*) PRP wore prepared from blood taken
at a single venepuncture. Bach of these plasma was divided into three.
One aliquot was stored at 37°C, and one each at R.T. and 4°C, for 20 to
30 mins. After re-incubation to 37°C. (2 mins in waterbath) the
specimen was stirred.
Results. Three experiments which gave similar results. A photograph
of one of these is shown in Pig. 7.1. Zucker's findings of shape changes
ware confirmed and are dnonstrated graphically. The change in citrated
plasma from disk shape to sphere on cooling (confirmed by microscopy)
was shown by the loss of oscillations in the tracing. The density of
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the plasma rose. Heparinised plasma showed the same sequence.
Microscopy of 37°C heparinised plasrra stirred for 60 sees showed
soma sphering and small aggregate formation. Coinciding with
this was a sli^it riao in the tracing and a small loss of
oscillations. TIany aggregates, again small, were found on
microscopy of the R.f. Heparin specimens. Stirring of 4°C citrate
plasma produced a fall in the tracing and aggregates of up to i HPP
siae were present. In the 4°C haparinised plasma a much greater
fall occurred and aggregates of 2-5HPF siae were present.
In HDTA plasma the platelets were spherical and remained single at
all temperatures. An unexplained reduction in plasma density
occurred at JUT.
Comments,
1. Citrated plasma gave a greater preservation of the in vivo
dish shape of platelets than the other anticoagulants and
this was optimal at 37°C.
2. The disk shaped platelets in citrated plasma were more
stable to stirring than those in heparinised plasma.
3. 37°C citrated plasma was optimal from these two viewpoints.
2. Variation in citrate concentration.
Previous work. Increasing the citrate concentration reduces platelet
aggregation and adding calcium increases the aggregation (121). Studies
of S.A. have not been reported.
Present study. PRP was prepared from blood diluted to 1/20 with 3»Wa
citrate. Immediately before testing 0.9 mis of the PHP was mixed with
(1) 0.1 mis saline => 0.19ij» citrate?
or (2) 0.05 mis 3»8^> citrate + .05 mis saline =* 0.36/fc citrate;
or (3) 0.1 mis 3*8$ citrate = 0.47^ citrate
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Table 7«U* Effect of varying citrate concentration on P.A.
(Citrate])
ADPpM producing 20$ P.A.






0.29 0.21* 0.37 0.37 0.27 0.37
0.68 0.37 1.2 1.3 0.80 1.1
1.1 0.68 1.9 1.8 2.3 3.0
Increase-x-
Increase*
Table 7-5. Effect of varying the citrate concentration on S.A.
CCitrate'J
S.A. point {ADPjjM/l}






l 0.3 3 3 0.73 0.3
3 1.3 10 Nil. 3 1.3




Dose response curves were carried out on all these concentrations,
running1 the testa of each concentration in parallel.
Results.
1. Primary Aggregation. Table 7.4.
Because of the wide range of responses which occurred, there
was no ADP dose level which induced aggregation at all levels of citrate
concentration, without inducing S.A. in some of the 0.19/5 citrate plasma.
An alternative standard, of the ADP concentration producing 20, P.A.,
was used. It was calculated from graphs of aggregation percent versus
ADP concentration. The results showed that P.A., like total aggregation,
was inhibited by citrate.
2. Secondary Aggregation. Table 7.5.
The S.A. activity decreased in all six plasma when the citrate
concentration was increased from 0.19/ to 0.38 «<^0,05). The increase
in concentration to 0.47/5 produced a further decrease in S.A. in four of
the five plasma still showing S.A.
In three subjects (3)» (4)» (5)» there was no S.A. activity
detectable at 0.47 citrate concentration. S.A. activity was detected
in two of these at 0.38/5 and appeared in the third at 0.19/ citrate
concentration. Thus S.A. was uncovered in these subjects by lowering
the citrate concentration.
Comments.
1. The inhibiting effect of citrate on aggregation was confirmed.
2. This inhibition affected both P.A. and S.A.
3. Lowering the citrate concentration uncovered a previously
undetected S.A. in one plasma.
4. It may be that S.A. would occur to some extent in all plasma
at a citrate concentration of 0.19/%
3. Heuarinised Plasma.
Previous studies. All workere agree that ADP aggregates platelets in
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Table 7.6. Comparison of citrate (0.38$) and heparin (lOu/ml)
as anticoagulants in paired plasma




0.75 2.0 2.0 3.0 3.0 6.0 7.3 Nil
Test Dose
ADPpM
0.25 1.0 1.0 1.0 1.0 1.0 1.0 1.0
P.A. percent
(1) Cit. PRP 12% 17% 2h% 19% 08% 06% 29% 18%
(2) Hep. PRP $2% 68% 52% 63% 70% 91% 63% 60% Increase-tBt-
The highest values are underlined
Analysis by Wilcoxon Signed Ranks Test
Table 7.7. Correlation between disaggregation in heparinised plasma and the
S.A. point of a paired citrated specimen.










5.5 2 1 h 10.5 8 8 m 27 m 33
Specimens (l) to (7) showed less disaggregation than specimens
(8) to (ill) -sh:-*- (Wilcoxon Sum of Ranks)
heparinised plasma, but there is disagreement about the comparative
effectiveness of the ADP. Some report an equal effect of ADP in
citrated and heparinised plasma (14), others that ADP has more effect
on platelets in heparinised plasma (118, 145, 174). S.A. has been
demonstrated on rare occasions (118) with Bom's technique, but using
ADP removing enzymes Haslaa (69) has uncovered a biphasic tracing more
frequently.
Present study. Citrated (0.38/0 and heparinised (10 u/ml.) specimens
of blood were removed from the same venepuncture.
Plan of study. It was found that after centrifugation at 150g less
platelets remained in a heparinised than in a paired citrated plasma,
and so the heparinised plasma was centrifuged at 140 g. Even so the
platelet counts in nearly all heparinised plasma were less than in a
paired citrated plasma (0 to 20^). Specimens from the citrated and
heparinised plasma pools were tested alternatively.
Results.
1« Primary aggregation. Table 7.6.
A markedly higher aggregation was present in the heparinised
plasma in all eight pairs (^ =</ 0.01). This increased P.A. activity
occurred inspite of the lower platelet counts in the heparinised plasma.
2. Secondary aggregation.
Ho S.A. tracing was obtained in any of the eight paired
specimens, and was only found once in the thirty specimens examined
during the work. In an attempt to uncover any S.A. reaction not shown
by the aggregation side of the process, d isaggregation was studied
(Table 7.7).
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Table 7.8. ADP-like aggregating activity released from paired citrated
and heparinised plasma, by the S.A. point ADP concentration,,
and during the second phase of adrenaline aggregation.
(1) S.A. to ADP
Subject no (1) (2) (3) (U)
S.A. point ADPjjM/L 1.0 1.0 3.0 U.o
Release ADP-like activity
[uM/L)
(a) Cit. plasma 5.7 u.o U.o 2.5














(a) Cit. plasma 12.0 7.5 3.6
(b) Hep. plasma 0.22 0.65 0.U5
She disaggregation occurring, after 10 adns stirring of the
sample of heparinised plasma which contained the S.A. point ADP
concentration of the paired citrate plasma, was measured i.e. if the
citrated plasma S.A. point was 0.5 ADP then the disaggregation in
heparinised plasma after 0.5JM ADF was measured, and for an S.A.
point of 5p1 the effect of 5pM ADP on disaggregation in the heparinised
pair (Table 7.7).
In spite of the higher ADP concentrations of 2 to 10jaM in the
specimen of heparinised plasma wiiose citrate pair showed weak S.A.,
these samples showed more disaggregation than that occurring after the
addition of 0.5 - t.OpH ADP to heparinised samples paired with chain-
reactive S.A. citrate plasma (|k =<^0.002).
Cpimefits.
1. Aggregation induced by ADP was much greater in heparinised
compared to citrated plasma.
2. Although an S.A. tracing was not demonstrated there was a
marked correlation between chain-reactive S.A. in a citrated
plasma and reduced disaggregation in the paired heparinised
plasma.
Furtl^r studies using hepariniaed plasma.
Haslam's work, and the preceding section, suggested that a
second process is affecting aggregation and disaggregation in heparinised
plasma, but to a lesser extent than in citrated plasma. It was possible
that a release-reaction was occurring but not showing on the tracing.
However no excess of ADP-like aggregating activity over added ADP was
found in four aggregated specimens of heparinised plasma (Table 7.8).
There was a definite release of aggregating activity in the paired
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cltrated plasma. In the one of thirty heparinised plasma in which a
second aggregation was detected only a minimal release of ADP-like
activity was detected (0.2jaM).
In citrated plasma there is a strong correlation between S.A.
to ADP and the presence of the adrenaline second aggregation phase
(see Chapter Six). Only suggestive evidence to show that S.A. occurs
in heparinised plasma to ADP has been found so far, yet adrenaline is
known to induce a second aggregation phase in heparinised plasma
(O'Brien 139), although of a lesser extent than that occurring in
citrated plasma (O'Brien et al 145).
The release of ADP-like activity during the second adrenaline
aggregation phase was measured in paired citrated and heparinised
plasma (Table 7.8 bottom). There was a marked release of aggregating
activity into citrated plasma but only a very small one into the
heparinised paired plasma (from 2-12 of that in the citrated plasma).
Varying the heparin concentration through the range 10 to 400 units
(6 experiments). The extent of aggregation was comparable for the
same ADP concentrations at each of the heparin concentrations and the
small variations which occurred were not systematic.
Summary of results in heparinised plasma.
1. A second aggregation process could only be detected in the
dose-response curve tracing of one of thirty heparinised
plasma. Any release of ADP-like activity from platelets
in heparinised induced by ADP was too small to produce an
excess over the added AD10 dose, with one exception.
2. Any secondary aggregation occurring in heparinised plasma
car only be inducing the release of a very small proportion
of the ADP available for release reactions.
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3. Disaggregation was significantly depressed in heparin!sed
plasma when the citrated paired plasma showed chain-reactive
S.A. This surgests that the increased aggregation
responsiveness/impaired disaggregation part of the S.A. process
may be occurring.
4. The adrenaline induced second phase of aggregation which occurs
in heparinised plasma produced only a very small release of
ADF-like activity, an order or more smaller than that occurring
in a paired citrated plasma.
5. Heparin has an inhibiting action on the S.A. process and so was
jin unsuitable anticoagulant for S.A. studies
4. iSPTA
Previous studies. EDTA is a powerful chelating agent and when used to
chelate calcium is much more effective than citrate; so much so that
only when more calcium has been added to the plasma can ASP produce
platelet aggregation (68). It is the only anticoagulant which, after
the separation of platelets from plasma, allows their re-suspension in
further plasma or in saline without large aggregates forming (68), and
so it has an important place in platelet research. Incubation of
platelets in KDTA plasma at 37°C makes them incapable of aggregation (58).
No studies into the effect of EDTA on P.A. and S.A. have been reported.
Present study.
Methods. The syringe containing BDTA was cooled before venepuncture
and trie blood-SDTA (3aft/ml) mixture was immediately transferred to glass
centrifuge tubes in ice chips (4°C). Centrifugation was at 4°C (10 mins).
Tlie plasma was stored at 4°G and aliquote were warmed to 37°C just before
testing.
The calcium addition was titrated in each plasma to find the
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Table 7 .9* Comparison of P.A. in paired EDTA (3mM) and citrate (0.38$) paired plasma
(1) (2) (3) (U) (5) (6) (7) (8) Change
S.A. point citrated
(ADPjjM)
1.0 1.0 1.5 2 3 7.5 Nil Nil
P.A. percent





1.0 1.0 1.0 1.0 1.0
Citiated plasma 1h% 19% 12% 22* COO 03% 13* U3*
EDTA plasma 30% U3% 30% 59* uo* U9% 52* 80% Increase**
Analysis by Wilcoxon Signed Ranks Test
Table 7»10• ADP-like activity in paired citrated and EDTA plasma










minimum addition which supported a maximal aggregation to IOOjjK ADF,
and this addition was used in further specimens of that plasma. It
varied from 2.6 to 3.4 eK in different plasma.
sm
1 • The aggregation response decreased rapidly when the plasma
was incubated at 37°C. After 15-30 mins incubation at 37°C no
aggregation response could be obtained, even with massive calcium
and ADP additions. The aggregation response sometimes showed a
small increase and sometimes a small decrease during storage at 4°C.
2. Primary aggregation. Table 7.9* Sight subjects.
P.A. was markedly greater in EDTA plasma compared with a
paired citrated plasma. ( j>0.01).
3. Secondary aggregation. 18 subjects (paired EDTA and
citrated specimens) were studied. In only one was an S.A. tracing
obtained. Unfortunately an ADP-like activity assay could not be
performed on this occasion.
The eighteen pairs included eight in which citrated specimens
showed chain-reactive S.A. The degree of disaggregation in 10 mins in
the EDTA plasma paired with these eight, was compared with the
disaggregation in the EDTA plasma paired with citrated plasma showing
less active or absent S.A. There was a significant depression of
disaggregation (Wlcoxon sum of ranks j) =< 0.002) in the EDTA plasma
paired with chain-reactive S.A. citrated plasma.
4. The release of ADP-like activity after aggregation by ADP was
measured in three pairs of EDTA and citrated plasma (Table 7.10).
Citrated plasma with chain-reactive (S.A. points 0.75. 1*0 and 1.0pf*/l»
ADP) were chosen and these showed a marked release of ADP-like activity.
The EDTA plasma of the pairs showed a fall in ADP-like activity from the
ADP addition level.
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Platelet aggregation could only be studied in EDTA plasma
which was stored at 4°C.
The P.A. response to ADP was much higher in EDTA plasma than
in citrated plasma.
Only one S.A. tracing occurred in eighteen plasma. Ho
ADP-like activity release was detected in EDTA plasma paired
with chain-reactive S.A, citratedplasma.
However there was a correlation between a failure of platelets
to disaggregate in EDTA plasma and chain-reactive S.A. in the
paired citrated plasma.
In S.A. studies citrated plasma is preferable to EDTA plasma.
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Table 7.11. Effect of fast and steady withdrawl of
blood on P.A. and S.A.
(1) (2) (3) (U) (5) (6)
P.A. percent (lpM/LADP)
Fast removal 22 21 3k 20 25 28
Slow removal 23 28 U2 25 28 28
S.A. point (AJDPjjM/L)
Fast removal 5 1.5 2 2 1.5 k
Slow removal 7.5 1.5 1.5 2 1.0 h




The effect of fast and stead? withdrawal of blood on P.A, and 3.A,
Ho previous work. The release of ADP from red blood cells is
sufficient for it to be the stimulus to platelet aggregation in
platelet stickiness tests. It is theoretically possible for such
, -i
a release to occur during a venepuncture and so affect the aggregation
of platelets in the subsequently separated platelet rich plasma.
Present study. Blood was withdrawn from a venepuncture into two
syringes j one as fast as vein collapse would allow (•fast*), and
the other at a steady unhurried rate (*steady*). The order of fast
and steady withdrawal was randomised. Six subjects were studied.
Dose response curves to ADP were performed, testing aliquota from
the •fast* and 'steady* plasma samples alternately.
Res-alts. Table 7.11 •
1. Primary aggregation was higher in plasma separated from
blood withdrawn steadily compared with the paired #fast* withdrawal
sample in five subjects, and equivalent in one subject.
2. Secondary aggregation was more active in two 'steady*
withdrawal plasma, less active in one, and equal in the other three
pairs. 'hen a difference was present it was only of one S.A. point
level.
Conclusion. P.A. was reduced by a fast withdrawal of blood.
Bo effect was detected on the S.A. point.
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Table 7.12. Comparison of P.A. and S.A. in the top and bottom
portions of the plasma column
(1) (2) (3) (U) (5) (6)
P.A. percent Change
(pM/LADP)
Top 12 2U 23 15 -
Bottom o5 26 2h 18 n - N.S.
S.A. point
(ADPpM/L)
Top 10 1.5 h Nil 3 1
Bottom 10 1.5 3 Nil 3 0.75 N.S.
The more active response in each pair has been underlined
ffzpcriac^t Jjyo
Comparison of P.-A. and 5.A. in plasm from the top and the bottom of the
plasma column.
Previous work. Aggregation percent has been found to be increased in
plasma taken from the top, over plasma from the bottom, of a plasma
column in a centrifuge tubo, at a test temperature of H.T. (Harrison
et al 66). This change was ascribed to degradation of ADP by the
white blood cells in the bottom portion of the plasma. The experiment
has not been performed in plasma stored and tested at 37°C.
Present study. Two citrated blood samples of 20 mis were taken from
the same venepuncture. After centrifugation the top halves of the plasma
columns were withdrawn and pooled and the bottom halves were treated
similarly. Dose-response curves to ADP were performed, testing specimens
from the two pools alternately.
Results. Six subjects. Tablet 7.12.
1. Primary aggregation. The plasma from the top of the column
gave a higher aggregation percent in two subjects and a lower reading in
three subjects. The differences were small.
2. Secondary aggregation. The S.A. point was equal in four plasma
pairs and one dose level more active in two of the •bottom* plasma.
Conclusion. No significant difference was detected between the
aggregation of platelets in the top and bottom portions of a plasma
column. The aggregation process occurs at a faster rate at 37°C and so
may be complete before any white cell effect on ADP can affect the result.
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Fig. 7-2.
Effect of R.B.C.'s on the dose-response curve of plasma to ADP
Plasma A shows S.A. point (with biphasic tracing) of 0.7ADP.
Plasma B is plasma A plus 32th. R.B.C.'s and has a shorter range of
response. The S.A. point is also 0.75>pM ADP.
Ssnasfagak
Bffec% of red calls on :;.A.
Bo previous work
Present study. Plasma from three subjects were each divided into two
equal aliquots. To ona of these a small drop of centrifuge! blood
was added. This produced a marked reddenning of the plasma and the
red cell count was 20 to 45th/cm.ma* The 3.A. point of each specimen
was measured.
Results. Pig. 7.2.
Samples from the aliquot containing red cells had an
elevated density. The red calls produced a visible swirling effect
and this produced oscillations in the tracing which persisted after
the addition of ADP.
with much smaller changes in plasma density during aggregation in the
red cell specimen. fticroacopy of the O.TfftiM tracing specimens showed
maximal aggregation In the platelet aggregates from both. The 3.A.
Summary. Intentional contamination with red cells did not affect the
S.A. point in three subjects.
The form of the tracing was the same in both allquote but
points were equal In the three subjects
2.5pM; and 4)'M and 4^M ADP).
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Reproducibility of •*. A. and A.A. in duplicate sauries.
Previous viork. Harrison et al (67) who tested aggregation at room
temperature, have found that the mean values of paired specimens
removed from the same venepuncture were equivalent.
Present study. Two blood samples were withdrawn from the sane
venepuncture in 3ixteen subjects. The blood samples wore processed
separately and samples from the resulting plasma were tested
alternately.
Rest its. Table 7.13.
1. Primary aggregation. The P.A. response was very similar
In eleven specimens and less equivalent in four (7), (9), (11), (13).
Higher aggregation percent was present in five 'first* specimens and
*seven* second specimens.
2. Secondary aggregation. The S.A. point was identical in nine
pairs of plasma. In the remaining seven pairs there was a variation of
one dose level or less.
Conclusion.
1. In duplicate specimens, P.A. was reproducible in most.
2. S.A. was reproducible to within one dose level in all specimens.
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Table 7»l5. The degree of extraction of platelets from whole blood to the


















1) 2U3 331 8.7 161 66
2) 181 332 10.3 196 108
3) 181 305 8.3 132 78
3) 130 180 7-9 79 61
3) 200 281 7.0 110 53
6) 183 333 9.0 166 90
7) 121 223 8.2 101 83
8) 233 300 8.7 135 62
9) 135 303 6.0 102 75
10) 199 253 9.8 139 70





Effect of T)lntoi->c co-.mt ' n • platelet oonulation on P.A. and 3.A.
1• percentage extraction of platelets from whole blood to platelet
yicfr
Present study. The percentage extraction Proa whole blood to platelet
rich plasma depends on the ccntrifugation procedure. She platelet
extraction percent of the centrifugfttion procedure used in this thesis
was measured, using citrated blood,
fits. Table 7*15. Eleven subjects.
The mean extraction of platelets from whole blood into the
supernatant plasma showed wide variation. There was a mean extraction
of 77>- and a range Of 55-1O^b.





















































































































2• The .Tret of platelet count on P.A. and 5.A.
A, Prinarg ,\g -relation.
Previous worfr. There is general agreement that aggregation decreases
with the platelet count. O'drien has attempted, to quantify this decrease
for total aggregation, to enable inter-plasma and intra-plasma comparison.
Ho work has been reported on S»A*
Present study. Plasma was diluted with it's own platelet poor plasma
(PPP) tc concentrations of SO, 60, 40 and 205£, immediately before testing.
The P.A. response of the plasma and it's dilutions, to 1jfi£ ADP, was
measured. The response of the parent (iQG£») plasm was then recheckod.
There were two series of measurements on each plasma.
Results. (Table 7.14) 5 plasma (giving 10 results.
The results were comparable in four pairs. They were
dissimilar in pair (2) where the control value increased by 64',.. during
experiment (a), and this result was not analysed. In the remainder,
a gradual reduction in response occurred with dilution, except for pair
(5) "diere there was a rise in P.A. at 805 and 60; dilutions above the
P.A. in 100; plasma. However the degree of reduction was far from
uniform. The inter-plasma pair differences were larger than the
intra-plasma pair differences, suggesting that the variations were
biological rather than technical.
Comment. P.A. decreased with the platelet count, but not sufficiently
uniformly for an accurate prediction of the change to be made.
3. 3econlary Aggregation.
No -previous work.
Present study. Plasma was diluted with it's own ??P to 75^ and 50/ , or
to 60/ and 30^. The 3.A. points of whole plasma and the two dilutions
were measured. Samples from the three plasma were tested alternately.
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Effect of dilution of PRP with PPP on the S.A. point (ADPpM)
Plasma was diluted to either 60 and 30 percent or 50 and 25 percent
with its own PPP. The S.A .'.points of the three resulting specimens
have been joined by a line. Nine subjects.
Results. Fig. 7.3. Sine subjects.
The three points for each subject have been joined. Flasma
specimens covered the 3.A. range. Using a logarithmic scale for the
ADF concentration of the 3.A. point, a linear relationship to O.D, and
comparable slopes between the plasma are suggested. Analysis of the
first and second slopes showed no significant divergence iron a straight
line, and the slopes of the 3.A. points of the 10 subjects did not
W Serial Medki/ve
differ significantly froa each other (kr.A Lute, FithHo ffcwlth Department,
Edinburgh)• The wear-, slope was 62.1°.
Stcna^rv. The changes in 3.A. point produced by dilution of a plasma
with it's own PPP were linearly related. In nine experiments the slops
of tliis change was similar. The mean slope was 62.1 °.
3. Effect of reducing platelet count by repeated cenfcrfJug&tloa oil
S.A. point.
|^t.Tvk-lucrh-iar.. a theoretical criticism which has been levelled against
methods using platelet rich plasma, is that the population of platelets
in FilP may not be a true sample of those in whole blood. The relationship
between, platelet siso and platelet aggregation potential is uncertain.
Some workers have shown a relationship between large size and youth
(105) arid others between large size and metabolic activity (95) and
Piatelet release reactions (95a). Both those groups of workers altered
the in vivo disk shape of the platelet to that of a sphere by using EDTA
in their experiments. These workers may therefore be showing that
resistance to the sphering effect of EDTA, youth, and high activity are
Intei-related. There is no work relating the size of the disk shaped
platelets of citrated plasma (which predominate in vivo and in this work)
to their aggregating ability.
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EFFECT of CENTRIFUGATION of PLASMA on S.A. POINT
S.A. point A D P jtM (Log.scale)
Fig. 7.U.
Effect of centrifligation of PRP on the S.A. point (ADPuM)
Plasma was recentrifuged twice at 210g for 5 mins. The S.A. point
of the three resulting specimens have been joined by a line. Seven
subjects.
Preset L i . In order to allow the larger platelets to sediment
plasma vas recentrifuged in the following way:- 15 mis of plasma from
the same subject were nixed and 4 mis removed. The remainder was
recentrifuged for 5 mins at 21 Qg. The supernatant plasma was removed,
leaving the bottom one cm and the sedimented platelets. 4 mis were
removed from the plasma and the remainder was similarly recentrifuged
and a 4 ml aliq\iot was again set aside. The S.A. points of the three
samples (original plasma and first and second rocentrifugatiens) were
measured, Specimens from the three samples were tested alternately.
Results. Fig. 7.4. Seven subjects.
The initial 0.1). was comparable to those in the dilution
experiment (Fig. 7.?} in three plasma and the same angle of slope
was present in both experiments. The initial ©.P. was lower than that
in the dilution experiment plasma in the other four end the slope angle
was also lower in these four plasma. A mean slope of 54.1° was present;
it may however bo in part lower because of the lower initial C.D.*s.
The difference between the slopes obtained by dilution
(62.1° mean) and by recentrifugation (54*1°aoan) was significant
(j) 0.05). To find out the practical effect of this difference in
slope, the S.A. point which would occur when a plasma of 0.3. 0.4 and
S.A. point t/M A3? was diluted or recentrifuged to halve the platelet
number (about 400,000 to 200,000 platelets per eiumn.), was calculated.
The S.A. point by diction v?ould be 2.5*® A3? and by rocentrifugation
8 small difference only. This suggests that changes of platelet
populatioh produced by centrifugation are of minor importance only, and





1. In seven subjects the effect on S.A. point of reducing the
number of platelets by centrifugation (thus allowing differential loss
of the more sedimentable platelets), was measured,
2. The effect of this manoeuvre on S.A. was to reduce S.A.
activity a little more quickly than dilution by PPF did. The difference
was small in practical terms.
3. It is likely that the method of plasma preparation used in
this work, produces a PRP population whose S.A. activity gives a good
measure of S.A. activity of the whole blood platelet population.
Summary of Kx-periment Bight.
1. The degree of extraction of platelets from centrifuged whole
blood into the plasma supernatant was a mean of TV with a range of
55-106$.
2. Reducing the platelet count by dilution reduced P.A. percent
and S.A. activity.
3. The degree of reduction in P.A. was too variable for accurate
corrections to be made for differences in platelet count,
4. The reduction in S.A. was uniform. Thus accurate corrections
can be made for differences in platelet count.
5. S.A. activity was reduced slightly more quickly by
recentrifugation than by dilution. The difference was small and may be
in part due to differences in plasma density, suggesting that the S.A.
response of citrated PRP is a good measure of that of the platelets in
whole blood.
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Experiment lilne.
Effect of testiiv: at RT and 37°C on P.A. and S.A.
1• The dose-response curve.
Previous work. There is general agreement that the degree of aggregation
is inoreased by testing a PRP at R.T, as against 37°C and that subsequent
disaggregation is decreased (for review see Ref.111).
Present stud:/. Plasma was stored at R.T. for 20 rains and then tested at
R.T, and 37°C. The same apparatus was used for both test temperatures,
and so the complete dose-response curve at a test temperature had to be
performed before the alternative temperature was used. The order of
testing was randomised. A temperature equilibration period for the
apparatus of 20 mins was used between the two dose-response curves.
Results. Table 7#16. Ten plasma.
1. Primary Aggregation. It was confirmed that P.A. is greater
at R.T. compared with 37°C =^'0.002). The degree of the increase
at R.T. varied widely and was in no way predictable from the result
at 37°C.
2. Secondary Aggregation. Son-phasic S.A. tracings were present
at R.T. but a biphasic tracing was not detected. The S.A. point ASP
was lower at R.T. (^ = <0.05) with the degree of the increase in S.A.
activity varying. It was zero (3 plasma), one level (1 plasma),
two (5 plasma) and three (1 plasma). The degree of variability was
not related to the level of the S.A. point.
2. Correlations between S.A. tracings and release of ADP-like activity.
Plan of study. The increased aggregation and decreased disaggregation
occurring at R.T, may have produced an S.A. tracing appearance in the
absence of ADP release or the presence of only a small release, and so
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the tracings were correlated with the ADP-like activity in the
supernatant, in three plasma. The tracings at 37°G testing have
bean found to correlate with the release of ADP-like activity
(see Chapter Five).
Results. Table 7,17.
In contrast to S.A. at 37°C, the- correlation between the
tracing and the release of ADP-like activity was variable at R.T.
(Table 7.17). In specimen (1) an S.A. tracing occurred before a
release and in specimen (2) an S.A. tracing occurred in association
with a small release which subsequently increased when the dose of
ADP was raised. Specimen (3) showed complete correlation between
tracing and release.
Summary.
1. R.T. testing increased P.A. The degree of the increase
varied widely and was not predictable.
2. A non-phasic S.A. tracing can be detected at R.T. and occurs
at a lower ADP dose. But it does not have always the same meaning as
the S.A. tracings occurring at 37°0, as it can occur without an ADP
release or only a small release.
85
Table 7.18. Variation in P.A. and S.A. through a day
Primary" Aggregation (%)
■
Time (1) (2) (3) (U) (3)
9 AM 26(1) 28(1) 29(1) 37(1) 08(1;)
12 MD 16 (U) 18 (U) 18 (10 36(2) 09(3)
3 PM 18(3) 26(2) 26(2) 33(3) 20(1)
6 PM 23(2) 20(3) 21(3) 31; (U) 13(2)
The ranking of each level is shown in brackets
Secondary Aggregation (S.A. point ADPpM/L)
Time (1) (2) (3) 00 (3) (6) (7) (8) (9) (10) (11) (12)
9 AM 2 . 3 3 1 2 2 1 1.3 2 3 h Nil
12 MD 2 7.3 h 1 2 3 1 2 1.3 3 h Nil
3 PM 3 h h 1.3 1.3 2 0.73 2 2 U 3 Nil





1 2 1 l l 2 l 1 l 1 1 0
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Intra-peraon and inter-person variations iv S.A.
Previous work. Variations with time in 3.A. to ADP have not been
reported but the changes in the related second phase of adrenaline
aggregation were studied in ten subjects over a month by 0*Brian
(140). 0*Brien used a single dose of adrenaline (5pM/L) and
detected the second phase on all occasions in four subjects, on
two-thirds or more occasions in four, and on less than half the
occasions in two subjects. He suggested that considerable
variations occur in S.A. activity from day to day
Present study. This differed in two respects from 0* Baden* s study.
First ADP was U3ed to stimulate S.A. Second the dose of ADP was
varied to detect the S.A. point erectly, thus obtaining a more
accurate measure of S.A. activity.
1 * Variation through a day.
Plan of study. The blood was taken from volunteers at 9 am., 12md.,
3 pm. and 6 pm. They were fasting for the first specimen, had a light
breakfast at 9»50 am., a fatty meal at 1 pm. and a light tea at 3»30 pm.
Results. Table 7.18.
1. Primary Aggregation was followed in five subjects. In four
subjects the peak of aggregation was 9 am., with a mid-morning fall and
a rise to near fasting (9 am.) levels in the afternoon. In the fifth
subject low morning values were followed by a peak at 3 pro. With the
exception of this latter person the values varied up to + 25% of the
mean.
2. Secondary Aggregation was followed in twelve subjeots.
Eleven subjects showed S.A., in the other (No. 12) there was no S.A.
throughout the day. Of the eleven, nine showed a variation of only
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Table 7.19. Variation in S.A. Day to Day and Week to Week
S.A. point ADP (pE/L)
Group one Group two
Subject (1) (2) (3) (U) (3) (6) (7)
Day 1 1.3 - - - 3 - ll
2 1.3 - - - 7.3 - li
3 l - - - 3 - 3
k 1.3 - - - 3 - 3
3 1.3 - - - 10 - U
8 1.3 2 3 h 7.3 7.3 li
9 1.3 1.3 h h - - 3
19 2 2 3 2 h 3 3
11 3 1.3 3 h h 7.3 3
12 - 2 h 7.3 - - li
Week 3 2 __ 2 7.3 h 3 2
u 1.3 2 3 li 7-3 3 3
5 - 2 (nil) h - - li
6 - 1.3 (nil) (7.3) - - li
7 - 1.3 2 (nil) - -
8-- - 1.3 2 3 - - -
Mean 1.7
'
1.8 2.6 h.6 6.h 6.0 3.6
Variation in
S.A. point level
1) day to day 3 l 1 h 3 1 - 3
2) Total time 3 l 2(6) M6) 3 1 3
one S.A. point level and in the other tiro it was 2 levels. A
systematic pattern could not be detected in the through a day
variation in S.A. point.
Comment.
1. The S.A. point was steady through the day.
2. P.A. showed, as in other experiments, more variation.
The results also suggest the possibility of a mid-morning
fall in P.A,
2. Variation from day to day and week to week.
Plan of study. Fasting volunteers (males aged IS tc 4S) were bled
at 9 am. on various days over two eight-week periods. The subjects
were tested in groups, one of four followed by one of three. This
allowed a cheek to be made for any systematic change across a group.
Results. Table 7.19. Seven subjects.
The top section of the table shows the day to day variation
in five-day periods (10 periods in all). The variation was one S.A.
point dose level (three subjects), three (three subjects) and four
(one subject). S.A. was present on all occasions.
The variation during the three to eight weeks period
(bottom section Table 7.19) was only slightly greater, and was
remarkably similar to the individual subjects day to day variation.
In group one, two volunteers, who worked together, showed a marled
fall in S.A. activity (subject (3) weeks 5,6 and subject (4) weeks
o,7) when they had an upper respiratory tract infection. The effect
of aspirin-like drugs was not known at the time of this survey and so
were not inquired into at the time. These two pairs of results are
in brackets and were not included in the analysis. The other
volunteer in group one maintained a steady response over this period.
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The mean S.A. point value varied widely, from 1,7 to
6.4pM ADP/L. The variation in S.A. point level (bottom table 7.19)
was low (1-2 levels) in three subjects and moderate (3-4 levels) in
the other four. The variation in the day to day and in the total
period were markedly similar in a particular subject. The presence
of low or moderate variation did not correlate with either low or
high S.A. activity.
Summary.
1. The variation in S.A. activity, tested at four times during
a day of normal eating and activity, varied by one dose level or less
in ten of twelve subjects. This is little different from the
variation found in duplicate estimations (Exp. Seven this Chapter).
In the other two the variation was one dose level higher.
2, The variation in S.A. activity day to day, and week to week
was low (1-2 levels) in three of seven volunteers and was moderate
(3-4 dose levels) in the other three. Two pairs of aberrant
results were present.
4. The degree of variation was similar in the day to day period
and the week to week period in any one individual.
5. These results suggest that S.A. activity may remain constant
in an individual although varying widely in it's level between
individuals. The degree of variation about the mean level may also
be constant in any individual.
3. The mean S.A. point ADP concentration varied widely
(1.7 - 6.^
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GEHE8AL SUMMARY OF CHAPTER SHYEN.
1. Citrated PHP stored at 37°C showed a relatively stable P.A.
percent response between 30 and 75 minutes of venepuncture; and an
S.A. response which was stable for 30 to nearly 90 minutes from
venepuncture.
2. Any variation in storage or test temperature produced
unsystematic and sometimes large changes in the aggregation response.
Because these changes were unsystematic corrections could not be made
for them.
3. Heparin and EDTA inhibited S.A., though evidence of slight
S.A. activity could be detected when the S.A. process was very active.
Heparin and EDTA are not considered to be suitable for studies of S.A.
4. The withdrawal of blood at a fast rate slightly affected F. A.
but did not affect S.A. Contamination of plasma with RBC's and WBC's
(bottom of plasma column) did not affect the S.A. point level.
5. Reduction of platelet count by dilution with PPP produced a
fall of widely varying extent in P.A., and a remarkably constant degree
of fall in S.A. point level. The changes in S.A. point level were
sufficiently constant for valid corrections to be possible for changes
in platelet count.
6. There was only a small difference between the effects on S.A.
point level of diluting a plasma (i.e. same plasma population) and
recentrifuging (i.e. loss of larger platelets). It is therefore likely
that S.A. activity measurements in citrated plasma are a good estimate
of S.A. activity in the citrated whole blood platelet population.
7. Through a day and over an eight-week period the level of S.A.
activity in a given healthy volunteer remained constant within a
variation of four dose levels (in moat it was less than four levels).
The mean level of S.A. activity varied widely.
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CHAPTER BIGHT
PRIMARY AND SECONDARY AGGREGATION IB HEALTHY BLOOD DONORS
Previous work. In the course of basic studies on small .groups of
volunteers and patients plus volunteers 3.A. has been found in about
80, of plasma by several workers (laomillan 106, Hills and Roberts 116,
Zucker and Peterson 197). There has been some variation in the
interpretation of the tracings in these reports which will be
discussed at the end of the thesis. Recently Hardisty et al (1970
ref 65) reported an incidence of S.A. of 100^ in 60 laboratory workers.
He used the Born principle, but had included a major modification in
technique.
The study reported in this chapter was on healthy blood
donors, and the intention was to survey both sexes and each decade
from 21 to 60 yrs. as evenly as possible.
Present study. This was made possible by the co-operation of
Dr. R. A. Cummingf, Director of the Scottish South Eastern Regional
Board Transfusion Centre. The blood donation centre was situated
very close to the laboratory and so quick transport of blood specimens
was possible.
The blood donors. Blood donors were asked to give a further specimen
of blood for research during a routine blood donation. The donors
asked were Caucasian. Initially all donors were asked who were aged
21 years to 60 years, both male and female. When 10 donors of the
one sex in one of the four decades had been surveyed no more in this
age/sex group were approached. In this way an almost even spread of
sex and age was achieved.
All volunteers were asked the following questions and if a
positive answer was given they were excluded
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2. Are you talcing any tablets, or medicines, or the birth
(contraceptive) pill?
3. Have you taken any of the following tablets in the past week:-
(a) Aspirin, aspro, codis, phenacetin, or other pain killing
tablets.
(b) Butazolidin, Tanderil, or other anti-rheumatic tablets.
Seven donors were rejected for minor illness, or aspirin ingestion,
or contraception with hormone tablets.
All the donors who were approached volunteered to take part.
The following estimations were mades-
1. P.A. percent to IpM ADP.
2. S.A. point dose ADP^m/L.
3. Plasma platelet count.
4. Hb., W.C.C., E.S.R. (1S^" hour Westergrem).
Those with Hb\T&> and/or E.5.R.^> 20 oms. were excluded.
On this basis two donors were excluded, one with an Hb. of
64% and one with an E.S.R. of 35 rams t hour.
The results of the survey of the remaining 74 donors are given below.
Results.
The full results for the 74 donors, arranged by sex and age
by decade, are given in Table 8.1. For analysis the results were
sub-grouped into young adults (21-40) and middle aged adults (41-60)
and further sub-divided by sex. Each of these groupings contained
approximately twenty donors.
1. Primary aggregation. The average value for P.A. was highest
in the sub-group of middle aged females (33.9/"), next were young
females (31.3a)» then middle aged males (29,7%) and, distinctly lower,
were young males (t 9.1/®). The young males showed a significantly lower
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Fig. 8.1.
A comparison of P.A. (to lpM ADP/L) with S.A. point
The P.A. results of the blood donors with an S.A. point of 1.5pM ADP plus
are shown. The line joins the mean P.A. values for paired S.A. points
(1.5 and 2pM; 3 and UpM etc.)
a male female
a
SECONDARY AGGREGATION in BLOOD DONORS
No. of Donors
20 r-
0.25 0.5 0.75 1.0 1.5 2 3 4 5 7.5 10 Nil
S. A. Point ( ADP jiM/ L )
Fig 8.2.
Histogram of the-S.A. point ADP concentration of 7b Blood donors
P.A. response than each of the other three groupings (middle aged
males, both age groupings of femalesp = <0,05). There was no
significant difference between the other three groups.
2. Relationship of P.A, to 3.A. The pattern of the P.A./S.A.
relationship in males and females was the same and 3C the results have
been combined, Pig. 6.1. P.A. decreased as S.A. became less active,
from 41$ at 1,5}M ADP to 16$ for P. A.-only. The pattern of this
decrease was a rapid fall from 1.5;* to 3pM followed by a plateau
which had an aberrant peak at 5pK. The differences in P.A. between
pairs of S.A, points were analysed. The fall of P.A. percent from the
S.A. points 1.5 and 2juM ADP to the S.A. points 3 and 4j* ADP was
significant =< 0,002), The differences in P.A. percent between
the j^uM + 4^M S.A. points and the other pairs of S.A. points were not
significant.
This relationship between S.A. and P.A., which occurred when
the S.A. point was near to the P.A. test dose, could be due to either
process influencing the other. However, as the S.A. process is acting
before the fully developed form used in the definition of the S.A.
point (see Chapters Pour, Five), it is more likely that S.A. is
increasing the P.A. response than the reverse.
3. Secondary Aggregation.
(1) Total results, (fig. 8.2)
The S.A. points in the blood donors ranged from 0.75pM ADP
(one) to Nil S.A. i.e. P.A<-only (three). The mode value
was ^uM and the average was 3*£pH» The histogram shows a
regular rise and prolonged tail indicating a slight skew
to the left. The percentage of donors showing the
different degrees of S.A. activity were:-
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Fig. 8.3.
Histogram of the S.A. points (ADPjjM) of 7h blood donors divided into
age groups (21 to Ij.0 yrs, and lj.1 to 60 yrs) and subdivided by sex.
(1) chain-reactive S.A. - 12 (16; ).
(2) self-limiting S.A. - 59 (80?>)
non-phasic (73, )
level (7/ )
(3) P.A.-only - 3 (4^).
(2) Sex and age sub-groups.
The mean values for S.A. point ADVfM/l) in these groups (Table 8.1)
show that the most active S.A. response occurred in young adult
females (2.2), next in middle aged females (3.4), then in middle
aged men (4.2) and least active were young adult men (4.7).
A histogram of these sub-groups (Fig. 8.3) showed that three of the
groups had a mode value of SjjuM Ai)P and middle aged males had the
slightly more aotive mode value of 2jil1 ADP. The high average S.A.
activity in the youn: females i3 seen to be due to 'front loading'
of the values with the absence of a 'tail', rather than to higher
absolute values. In the remaining three groups a 'tail* was
present, and in F 41-60 and H 21-40 there was the suggestion of
a second 'hump' at 7.5 /uK, i.e. of two populations.
Analysis of these results showed a significant difference (j^=^0.05)
beWeen the young adult females and the young adult males groups and
a nearly significant ({3= 0.06) difference between the young females
and the middle aged males. Other differences were not significant.
(3) Intra-, youp differences in females.
To see if the menstrual cycle was affecting the S.A. point, the
twenty-four menstruating women were analysed further, for differences
between the first half (haemorrhage effect? hormonal effeot?), and the
second half (hormonal effect?) of the cycle. Only seven out of the
twenty-four were in the first half of their cycle, indicating self-
selection. The average S.A. points were, first half 3«3pM and
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second half 2.8jiH (N.S.). So any intra-eyele differences was not
detectable in these small groups. Next the twenty-four
pre-menopausal women were compared with the thirteen post-menopausal
women. The average S.A. points were 2.9 and 3.1^1-1 respectively (U.S.).
(4) Differences in Hb. (and citrate concentration).
The higher citrate concentration in plasma derived from whole blood
with a high Hb, could have influenced the calcium dependent platelet
aggregation in the male plasma. The mean Hb ($) and mean S.A.
point (ABP) for the groups were; young adult man, 96.8$ and 4.7)uM»
and women 88.8$ and 2.2juM; middle aged men, 96.1$ and 4.2jJf, and
women 84.4/ and 3.2pM. The highest values of Hb and S.A. point
were associated, but the lowest values were not.
Spearmans correlation test was applied to the values for Hb and S.A.
point ADP concentration. For the total female group z - 1.81, and
for males plus females 2 » 1.86 (j) ~<0.10)>0.05). This suggests
that some association is present but that it is a weak one.
The histogram (Fig. 8.3.) does not suggest that the values for S.A.
point are moving because of a change in citrate concentration. The
shape of the histogram varies in the different groups of age and sex
as opposed to being similar in shape but in different positions;
also the most active S.A. point and S.A. mode value are not in the
group with the most active mean S.A. point value (F21-40). The main
difference between F21-40 and the other groups is absence of a 'tail* -
and a 'tail* is present in the group with the lowest mean Hb
concentration (F41-60).
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SUMMARY OF CHAPTER EIGHT.
1. A survey was conducted of P.A. and S.A. in specimens from 74
healthy dcmors. The age group 21 to 60 years was studied and
both sexes included. The donors were questioned about minor
illnesses and drugs before being admitted to the survey.
2. P.A. appeared to be influenced by an active S.A. process (1.5*
2 joM ADP S.A. point), probably due to the early stages of the
S.A. process. P.A. percent was lower in males aged 21-40 than
in the other groups of blood donors.
3. The range of S.A. point was 0,75pV ADP to absent; the mode
value was 3pK and the values were skewed slightly to the left.
S.A. was chain-rea ;tive in 16/5, was self-limiting in 80£5, and
was absent in 4/5 of the donors.
4. Analysis of the results by age and sex showed S.A. to be most
active in young females and least active in young males. The
difference between these groups wa3 significant (j? =<(0.05).
Menstruating women did not show a higher S.A. activity than
post-menopausal women, and there was no difference between women
who were examined in the first 14 days of the menstrual cycle
compared with those examined at a later stage of the cycle.
Differences in Hb level did not account for more than a small
part of the difference.
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CHAPTER NIKE
tfim ILLK?SS 4KD 5tA.
IHTRODUCnOH.
Following acute illness humans become highly susceptible to
venous thrombosis. The three components of this hyperthrombotic
state are the vein wall, changes in blood flow, and changes in the
blood. There is firm pathological evidence that the initial event
in a venous thrombosis is a white (i.e. platelet rich) thrombus
developing in the turbulent blood flowing around venous valves (see
review Chapter One). Subsequent red (coagulation) thrombus develops
downstream to the block caused by the white thrombus.
While white thrombus formation is the initiating event, it
is the red thrombus which produces disease, either by blocking the
vein and so preventing the return of venous blood to the heart (a deep
vein thrombosis), or by becoming detached and passing to the lungs
(a pulmonary embolus).
Deep vein thrombosis and it's sequelae are important in
both medical (169) and surgical patients (106). Clinical signs are
notoriously unreliable for detecting deep vein thrombosis, because
many thrombi do not cause local symptoms, and also because the
clinical features which suggest thrombosis are not always due to
thrombosis (161). So venography and radio-active fibrinogen are used
to detect subclinical venous thrombi, (venography correlates well with
necropsy findings (103) and such a study is not yet available for
radio-active fibrinogen). Reliable estimates of the incidence of
venous thrombosis depend on results from these special investigations
and on post-mortem studies
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In post-iTorten studies the incidence of deep rein thrombosis
varies fron about 20 to 60 percent depend ing on the patients age and the
severity, site, and duration of the preceding illnoss ' 162, 103). In
prospective sttidiea on surgical patients an incidence of 40 percent
was present in elderly trauma patients (venography, 47) and of
21 peroent in routine surgical cases (radio-active fibrinogen, 22).
It can therefore be stated that deep venous thrombosis is
a coaaon occurence after acute illness. The incidence of small
platelet-fibrin thrombi on venous valves is not known.
Previous work. Table 9.1.
The first study of platelet behaviour in vitro in acute
illness was undertaken in 1942 by Fayling Wright (186), using her
rotating bulb method of measuring 'platelet stickiness*. She found
a slow increase in platelet count after operations and also an
increase in platelet stickiness. Since 1942 several investigations
of post-operative and post-parturn patients have been carried out using
platelet stickiness teats and one investigation using platelet
aggregation.
All investigations have found a post-operative rise in
platelet count occurring after several days, and in on© investigation
a fall was detected during the first 48 hours (59). Platelet stickiness
has been found unchanged by some workers and increased by others
(see Table 9.1).
In the one investigation of platelet aggregation Hansons et
al (42) studied, in eighteen post-operative patients, the Mai
aggregation response (i.e. P.A. and 3.A. not separated) at room
tenperati.ro, to fixed doses of ADP and adrenaline. Samples wore taken
poat-oporatively, and at nine to ten days, and thirty plus days post¬
operatively. A significant Increase in the mean aggregation percent
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was present at the nine to ten days observation point, with a return
towards pre-operative levels at thirty plus days. The authors
noted that there was wide variation in the changes in individual
patients and, also, in one woman examined from day to day. They
were unable to correlate the aggregation increase with age, sex, and
the magnitude of the change in platelet count, nor was aggregation
greater after 'major' compared with 'minor* operations. The purpose
of the present study was to separate P.A. and 3,A. changes. The gaps
in the Table 9.1. indicate the desirability of also studying a control
group and acute medical illness, as well as the post-operative state,
and this was done.
Plan of study.
1• Pilot study. Experiment Tea Chapter Seven investigated
the changes in S.A. point through time in healthy subjects, but
in illness this might differ so four patients were studied day
to day for about two and a half weeks and less frequently for a
further two weeks.
2. Main study. On the basis of the results of the pilot study
the remainder of the patients were studied at admission (or pre¬
operative^) and at three further times of 5-4 days, 7-8 days and
10-12 days after admission or operation.
Observations and measurements.
(a) Diagnostic and prognostic measurements were recorded on the
patients illness and it's severity. Especially useful was the
E.S.R.
(b) Therapeutic measures■ Many drugs are now known to affect S.A.
(142, 145, 62), particularly aspirin. No patient under study
received aspirin or related anti-inflammatory drugs in hospital.
Other drugs given are noted in the results. Some acute admissions
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may have received aspirin before admission, as only the later
patients were questioned about aspirin ingestion because
during the earlier stages of the survey the anti-S.A. action
of this drug was not known.
(0) Laboratory measurements.
Platelet count (blood and plasma),
Hb., V.C.C. , 5,3.R.,
P.A. percent (1^iM ADP).
3.A. point ADPpM.
The specimens of blood were removed on admission, and thereafter
at 8-30 to 9-30 a.m. after breakfast.
The Patients.
(1) Pilot study. Pour patients who were in bed for at least
two weeks, one without an acute illness, one with a minor illness,
and two with a major illness.
(2) Control group. Seven patients with chronic, but not acute,
illness (hypertension and ischaemic heart disease) who were in
hospital for investigations were kept in bed for seven days, only
being allowed up for toilet purposes. Six ambulant volunteers
were also studied because some patients in the study were mobilised
early.
(3) Acute medical illness. Only patients who became acutely ill
in the 48 hours before admission were studied. Within this
restriction, as wide a group of conditions as was possible were
included. There wore twenty patients with conditions ranging
from acute myocardial infarction and cerebrovascular accident to
haeraatemesis and urinary infection, and both mild and severe illness.
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(4) Acute surgical illness. Both patients undergoing cold
surgery and emergency admissions (within 48 hours of onset of
illness) were studied. Again several conditions and differing
degrees of illness were included. There were twenty patients
in this group also.
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Graphs of P.A. and S.A. in four patients followed for three to four weeks
® = S.A. Vertical lines = P.A.
TOE PILOT STUDY
Four patients were studied in detail and the results are shown in
Fig. 9.1.
(1) This patient had 5 rains of severe cardiac pain at rest,
and special investigations failed to detect evidence of ragrocardial
infarction.
Nonspecific tests of tissue damage suoh as temperature, white cell
count and E.S.R. were normal.
S.A. remained steady throughout the observation period. P.A.
tended to mirror the S.A. changes but with a wider variation than
for S.A.
(2) Patient two had a mild hemiplegia on the day of admission from
which he made a complete clinical recovery. S.A. was abnormally
active on admission and remained so for 10 days before falling
slightly. S.A. was too active for P.A. measurements to be made.
(3) Patient three had a two pint haematemesis from a duodenal
ulcer on the day of admission, and continued to bleed intermittently
for the next three days. S.A. was absent on admission and rose
to abnormally active levels in four days. It remained elevated
for four days and then slowly returned to the pre-admission level
over three weeks.
P.A. mirrored the S.A. changes.
(4) This patient had a partial gastrectomy for chronic duodenal
ulceration. After operation S.A. activity increased quickly h7
a small amount, then remained on a plateau for 10 days, finally
reaching a peak at fifteen days. Over the next two weeks S.A.
activity returned to the patient's normal. P.A. showed more
variation than S.A. It tended to be higher when S.A. was active.
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Comments on the pilot study.
(1) In the absence of acute illness (patient 1) S,A. activity
showed a variation of three S.A. point dose levels. This
degree of steadiness of response is within the limits found in
normals (Chapter Seven, Experiment 10).
(2) In the two patients (Nos. 3 and 4) showing a rise in S.A.
activity the day to day readings showed remarkably little
variation about the mean trend.
(3) The peal S.A. activity was 4 to 7 days after the haematemesis,
with a later peak after the partial gastrectomy. The high level
of S.A. activity after the C.V.A. (patient 2) was maintained for
14 days.
(4) P.A. tended to follow S.A. In the patient with the greatest
number of S.A. points of 1.5 and 2 juM (No.3) there was a positive
correlation between the levels of S.A. and P.A. (|?=<(0.01); in
the others the correlation was not significant.
(5) It was concluded that variations in S.A. about a trend line
day to day were small enough to allow less frequent readings to
characterise a trend. This allowed a larger number of patients
to be examined. In order to detect both the timing and height of
any increase in S.A, activity, measurements were taken at 3-4 days,
7-8 days, and 10-12 days. This schedule seems likely to detect
most of the changes in S.A. activity.
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Table 9«2. Mean values of platelet counts (10 /cu mm)
n Day 0-1 Day 3-h Day 7-8 Day 10-12
Control Blood 7 180 200 193 2b0*
(Bed rest only) PRP U01 396
/
U50 b60
Medical Blood 20 180 185 231* 210*
PRP 375 372 398 U58**
Surgical Blood 20 219 239* 21U* 278***
PRP 377 371 h02 1+82*
Analysis by Wilcoxon Signed Ranks Test
Table 9.3. Mean values for P.A. in acute illness
Day
PA percent lpMADP
0,1 3,b 7,8 10-12
Acute Medical
Acute Surgical
22.8 23.1 22.2 21+.2
23.5 23.6 22.7 21.1
RESULTS OF MAIN STUDY
Platelet count.
The individual results are given in Table 9*10 (at end
of chapter). There was wide variation from the initial value in
both directions. The individual results were analysed by intra-
individual comparison and table 9.2 gives the mean values and the
results of the analysis.
The blood platelet count rose in all groups to become
significantly elevated by 3-4 days in the surgical group, by 7-8 days
in the medical group and by 10-12 days in the control group. The
PBP count remained steady in all groups at 3-4 days. It then rose
and this change was significant by 10-12 days in the acute illness
groups.
Primary aggregation.
The full results are given in detail in Table 9.11 at the
end of the chapter. As the S.A. activity (see next section) rose
to IpH and above in many patients, there were several occasions on
which P.A. could not be measured. On the available results no
significant changes occurred (Table 9.3)•
Secondary aggregation.
(1) Control group. Table 9.4.
During the period of observation the seven patients in bed
and six ambulant normals showed no change or only a small one (rise
of two dose levels patients (3) and (4). These changes were not
significant.
(2) Acute medical illness. Table 9.5.
The group contained eight patients with myocardial infarctions,





































































































































































































































































































































































Abreviations A= aminophilline Anticoag=dividevan orwarfarin Atrop=atropine B=arbiturate Beth=ethanidine C=chloral Chp=chlorpromazine Chpd=chlorpropamide D=chlorothiazide durectics Dig=digoxin 1=iron M=morphine,pethadine MD=methyldopa Mog=mogadon Mxmandrax Pen=penicillin Prop=propantheline
M.I.=myocardialinfarctionC.V.A.cerebro-vascularac ident*='m j r'illne s AnalysisbWilcoxonS gnedR kTe t.hpeakct vityisunderl ned
and one each with six other conditions ranging from urinary infection
and pericarditis to allergic purpura. The dru administered during
hospitalisation are noted in the table.
The initial level of S.A. activity was low, as eight out of
twenty patients had no S.A. activity. This low level was near to
significantly lower 0.05) than the level in age and sex
matched blood donors taken from the normal population described in
Chapter Eight. In one patient (Ho.11) the initial S.A. point dose
was above the normal range at 0.5 ^ ADP, and another (No.lO) was
at the highest normal level (of 0.75 ADP).
patients. The S.A. activity rose above the initial level in fifteen
of the eighteen by 3 to 4 days and in all eighteen by 7-8 days. The
peak value for S.A. activity was reached by four patients in 3-4 days,
by seven in 7-8 days and in the remaining seven at 10-12 days. At
the peak values 80 percent of the patients were showing chain-reactive
S.A. (compared with 16 percent of the blood donor population).
Analysis of these results will be given with those of the surgical
group.
(3) Acute surgical illness. Table 9»6.
(three a cholecystectomy, two a partial gastrectomy, two a hernia
repair, and one a prostatectomy). The acute surgery group consisted
of one patient with perforation of a duodenal ulcer, seven with acute
appendicitis, and four with Colles fracture.
Post-operatively the S.A. activity rose in seventeen of the
twenty patients? in ten by 3-4 days, thirteen by 7-8 days and the full
A rise in S.A. activity occurred in all the other eighteen
Eight patients in this group were undergoing cold surgery
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Table 9.6 Changes in S.A. point after Acute Surgical Illness
S.A. point ADPpM/L
Patient Age Sex Day 0,1 3,U 7,8 10-12 ESR range
1 Cholecystectomy 70 M 2 1.5 1.5 0.5 -
2 Gastrectomy 52 M 5 1.5 2 1.5 io-5i*
3 Cholecystectomy 57 F 1.5 2 0.75 o.5 3-61*
b Hernia 59 M Nil 3 3 3 5-30
5 Cholecystectomy 67 F 1.5 1.5 l 0.75 30-62*
6 Hernia Ml F 3 l b Q.5 3-U6
7 Prostatectomy 6b M 1.5 1.5 0.75 Q.5 15-60*
8 Gastrectomy kb M 10 2 3 2 12-22
9 Perfor ated D.U. bo M 2 1.5 2 0.75 -50*
10 Appendicectomy 31 F 3 1.5 0.75 1.5 -
11 it 53 M 2 2 2 2 35
12 it 26 F Nil Nil 3 2 1U-21
13 ii 56 M Nil 1.5 2 DVT -99*
"ilU ii Mi F b 7.5 2 2 -53*
15 it ii3 F Nil 2 1 1 10-30
16 ii 53 F b 3 1.5 3 -22
17 Coll€s fracture 69 F 5 - 0.75 0.75 7-Ul
18 it 56 F 3 - 10 3 6-10
19 ii 52 F 3 - 3 3 19-32
20 it 62 F 3 - 0.5 0.25 15-10
Mean (at Nil =10) li.B - 2.2 1.5
Tile peak value is underlined *-='major' illness
Analysis by Wilcoxon Signed Ranks Test
seventeen by 10-12 days. In three patients, one after an
appendicectomy and two after Colles fracture, no rise
occurred. The peak values were reached by four in 3-4 days,
by five at 7-6 days and the remaining eight at 10-12 days.
The increase affected some patients with all the
conditions examined and this included two of the patients with
the relatively minor incident of a Colles fracture.
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Table 9.7. Analysis of the increase in S.A. following acute
medical and surgical illness
Day 0,1 3,h 7,8 10-12
Acute Medical incident: -
■jbbfr •jbbs-k- -jbbb5-
- - tt *
- / - - N.S.
N.S. -x- -sbbb:- -;bbb«-
(1) Initial result (Day 0,1)
(2) Day 3,k
(3) Day 7,8
(It) Matched blood donors
Acute Surgical incident:-
(1) Initial result (Day 0,1)
(2) Day 3,k
(3) Day 7,8




N.S. N.S. * ***
Intragroup analysis by Wilcoxon Signed Ranks Test
Intergroup analysis by Wilcoxon Sum of Ranks Test
* =f>< 0.05
■SBc = p <C 0.01
-iBB!- = P< 0.002
-iBBHc =p< 0.001
ANALYSIS OF S.A. CHABCMS FOLLOWING ACUTE ILLNESS.
(1) Changes in S.A. activity in medical and surgical acute illness.
The changes in S.A. were analysed by intra-individual
analysis, and were also compared by group with an age and sex matched
sample of the blood donors.
In both the medical and surgical groups there was a highly
or very highly significant rise in S.A. activity. This significance
was achieved by 3-4 days (p~ <0.002) in the medical group which also
showed a significant (j> =<0.05) further rise between 3 to 4 days and
the later times. In the surgical group the rise occurred more 3lowly
and only became significant at 7 to 8 days. It reached a peak of
significance at 10-12 days. The 10-12 day values were significantly
{p = <0.05) higher than the 7-8 days values.
The comparisons with age and sex matched donors produced
the same pattern of significance, although because the donors had
higher baseline S.A. point values, some of the levels of significance
were lower (Table 8.7). This comparison with normals shows that the
rise in S.A. activity after acute illness was an absolute one.
The peak S.A. point values occurring during acute illness
and those of the blood donor control group are shown in Table 9.8.
They are arranged into No-S.A. plus self-limiting S.A., and chain-
reactive S.A. (Table 9»8 CO )• The chain-reactive S.A. was then
sub-diviclfed into two levels of chain-reaction potential (Table 9«8, GO ).
The acute illnes3 patients had 29 (12} ) of peak values showing
chain- reactive S.A. as against 6 (15/9 for blood donors, a very highly
significant increase (j^~ <0.001). Within the chain-reactive group
itself, the values reached by the patients were significantly higher
than the levels of chain-reactive S.A. shown by the donors (jo- < 0.05).
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Table 9.8.
(1) Comparison of Chain-reactive S.A. in donors and peak level daring
acute illness
No S.A. and
Self-limiting S.A. Chain-reactive S.A.
Donors 3h 6
Acute illness 11 29***
peak level
S0% probability test (1713)
(2 ) Comparison of degree of chain-reactive S.A.
Chain reactive S.A.
1.5 and I.OjjMADP 0.75> and O.^pMADP
Donors 6 0
Acute illness 11 12*
peak level
Binomial Test (1713)
This absolute increase in S.A. will be associated with a very marked
increase in the aggregation chain-reaction potential (the very large
s
increase^ in potential* inherent in it's eonetric progression* for
small changes in the chain-reactive S.A. point ADP concentration*
were described in Chapter Five)•
(2) Effect of Platelet count changes on the rise in S.A. activity.
The mean rise in plasma platelet cotaat of about 85th in the
medical group and about 100th in the surgical group would only elevate
the S.A. point by one to two levels (see Chapter Seven, Experiment 8).
Also the peak values of S.A. point in the medical group occurred
earlier than the peak values of platelet count (coincident in three,
divergent in fourteen). The peak values for S.A. occurred later in
the surgical than in the medical group, but even so only coincided
with the highest platelet count in seven patients, being divergent in
eight patients. Thus the increase in S.A. activity was not direotly
relatable to the rise in platelet count. When the S.A. activity
results were adjusted to a constant platelet count the pattern of change
was not altered and the significance levels were little affected,
(3) Effect of tho severity of the acute illness.
Estimates of the severity of the illness, based on the
clinical course and investigations, correlated well with the peak E3E
value. The illnesses in which the peak ESE was 50 (twenty-three)
were compared with those with a peak ESR of 50 pip© (thirteen). The
patients constituting the severer illness group were two with
haematemeses, the viral pericarditis and allergic purpura patients,
two patients with G.V.A'a., two who had cholecystectomies, two post-
appendlcectomy patients, one after gastrectomy and the man who had a
prostatectomy.
The peak S.A. activity in the thirteen patients who had the
severer illness was higher than that in the twenty-three patients with
107




























































a less severe Illness ( j> = <(5.02).
The rises in S.A. activity in the twenty-three patients
with the less severe illness were analysed alone. The rise in S.A.
activity in this less severely ill group was still significant (j? = <<0.01).
(4) Age and Sex.
The peak values for the ages by decades are shown in Table 9.9.
The over 60 age group v sixteen) had peak values which were highly
significantly (|? = <0.002) greater than those in the 51-60 age group
(fifteen). The number of severe illnesses were comparable in the two
groups (six for age 61+ and five for ages 51-60).
(5) ftruga.
Many anti-inflammatory agents markedly depress S.A. and none of
these were given to the patients in this survey. Self-medication before
admission cannot be excluded and was suspected in the medical group.
Some other drugs have a smaller effect on platelets, but usually only
in high concentration. These include drugs used for heart disease (62).
No suppressive effect was apparent from dlgoxin (Medical patients No.6
and 12). Nor did any other of the drugs show a consistent inhibitory or
enhancing action on the S.A. point.
Interestingly the two patients on oral anticoagulants (medical
patients Nos.15 and 17) showed an increase in S.A. activity comparable to
that in other patients with a similar severity of illness.
(6) Nature of illness.
Only myocardial infarction patients (eight) and append!ceotony
patients (seven) were sufficiently numerous for comparisons. Within
each of these two groups there was a wide variation in the initial level,
the degree of increase, and the peak value of the S.A. point. Severity
of illness appeared to be most important determining factor of this
variation.
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SUMMARY OF JilAPT'iR HIHB
1. The changes in S.A. activity occurring in the two weeks following
the onset of the acute medical (20 patients) and surgical illness
(20 patients) have been studied.
2. In a control group of seven non-acutely ill patients in bed, and
of six ambulant normals, there was no significant change in S.A.
activity or P.A. percent.
3. After acute medical and surgical illness the S.A. activity rose
to a highly significant degree. This rise occurred earlier in
the medical group. P.A. did not change significantly.
4. Chain-reactive S.A. was very highly significantly more prevalent
in the acute illness group than in a normal group (blood donors).
Also the level of chain-reactive S.A. was higher in the acute
illness group than in the normals, which means an even greater
elevation of the aggregation chain-reaction potential (see
Chapter Five).
5. The increase in S.A. activity was only slightly due to the rise
in platelet count. Thus the major part of the change in S.A,
was due to changes in the platelets or the plasma.
6. The rise in S.A. aotivity was significantly greater in those
patients with severer illnesses, and in those patients aged over
sixty years. The rise did not correlate with the patient's type
of illness or with their sex, and no drug effects were detected
after admission.
7. Thus the 'hyperthrombotic' state which follows acute illness was
associated with a marked increase in S.A. activity, and in the




























































































































































































































































































































































































































































































































































































































































































































































































































































SECONDARY AGGREGATION IN ANIMAL PLASM.
IHTRODUCTIOK.
The detection of a powerful aggregation chain-reaction process
in nan makes one wonder if this could be playing a part atherosclerotic
disease in man, especially as pathologists are continually reminding us
that this is a thrombo-athero3clerosis (29, 50, 51, 122). Since the
main initial component of the thrombus on an atherosclerotic plaque is
a platelet mass (51» 122, 151), could it be that S.A., particularly
chain-reactive S.A., allows thrombi to form more easily in man than in
animals? It has proved difficult to induce marked fibrotlc (as opposed
to fat laden) lesions in animals (Cons tantinides 28, Hartroft et al 70)
and even more difficult to induce the thrombotic element. Constantinides
(28) was only able to produce thrombosis in rabbits when, in addition to
hyperlipidaemia, he induced both hypertension and hypercoagulability
(Russells Viper Venom). Even then only a limited thrombosis occurred.
Therefore it was considered worthwhile to investigate
different species of animals for S.A. activity. Within the limits of
availability 3pecies were selected for two reasons - first, similarity
to man i.e. other primates - and second, that they were commonly used
in the laboratory in investigations of atherosclerotic disease. Previous
work had already shown that platelet aggregation differs in different
species. Cat platelets aggregate more vigorously than those of man (15)
and it has recently been shown that the tracing is biphasic (Hacmillan and
Sim 110, Tschopp 179); some guinea-pig platelets give a biphasic tracing
to ADP (27); and rat platelets possess a very strong ability to
disaggregate (32, 170). Comparative studies of total aggregation to
one ADP dose have been reported on a group of mammals (Sinafeos and Caen
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Table 10.1 Details of animals and bleeding procedure
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Pigs - Slaughtered Carotid Artery 1
Rats Albino 100$ N2 Cardiac
puncture
h
Dog Beagle None Ante-brachial
cephalic vein
1
171) and on different sub-varieties of baboon (Hawkey and Synons 71).
Ifo one has yet surveyed a group of mammals for S.A. and in
particular chain-reactive S.A.
Materials and Methods.
Table 10.1 shows the species studied, and details of specimen
collection (anaesthetic, if any; puncture 3its; and number of animals
per plasma specimen, which was usually one).
The sensitivity of S.A. detection was increased by reducing
the citrate concentration to 0.19a, except in rabbit blood where 0.38f
was required to prevent coagulation. Specimens were maintained at
about 37°C during transfer to the laboratory. The centrifugation was
at 140 to 310g and was continued for 4-10 ndns, depending on the species,
so as to produce the best combination of plasma yield and platelet count.
The platelet count varied from 300-1 ,000x1 (P per cu.ram.
Storage and testing were performed at 37°C as for human plasma.
Plan of study.
Each plasma was tested with ADP, and a dose response curve
using concentrations up to 100 ADP was performed. The S.A. point
concentration of any S.A. activity present was determined and some of
the plasma showing S.A. were tested for a release of ADB-like activity.
Each plasma was also tested with 1OQjaB adrenaline, and if a second
phase of aggregation (i.e. S.A.) occurred the S.A. point concentration
for adrenaline was determined.
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Fig. 10.1.
Rat plasma. Dose response curve to ADP. Only P.A.
Aggregation increased as the ADP was increased, up to lOOpM,
and was followed by a very marked disaggregation. A P.A.-
only tracing.
Fig. 10.2. -
Rabbit plasma. Dose response curve to ADP. Only P.A.
. Aggregation increased as the ADP concentration increased up to
lOOpM. Disaggregation was marked but less than in the rat
plasma. A P.A.-only tracing.
Dose response curves showing S.A. and P.A.-only tracings are
shown in Pigs. 10.1 tof0.8.
The findings are explained in the legends.
I
No S.A. response to ADP or adrenaline was detected in the foilowing
In plasma showing only P.A., doses of 10pK ADP (and above)
were followed by disaggregation. The extent of the P.A. response
was highest in baboons and rabbits, with humans a little less
(all with 0.38/ citrate, five experiments).
S.A. was detected in some or all of the -animals studied in the
following speciesi-
(t) Humans (see previous chapters).
(2) Papio cynecephalus (baboons).
(3) Cats.
(4) Guinea pigs - rosette, piebald and albino.
(5) Dogs
The form of the S.A. tracings in the species showing that
response was biphasic in the cats, rosette and piebald guinea-pigs,
and the dog (in vfcich it developed very slowly), and was non-phasic
in baboons and albino guinea-pigs.





15 experiments (n *» 15)
3 experiments (n = 3)
8 experiments (n = 8)
6 experiments (n = 24)
6 experiments (n = 6)
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Fig. 10. 3.
Albino guinea-pig. Dose response curve to AFP. Non-phasic S.A.
0.3pM ADP produced a P.A. response -with marked disaggregation.
l.OpM ADP was followed by marked aggregation with impaired
disaggregation and 2.0jaM ADP by a marked and continuing
aggregation, which was only a little increased by lOpM ADP.
A non-phasic S.A. tracing
(.... = response expected from only P.A.)
i
i 1 1— 1 1
O I 2 3 4
MINS
Fig. 10.U- • • !
Rosette guinea-pig. Dose response curve to ADP. Biphasic S.A.
0.5pM ADP produced only a small aggregation and there was a
rapid return of the disk shape. The l.OpM dose produced a
moderate aggregation followed by impaired disaggregation, and
after ~L.$pK ADP a biphaisic aggregation response occurred which
was finally nearly as extensive as that produced by 100_pM ADP.
A biphasic S.A. tracing




Baboon (Papio cynecaphalus) plasma. Dose response curve to ADP.
Only P.A.
This plasma showed a P.A. response, with disaggregation still occurring




Baboon (Papio cynecephalus) plasma. Dose response curve to ADP
Non-phasic S.A.
The P.A. response occurred until the impaired disaggregation
following the 5pM addition. The 7«5pM dose was followed by a
fusion of P.A. into S.A. and produced aggregation almost as marked
as that occurring to the lOpM dose. A Non-phasic S.A. tracing
(.... = response expected from only P.A.)
Fig. 10.7•
Dog plasma. Dose-response curve to ADP. Biphasic S.A.
A P.A. response occurred to l.OpM ADP. After the 3.0juM dose a small
secondary aggregation occurred which was followed by partial disaggregation.
The S.A. became more marked as the ADP dose was increased to 5.0joM, when
it was almost as extensive as that ocurring with IOjjM ADP. Biphasic S.A.
present. (....= response expected from only P.A.)
|
O I 2 3
MINS.
Fig. 10.8.
Cat plasma. Dose-response curve to ADP. Biphasic S.A.
0.25juM ADP produced a small aggregation and there was slight disaggregation.
The 0.35jfVI dose produced an initial small aggregation which was followed
by a very marked S.A. response, and after 0.75/iM ADP the onset of S.A. was
more rapid. Biphasic S.A. present.
( .... = response expected from only P.A.)


















































4. The fall results for the spocioa showing 3.A. are iven in
Table 10.2.
Ill© results for man ar© from the preceding chapters, and it
will be remembered that the citrate concentration in those was 0.38,
rather than the 0.19;" present in the animal plasm. (Experiment 3
Chapter beven showed that tho 3.A. point A3)? concentration in plasma
from man decreased by about three S.A. point dose levels when tho
citrate concentration was reduced from 0.3© to 0.19 )•
The baboons were a selected group. Experiments soon showed
that S.A. was wove frequent and more vigorous in adult females (as in
man, Chapter Eight) and there was a preponderance of these in the
group. Other animal groups were not pro-selected for their S.A.
response but numbers are too small for percentage frequencies to
act as nore than a rough guide.
The percentage showing S.A. was high in man, baboons, cats (all)
and albino guinea-pigs; and 50 to 70^ of rosette and piebald guinea-
pigs end dogs showed S.A. The S.A. point ALT dose possess two
characteristics, level and range. Low S.A. point dose levels
combined with a small range (i.e. all were low), were present in cats
and the rosette and albino guinoa^pigs. Mle the S.A. dose level
was low in some baboons and humans the range of doso level was wide.
Logs had a high S.A. point AS? dose. The S.A. response of adrenalin©
aggregation (O'Briens* second phase) occurred only in those animal
plaersa which bad shown S.A. to added ALP, but several AEP-3.A.-
reopensive plasma did not show S.A. to adrenaline 1OQuB (Table 10.2),
and that of albino guinea-pigs never did so. These results differ
from those in man where there was a complete correlation between S.A.
to ADP and to adrenaline. Tho only animal plasm which showed a
complete correlation was the cat plasma, in which very low adrenaline
concentrations initiated the S.A. reaction.
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n 19 U 7 9
S.A. point
(ADPpM/L)
0.2^-10 0.25-0.75 0.25-1 o.oi5 to 5
ADP-like release
(pM/L)
12-0 .h 2.25-1.2 0.2-2 O.U to 0
Aggregation chain
reaction potential
37 to O.U 9 to 3.U 0.8 to 0 0.25 to 0








5. The ADP-like activity present after S.A. was measured in a small
group of the S.A. responsive animals (Table 10.3). A definite
ADP-like aggregating activity release was detected in only the cat.
In the baboon and guinea-pig there was little or no excess activity
over fee ADP addition. The total aggregating activity present after
S.A. was measured in four baboon plasma to see if some aggregating
agent other than ADP was being released. None was detected.
The low or absent release of ADP in baboon and guinea pig
plasma was not sufficient to initiate an aggregation chain-reaction
(Table 10.3)# and 30 the S.A. in these animals was self-limiting.
In contrast, a marked chain-reaction potential was present in all
the cats tested, i.e. S.A. was chain-reactive. Chain-reactive S.A.
was more prevalent in the cat than in the human plasma but it must
be remembered that the citrate concentration was lower in cat plasma
(0.19%) than in human plasma (0.36/ ), and that the concentration of
ADP-like activity released by platelets from man was higher than
that for the cat (see Chapter Five).
6. Two intra-varisty differences in the presence of S.A. were detected.
In the baboons, S.A. was present in some cynecephalus animals but
not in any anubis ones. The rosette and piebald guinea-pigs
sometimes showed biphasic S.A. to ADP and adrenaline, whereas the
albino guinea-pigs all showed non-phasic S.A. to ADP but none showed
S.A. to adrenaline.
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SUMMARY OF CHAPTER TEN
1. Nine varieties of animal species were surveyed for S.A. One
sub-variety was examined in six of the animals, two of baboon,
and three sub-varieties of guinea pig.
2. S.A. was not detected in rabbits, rats, pigs, and squirrel monkeys.
3. S.A. to ADP was detected in baboons, guinea pigs and dogs. The
S.A. was self-limiting with little or no ADP release. The low
or absent release suggests that an increased aggregation-
responsiveness of the platelets to ADP was the major factor in S.A.
in these species (as it probably was in 'level' non-phasic S.A. in
man, Chapter Five).
4. Differences were detected between sub-varieties of baboons and
guinea-pigs.
5. Chain-reactive S.A. was detected in all of six cat plasma and low
adrenaline concentrations initiated S.A. in these plasma.
6. Of the animals tested only the cat showed an S.A. activity
comparable to that occurring in S.A. in humans.
COMMENT.
The cat is the only animal so far known to develop disease in
it's natural environment from a platelet-fibrin thrombus. Occasional
instances of aorta-femoral block (the Leriche syndrome) have been
detected in cats, and post-mortem has shown thrombus as the cause of
the occlusion (Freak 46, Mitchell 120a). It has been postulated that





In 'Chapter one the discovery of ADP as the stimulator of
the aggregation of blood platelets was described. AJJP is the final
common pthway for the aggregation-Inducing action of all known
stipulators of this process, baring the first phase of catecholamine
aggregation. The morphological evidence showing that aggregates of
platelets form the major and initial mass of haemostatic plugs and
white thrombi was also reviewed, as was the increasing evidence that
white thrombi are the major factor in the pathogenesis of
atherosclerotic plaques, are the main cause of coronary and cerebral
artery occlusion, and ft© the initiating event of deep vein thrombosis.
Platelet abrogation was studied in this thesis by the
turbldimetric method of Born lChapter two) using equipment made in
Professor Bern's department. This method Ives a continuous
recording of the aggregation and disaggregation of blood platelets.
Chapter two also describes the methodology of the further investigations
which the method of Born permits, namely removal of samples which can
then be used for microscopical studios or for investigations of changes
in the aggregating activity of the plasma. The aggregating activity
present in a plasma was measured biologically by recording it's effect
on further specimens of platelet rich plasma. 3ueh readings measure
the sum of the interaction of the stimulators and inhibitors present
in a plasma, and so say be more relevant than chemical estimate* to the
biological calculations for which they wore used in this thesis The
total aggregating activity in a plasma could be measured, or by the use
of substances which specifically inhibited other aggregating agents,
only the ADP-like aggregating activity. The values obtained in this
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biological system are comparable to those obtained by chemical methods
(firefly method and PK-PEP system, Kills et al 116, 120, Hardisty et
al 65).
Chapter three outlines the development of the different methods
for measuring the adhesion and aggregating behaviour of blood platelets and
then the advantages and disadvantages of these methods were described.
In essence, one can either measure both adhesion and aggregation processes
using whole blood, thus obtaining a composite result (platelet 'stickiness1)
which is good as a screening test. Or one can separate the platelets from
the red blood cells and examine a single process in detail, either adhesion
or aggregation. Such a separation nearly always necessitates using
anticoagulants. Their use inserts a barrier to the relating of in vitro
investigations to the behaviour of blood platelets in the intact animal
which can only really be overcome by doing in vivo confirmatory studies.
In Chapter four, the appearance of platelet aggregation -
disaggregation dose-response curves to exogenous ADP (0.25-1OpM) was
described. All plasma from man showed a response of increasing aggregation
as the (ADP) was raised, and this was followed by a decreasing degree of
disaggregation (the 'primary' aggregation or P.A. response). A study
combining tracings with microscopy, demonstrated that the change of
platelet shape, from a disk to a sphere, produced by ADP (Zucker and
Borelli 195), can be followed in the -tracings. A further microscopical
study, this time of the aggregation - disaggregation process, showed a
rapid aggregation of most platelets and that increasing inter-platelet
adhesion occurred in the aggregates as the extent of the aggregation
increased. This finding confirms the work of Bom and Hum (19). In
addition, it was found that large aggregates are already present before
the tracing starts to fall, showing that aggregation is faster than the
tracing suggests. Also, the degree of disaggregation which followed the
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aggregation was less microscopically than that suggested by the tracing.
In addition to *primary* aggregation, most plasma from nan
showed a further (•secondary*) aggregation process (S.A.). This process
resulted in a very marked and persistent aggregation response (microscopy
showed that nearly all platelets in the plasma were in aggregates showing
marked, inter-platelet adhesion). When this process was initiated by
small doses of APP (0.25 to about 1,5pH) a markedly biphasic tracing
occurred, for the S.A. process was powerful enough to reverse the
disaggregation which followed the P.A. response (•biphasic* S.A.). '/hen
larger doses of APP were required to induce S.A. (2jM APP/or more), the
tracing was continuous or showed a slight 'bump* ('non-phasic' S.A.5.
These results showed that S.A. is a process which converts a small
(•biphasic* S.A.) or moderate (norv-phasic S.A.) and temporary P.A.
aggregation into a very marked persistent aggregation.
Investigation of the mechanism of S.A. (Chapter five) showed
that it was accompanied by the release of an aggregating substance by the
platelets, and that P.A. was not. The released activity behaved like
AP^S and no additional aggregating activity could be detected from the
5H-T which is also known to be released during S.A. (Zticker and
Peterson 196). The size of the release of ADP-like aggregating activity
was insufficient (especially so in some plasma) to explain either the very
marked aggregation of S.A. or it's property of persistence. Presumably
during S.A. the platelets, in addition to releasing APP, became both
more aggrega1tion-responsive to the ADP and less able to disaggregate.
Further support for this hypothesis was given by the subsequent demonstration
that platelets could release an equivalent amount of APP-like activity to
that released during S.A, when they were stimulated to abrogate by thrombin
(Chapter six), and yet retain the ability to undergo quite marked
disaggregation; and by the finding, still later (Chapter ten), that the
118
properties of increased aggregation-responsiveness and aggregate-
persistence occurred in platelets from baboons, to produce an s.A. tracing,
even although there was no increase in aggregating activity in the plasma.
Thus, in the baboon, the only factor which was found to explain S.A. was
the increased ADP-responsiveness of the platelets.
The observation that S.A. was associated with a release of ADP is
probably the most important finding in this work. Hitherto aggregating
agents have been shown to act through a two tier system (Fig. 1.2 review),
which i3 an inherently self-limiting process. Any given dose of
aggregating agent (e.g. thrombin and collagen) produces a dose-dependent
ADP release fVom the platelets and will then cease to have any further
ADF-release inducing action. But when ADP itself induces a release
reaction the process becomes a single tier one, for the released ADP, in
addition to causing aggregation, is at the same time increasing the
stimulus for a release of more ADP from more platelets. A self-
propagating platelet aggregation/ADP release reaction is thus produced,
which has as it's aggregation expression the S.A. process. The self-
propagation is aided by the increased aggregation responsiveness to ADP
described above.
The discovery that s.a. was due to a self-propagating
aggregation-ADP release reaction suggested that the released adp may
have the power to induce further specimens of the same plasma to undergo
s.a., and so initiate an a -gregation chain reaction. Experiments
(Chapter five) showed that this occurred, however, this effect was only
marked in plasma showing the active biphasic s.a. response. The
aggregation chain-reaction potential of a plasma depended on two factors,
the concentration of adp-like activity released, and the adp required to
induce s.a. in the plasma , i.e. the s.a. point (adp), Calculations of
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the chain reaction potential for different levels of the S.A. point showed
(Chapter five) that the potential was very high for an S.A. point of 0.25juM.
It then fell precipitously to reach small levels for S.A. points of 2)uM ADP
or more. The S.A. in those plasma with a high potential (S.A. points
0.25-1 was called ♦chairwreactive* S.A. and that in the remainder
•self-limiting' S.A.
The calculations of the aggregation chain-reaction potential of
S.A. at different S.A. point levels demonstrated a basic fact of chain-
reactions, namely that when they are initiated by a wide range of
concentrations of a substance, the variations in the power of the chain-
reaction are related not to the linear scale of the initiating range of
concentration, but to the geometrio one of chain-reactions. The corollary
of this relationship is that small falls in the initiating concentration
produce very large increases in the size of the chain-reaction.
The values used to calculate the chain-reaction potential are the
ADP-like activity release and the S.A. point (JLDP). The levels of ADP-
like aotivity release found in Chapter five are comparable to those of
ADP found by Mills et al (116). The levels of S.A. point (AD0 recorded
in this work are close to those of Mills (115) (who used the same technique)
and, when differences in the interpretation of tracings are allowed for,
to those of Zucker and Peterson (197). Using a very vigorous stirring
technique and a storage procedure for the plasma that increases S.A.
aotivity, Kardisty et al (65) found an S.A. point range of 0.2-1,2pK ADP
in a normal population. Presumably iardisty's technique would give a range
for pathological states starting at 0.05-0.1jjK ADP. When the S.A. point
(ADP) range found by Pardisty et al is used in calculations of the
aggregation chain-reaction potential of S.A. a higher potential is obtained.
However, since the width of the range found in Chapter four and in the work
of Hardisty et al is the same, changes in S.A. point ©n either scale produce
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comparable changes in the chain-reaction potential i.e. the potentials
for the two ranges are at different absolute levels but mm parallel to
each other.
The question of how relevant the S.A. process is to platelet-
fibrin mass formation in vivo will only be answered with certainty by
in vivo investigations. The reader will realise that the platelet
concentration is higher in plasma than in whole blood, and that the
turbulent maximal stirring in the titrator will produce a higher number
of platelet to platelet 'hits* than occurs during laminar flow in a blood
vessel. This enhancement of aggregation in the titrator is in part
counter-balanced by the marked depression of aggregation produced by the
eomplexing calcium ions by the citrate anticoagulant (Mitchell and
Sharp 121, Chapter Seven, Experiment 3). In laminar flow situations in
blood vessels, any ADP released by platelets would probably be rapidly-
dispersed and so soon reach an inactive concentration. On the other
hand in the turbulent flow areas surrounding a projecting thrombus, where
there are slower changes in the layer of plasma immediately adjacent to
the platelet aggregates, the circumstances are not all that far removed
from those occurring in the titrator. Also, a build up of ADP probably
occurs during haemostasia, as the flow of blood out of a damaged vessel
is slowed by vessel contraction and by the foimation of blood platelet
masses. In summary, it would seem likely that S.A. would have little
effect in a laminar flow situation, but could be exerting a marked effect
at sites of haemostasis and thrombosis where turbulent flow tends to
develop.
Up to this stage in the work, the S.A. process was studied by
using an ADP stimulus which was exogenous to the platelets. In Chapter six
the effect of the S.A. process on the aggregation response of a plasma to
thrombin, collagen and adrenaline was studied i.e. a situation where the
ADP was derived from platelets themselves. In F.A.-only plasma these
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substances produced an aggregation which was dose dependent i.e. *primary'
thrombin, collagen, and adrenaline aggregation. The primary thrombin
aggregation was marked but was followed by partial disaggregation, that
induced by collagen was moderate, and that by adrenaline, small. Plasma
showing S.A. to exogenous ADP also showed S.A. to the endogenous ABP release
induced by thrombin and collagen, and to adrenaline. Furthermore, the
degree of S.A. activity which a plasma showed to ADP was mirrored by a
comparable degree of S.A. activity to testing with other aggregation agents.
The presence of S.A. activity in a plasma enhanced it's aggregation
response to thrombin, collagen and adrenaline in three ways. Firstly, it
produced persistent aggregates. Secondly, it increased the degree of
aggregation achieved to maximal (this meant a small increase for thrombin,
a moderate increase for collagen, and a very marked increase for adrenaline}.
And thirdly, this enhancement of aggregation occurred with doses of these
substances which would have produced only a small aggregation in the absence
of S.A.
A corollary of the demonstration of a cross correlation between
the concentrations of the four aggregating agents required to initiate S.A.
in any one specimen of plasma, is that the level of S.A. activity (and
changes in this level) could be monitored by any of the four substances.
These conclusions on S.A. during the aggregation induced by
aggregating agents other than ADP, were of necessity based on the appearance
of the dose-reaponse curve tracings. They are supported by the two other
findings. First, patients with a congenital absence of S.A. to ADP
(Hardisty and Hulton 63, Weis et &1 182), and second, patients in whom S.A.
has been inhibited by aspirin (O'Brien, 142, H3» Zuaker and Peterson 197,
Hacmillan 107), showed aggregation tracings to thrombin, collagen and
adrenaline which were identical to those for the 'primary' responses to
these substances found in Chapter six.
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The other important finding in Chapter six. was that plasma
showing chain-reactive S.A. to exogenous ADP were stimulated to start
this reaction by thrombin, adrenaline and colla ;en. Thus all sources
of ADP (platelet release reaction and cell damage) are able to initiate
an aggregation chain-reaction in vitro.
Chapter seven reports the many investigations carried, out into
the effect of laboratory manipulation and time of sampling on the S.A,
process. It was found that for reproducible estimation of S.A. it was
necessary to anticoagulate blood with citrate, to store the plasma at
body temperature, and to test for S.A. at this temperature and within
75 rains of venepuncture (Experiment One, Two and Nine). Anticoagulation
of whole blood with heparin and BDTA produced inhibition of the S.A.
reaction (Experiment Three), Contamination of the plasma with rod and
white blood cells did not affect their S.A. activity (Experiment Pour and
Five).
The comparability of the plasma platelet population to that of
whole blood, and the effect of changes in platelet count, were studied in
Experiment Eight. It was found that the percentage extraction of
platelets into the supernatant plasma varied widely. A graph of the
changes in S.A. activity produced by lowering the platelet count of a
plasma by dilution, showed very similar slopes for plasma derived from
nine subjects. So accurate corrections can be mad© for differences in
platelet count. Evidence was also found that the plasma platelet
population may he a good mirror of the whole blood platelet population,
for plasma of comparable density showed the same slope of decrease in S.A.
activity, irrespective of whether "Hie density was reduced by dilution, or
by centrifuging down the more sedimentable (? more reactive) platelets.
More work ia needed on this point.
123
The S.A. activity of healthy volunteers (Experiment Nine) remained
remarkably steady through a day and from day to day in any one Individual,
while showing considerable variation between individuals. This suggested
that single estimates derived from a healthy population of volunteers would
give a satisfactory measure of tho normal range of S.A. activity.
Chapter Eight reports the S.A. activity measurements made in
seventy-four blood donors who were evenly distributed over both sexes and
the age range 21 to 60 years. Care was talcen to exclude any donor who
was on drugs (whether prescribed or from self-medication) and who had an
intercurrent Illness, no matter how minor.
The histogram of the results showed a mode value for the S.A.
point of liffl AC? and there was a preponderance of results at the active
S.A. end. The S.A. point in this normal population varied from 0.75pH
ADP (one) to S.A. absent (three). The S.A. was self—limiting or absent
in S4fo but in Idle remaining \6% was of the chain-reactive type.
The levels of S.A. point found in the donor survey are comparable
to those found by Hills (115, 118) in thirty-three volunteers, and lower
than those found by Hardisty et al (65) for the reasons noted earlier.
In both the survey made by Hardisty et al and the donor survey
in Chapter .Eight, S.A. activity was higher in young adult women., Hardisty
ascribed his results to the lower PC7 values he found in woman, but this
explanation was only a small part of tho reason for the difference in the
donor survey. Ho explanation was found for this increased S.A. activity.
Chapter nine describes a study of the changes which occur in S.A.
activity in the ♦thrombogenic* period which follows acute illness.
During this tlarombogenic period many teats of platelet function show
changes (see Table 9.1), and a previous study of the total aggregation
response of plasma from eighteen patients undergoing an operation has shown
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an increase in total aggregation at nine days post-operation over the
pre-operatlon levels (Baraons and Mitchell 42). These authors found
the total aggregation response varied widely from day to day.
The purpose of the present study was to look for changes in
S.A. activity from the steady day to day pattern found in normals, and
for the development of chain-reactive S.A. A pilot study of the day to
day changes in four patients with acute illness (chapter nine) showed
little variation was occurring around the mean trend, and so a baseline
reading and three further readings over the next twelve days were
recorded.
In a control grow of non-acutely ill patients kept in bed, and
of ambulant volunteers, there was little change in the S.A. activity over
the twelve day period. In forty acutely ill patients (20 ♦medical',
20 *surgical*) a rise in S.A. activity occurred in thirty-seven. This
rise was detected at four days in most and by 7-8 days in all of the thirty-
seven.
The peak S.A. level was reached by 7-8 days by most *medically*
ill patients and a little later by the 'surgical' patients (M.S.). At
this peak point chain-reactive S.A. was present in over lOf of the acutely
ill group (of only 18- in matched blood donors). Also, during acute illness
very high S.A. points of 0.25 to 0.75uM ADP were frequent (of only one donor
at 0.75pM ADP). The increase in chain-reactive S.A. was highly significant,
and the level of chain-reactive S.A. at the pea1 was significantly higher
than that of chain-reactive S.A, in the donor population. Thus not only had
the frequency of chain-reactive S.A. increased, but also the aggregation
chain-reaction potential had reached levels which were not seen in normal
people. \
i
A closer examination of the results showed that 'ma.ior' illnesses
produced a hig^ior peak S.A. activity than 'minor' illnesses (J&nmons and
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Mitchell failed to show this in their smaller group), and that the peak
level was higher in patients aged over 60 years. An interesting finding
was that a rise in S.A. of expected degree occurred in the two patients
who were receiving effective oral anticoagulant treatment.
Analysis also showed that the increase in S.A. activity was
only in very small degree due to the increase in the plasma platelet
count. The mechanism of the S.A. activity increase was therefore not
detected by the present study. The time relations of the rise in S.A.
activity show that it would be possible for the proportion of new
platelets in the plasma to have increased to high levels, and further
studies on this possibility are desirable. The inability of plasma
transfer to influence S.A. activity (found in Chapter five), suggests
that the change will be found to reside in the platelets themselves
rather than in the plasma.
As wide a spectrum of acute illness as was possible was studied
and the results showed that rises in S.A. activity occurred in all these
types of diseases. The two largest groups of disease were myocardial
infarctions and appendioectomies, and in these groups the rises
parallelled the severity of the illness. The results suggest that a rise
in S.A. activity will occur in nearly all acute illnesses of more than very
minor severity, and that chain-reactive S.A. will develop in most ♦major' acute
illnesses. Since platelet-fibrin thrombi are the initial event of most
deep vein thrombosis formation (Sevitt 163), rises in S.A. could be an
important factor in the initiation of these thrombi.
The final study (Chapter ten) was a. survey of raamalian laboratory
animals and of primates. Many of the animals (rabbit, rat, pig) which are
used in thrombosis and thrombo-atherosclerosis research failed to show S.A.
One sub-variety of baboon and some guinea-pigs showed a self-limiting S.A.
response, during which there was little or no release of aggregating
activity by the platelets.
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Chain-reactive 3.A. was found only in the cat* It could
be significant that the cat is the only animal which, in itfs natural
environment, is known to develop a platelet—fibrin mass large enough
to occlude a major artery (aorta) (Freak 46, Hitchell 120a).
The animal study also showed that the P.A. response of
platelets from man was no greater than that of the animal platelets,
so it was only by virtue of an S.A. reaction with release of ADP




The work in this thesis has shown that the S.A. process
generates large platelet aggregates which show marked inter-platelet
adhesion and marked persistence. These firm persistent aggregates
are releasing a stimulus for further similar platelet aggregation (ADP)
and promoting the formation of fibrin around themselves by releasing
Platelet factor 3 (t96). As was pointed out earlier in the discussion,
this powerful self-propagating in vitro thrombogenic process would be
most able to express it's potential in vivo at sites of reduced blood
flow, where ADP and Platelet faotor 3 will accumulate (e.g. sites of
haemostasia), and in areas of turbulent blood flow, which enhance
platelet to platelet contact, and again allow the thrombogenio substances
released by the platelets to accumulate (e.g. diseased arteries and
around venous valves).
The study of S.A. is still in it's infancy and so in vivo
studies are few and are of associations. Hereditary absence of S.A.
associated with a mild bleeding tendency has been detected by Weis et
al (182) and this association has also been shown by Hardisty and
Button (63). Aspirin and other anti-inflammatory agents inhibit S.A.,
and a mild bleeding tendency can occur in this instance (O'Brien 142,
143), but as aspirin also affects other parts of the haemostatic process
the interpretation of this finding is difficult. S.A. may thus be
contributing to haemostasia in man.
Associations between S.A. and thrombosis, are the marked
increase in frequency and potency of chain-reactive S.A. in the
'thrombogenic' period which follows acute illness (Chapter nine), and
the presence of chain-reactive S.A. in the two animals, oat and man,
known to produce large platelet-fibrin masses in their natural
environment (Chapter ten, Hacoillan and Sim 110). The associational
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nature of this evidence indicates the need for further in vivo studies
in animals, especially the cat. It is encouraging to remember that
in vivo work has so far confirmed in vitro observations (see review).
While suggestions as to the place S.A. has in disease in man
are, for the present, speculative, some can be made. The increasing
evidence that thrombosis on plaques in arterial walls plays a major
part in the pathogenesis of atherosclerosis, was described in the
review (Chapter one). While many animals have been induced to form
small to moderate sized atherosclerotic plaques with hyperlipidaemic
diets (Hartroft and Thomas 70, Constantinides 28), no animal model has
been found which shows more than occasionally the occlusive thrombo-
atherosclerosis found in man. This failure of experimental research
has occurred inspite of the use of *throrabogenic' diets, hypertension,
and even Russells Viper Venom, in conjunction with diets of fat (70, 28).
The discrepancy between the animal models and man has sometimes been
ascribed to the relatively short duration of the animal experiments,
but a further possibility is the absence in animals of a factor
essential for atherogenesis. The morphologic evidence (Lindsay and
Chaikoff 101a, 70, 28) suggests that such a factor would be a
thrombogenic one. The marked thrombogenic potential of S.A. shows
that it could easily be this 'missing link*. Thus it may in time
prove to be significant that S.A. is absent (rabbit, rat, pig), or
minimal (baboon) in the animals used at the present time for studies of
atherogenesis.
The hypothesis that an active S.A. process may play an essential
part in the genesis of thrombo-atherosclerosis could be tested in an
animal which both responded to lipid diets with early atherosclerosis
and exhibited S.A. with ADP release, but it may be that only man shows
both these factors. An alternative line of investigation is through
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epidemiological studies. Most sub-varieties of animals show variations
in the way their blood platelet aggregate (Chapter ten, Oonstantine 27,
Ilawkey and Simons 71) even to the extent of presence and absence of S.A.
(baboon sub-varieties Chapter ten), There is thus a very real
possibility that S.A. may be absent in some rases of man and, when
present, it may vary in it's activity in different races. The author
is assistin; in the planning of 3uch a comparative study.
Another type of study that is desirable is one to find out
if the S.A. activity of patients with atherosclerotic arterial disease
is higher than that of 'normal' people (i.e. with no detectable evidence
of the disease). Even more important, is to include the measurement of
S.A. activity in the battery of tests used in the prospective studies
which are investigating the factors associated with the development of
ischaemic heart disease. Such prospective studies are the best method
of determining whether a high level of S.A. activity increases a persons
risk of developing arterial disease, and also of determining the inter¬
relationship between S.A. activity and hyperlipidaeraia or hypertension.
This relationship cotuLd be additive or synergestic. A simplified
method of measuring the S.A. point (ADP) of a plasma would be of
considerable help in prospective studies because of the large numbers
involved, and one is being developed by the author.
? (
Since many occlusive thrombi have several layers of apparently
different age (Crawford 30), it may prove revealing to follow the S.A.
activity of patients with ischaemic heart disease at regular intervals.
In this way a period of high S.A. activity preceding a myocardial
infarction, which could have been responsible for the initial layer of
the thrombus, would be detected.
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Friedman and his co-workers (52) have shown that the incidence
of myocardial infarction is higher in people with a striving personality
and prone to emotional stress. Von Euler et al (43) have demonstrated a
correlation between emotional stress and the release of catechol amines,
and cateohol amines are able, by way of the 3.A. reaction, to produce a
marked aggregation response from blood platelets. It is thus possible
that stress may, through catecholamine release, induce a *hyperthrombotic'
state. Catechol amines have a further important action on platelets.
They produce a potentiation of ADP induced platelet aggregation which
persists without diminishing for as long as the catechol amines persist
(Mills et al 117, Hacmillan 108). This persisting potentiation is to
be contrasted with the short-lived ability of platelets to aggregate when
they are stimulated by ADP, for in less than a minute they become
refractory to the ADP, and their response to further additions of ADP is
impaired (llacmillan 108). ilarrison et al (67) failed to find an increase
in the total aggregation response of plasma collected from students
undergoing the stress of examinations. But the effects of emotional
stress on the S.A. activity of an individual have yet to be investigated
and this would seem to be desirable.
Finally, what is the place of anti-platelet drugs (including
inhibitors of the S.A. reaction) in the therapy of thrombotic disease?
The theoretical potential for anti-platelet drug3 as effective anti¬
thrombotic agents, is higher than that for any other measure yet
considered. Platelet adhesion and aggregation is the first event of
the thrombotic process (see review) and platelets form nearly all the
mass of a white thrombus. Thu3 prevention of this process will probably
prevent an obstruction ever occurring. Conventional anticoagulants have
a more difficult task, for they do not act until after the platelet
aggregates have formed, and by this stage the 'coral-like* structure
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of a platelet aggregate (Poole and French 151) contains stagnant columns
of plasma, rich in the platelet factor 3 released by the platelets.
There are three spheres of the treatment of atherosclerosis
where anti-platelet drugs could be useful; prophylaxis in healthy
people with markers of an increased proneness to atherosclerosis, treatment
of patients with established atherosclerotic disease, and as an adjunct
to arterial surgery, where they may make thrombo-atherosclerotic
endarterectomy a highly successful procedure, by deterring reblockage.
The problem will be to decide which type of anti-platelet
aggregation drug to use. Total inhibition of either adhesion or of
aggregation (i.e. of P.A.) is virtually certain to produce a severe
haemostatic defect. P.A. inhibition would have an effect comparable to
severe thrombasthenia and so a high incidence of side effects, especially
bleeding complications, would probably occur. In contrast, absence of
S.A. produces only a mild haemostatic defect (¥eis et al 182).
Only inhibition of S.A. would be probably acceptable for
prophylaxis against atherosclerosis, for the other types of inhibition
would almost certainly have too high a complication rate. The degree of
inhibition of platelet P.A., S.A. and adhesion necessary for effective
therapy of established atherosclerotic disease will have to be established
by clinical trial. A possible ideal may be the combination of S.A.
inhibition with -partial inhibition of platelet adhesion to collagen.
These thoughts on the therapeutic use of anti-platelet
aggregating agents are no idle look into the future, for, in addition to
the inhibitors of P.A. (114, 115) and S.A. (142, 143) already reported
in the journals, many more are being studied by the thrombosis research
groups of I.C.I. (Haslam), Glaxo (Ireland), Beechans (sira), Pfizer
(Constantino) and CIBA; and some of the more promising inhibitors
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are already undergoing toxicology trials in animals.
The outlook for a therapeutic breakthrough in the prevention
and treatment of atherosclerotic and other thrombotic disease in man
is therefore promising.
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